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Abstract 
 
 
Wound repair is a highly ordered biological process that is essential for the maintenance of the skin’s 
barrier function. For optimal healing, the inflammatory, proliferative and remodelling phases of repair 
must occur in the correct sequence with appropriate stimuli to prevent insufficient or excessive 
activity at critical stages. The inflammatory and proliferative phases of repair can influence both the 
rate of wound resolution and the skin physiology of newly resolved tissue and subsequent 
remodelling. Optimisation of these processes has the potential to both enhance closure rate and 
minimise microorganism colonisation, reduce scarring and enhance wound tensile strength. There are 
many local and systemic factors that can severely impede healing and promote wound progression 
from an acute to a chronic state. This is particularly evident in the elderly whom are prone to various 
comorbidities that can influence the immune, circulatory and respiratory systems and often rely on 
medical intervention to assist healing.  
 In recent decades the anti-inflammatory and antioxidant properties of marine natural products 
(MNPs) have attained global attention due to their potential implications for human health. Omega-3 
fatty acid enriched oils (carbon dioxide and dimethyl ether extracted oils; CO2 and DME oil) extracted 
from the New Zealand green lipped mussel, Perna canaliculus, have demonstrated potent  
anti-inflammatory properties. 5β-scymnol, a shark bile sterol, is another MNP with beneficial health 
implications due to its potent antioxidant abilities. However, the wound healing potential of these 
MNPs remains broadly unknown. In this study, the effects of these three MNPs on the inflammatory 
and proliferative phase of repair were explored in vitro. Results indicated that the two marine oils 
demonstrated inhibition of the pro-inflammatory metabolites of the 5-lipoxygenase and 
cyclooxygenase pathways in a dose-dependent manner, but did not stimulate keratinocyte or fibroblast 
growth. Similarly, 5β-scymnol displayed no effect on the growth of keratinocytes and fibroblasts, but 
was also shown to inhibit cyclooxygenase metabolite production.   
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Of equal interest is the recent application of natural and synthetic biomaterials in tissue 
engineering and wound healing. Wound healing products containing nano-silver – primarily used for 
its antimicrobial properties – are currently utilised for wound management. However, other metal 
oxide nanoparticles (NPs), including zinc oxide (ZnO), have not been sufficiently tested for their 
ability to aid healing. In the second arm of this study, the effects of the ZnO NPs were similarly 
assessed in vitro. The ZnO NPs significantly enhanced scratch closure in human keratinocyte 
monolayer cultures in a dose- and particle size-dependent manner, while larger ZnO particulates were 
less effective. Furthermore, examination of surfactant-dispersed ZnO NPs revealed that the 
agglomeration state of the material was an important characteristic. Additionally, titanium dioxide 
(TiO2) NPs similarly enhanced keratinocyte re-epithelialisation, while fibroblasts were unaffected by 
nanomaterial exposure. These results suggest that the observed scratch closure enhancement effects 
were dependent on agglomerate size and cell type, and may not be nanomaterial specific. 
Furthermore, ZnO exhibited 5-lipoxygenase and cyclooxygenase modulating activity.  
The effects of ZnO NPs were further examined in an in vivo model of wound repair as these 
were the most potent in the in vitro test systems. Nanoparticulate ZnO was directly compared to its 
surfactant-dispersed equivalent, bulk ZnO particulate and the TiO2 NP, after application to skin 
biopsy punch wounds on the shaved backs of C57BL/6 female mice. Enhanced wound healing was 
evident in undispersed ZnO NP-treated wounds only. Histology of skin wounds at day 7 revealed a 
markedly reduced epidermal thickness and decreased cytokeratin-14 and Ki-67 expression in ZnO 
NP-treated wounds compared to saline-only controls. A reduced proportion of type-III to type-I 
collagen was also evident in the dermis of ZnO NP-treated wounds. However, no differences were 
seen in the amount of immune cell infiltrate or angiogenesis. ZnO NP-treated wounds showed more-
ordered healing and were further along the healing process at day 7 compared to untreated controls. 
However, by day 14 no differences were detectable between ZnO NP treatment and controls in fully-
healed skin. These results suggest that ZnO NP-treated wounds heal at an accelerated rate, and in a 
more organised fashion. 
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Taken together, these findings show that MNPs and NPs show potential for modulating both 
the inflammatory response and the rate of epidermal cell re-epithelialisation in healing wounds, both 
of which are rate-limiting factors for efficient repair of human skin.    
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1.1 INTRODUCTION 
 
The skin is the largest and arguably most important organ in the human body that provides protection 
from pathogens, ultraviolet radiation and toxic agents. In addition, it functions to limit excessive water 
loss, provides temperature regulation, sensation and protection from mechanical stress. There are 
three structural layers of the skin, which are the epidermis, the dermis and the subcutaneous tissue, as 
outlined in Figure 1.1 below.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Cross section of mammalian skin. The skin is the largest organ in the human body 
comprised of three key structural layers. These are: the epidermis, the dermis and the subcutaneous 
tissue. Biological components of the skin include: the hair follicle and shaft, sebaceous glands, sweat 
glands, arteries, veins and adipose tissue (1). 
 
 Each structural layer differs functionally through its cell composure. The epidermis is the 
outermost layer of the skin, composed primarily of keratinocytes, and it also contains melanocytes 
and Langerhans cells.  Keratinocytes are keratin producing cells that originate from the lowest layer 
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of the epidermis, called the basal layer. Keratinocytes constantly shed at the skin’s surface, however 
they are replaced in an orderly fashion due to the continuous migration of dividing cells from the 
basal layer. This process ensures that a physical barrier protecting the body from the external 
environment is permanently available (2).  
The dermal layer, separated from the epidermis by the basement membrane, is an area of 
connective tissue, primarily made up of type I collagen, providing support for blood vessels and 
nerves (3). The most abundant cell type present are fibroblasts, which are widely distributed to 
maintain structural integrity of the connective tissue via the secretion of extracellular matrix (ECM) 
proteins such as collagen, glycoproteins, and reticular and elastic fibres (4). Additional biological 
components are sweat and oil glands, hair follicles and cell types including macrophages and mast 
cells. The subcutaneous layer, located directly below the dermis, is mostly comprised of loose 
connective tissue and adipose tissue, providing insulation and mechanical protection to major organs 
(2). 
1.1.1 Wound repair     
A discontinuity of the epithelium and underlying connective tissue due to injury or damage impairs 
the body’s ability to provide protection from the external environment. It is therefore the body’s top 
priority to rapidly re-establish a functional epidermis. This occurs via a cascade of overlapping events, 
termed wound repair.  
Wound repair is a highly ordered biological process required for the maintenance of the skin’s 
normal barrier function. Repair is achieved via the body’s ability to replace lost structure with viable 
tissue and by formation of a scar. Wound healing occurs in four phases, which are haemostasis, 
inflammation, proliferation and remodelling. Prolonged time spent in the inflammatory or 
proliferative phase will cause delayed and poor healing, promoting excessive scar tissue formation. 
This is considered abnormal wound repair (2).  
Wounds can be divided into two main categories; acute and chronic. Acute wounds occur due 
to the result of surgery or trauma and progress through the normal stages of wound repair, healing in a 
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timely and well-organized manner. Chronic wounds fail to heal even after long periods of time and 
can be very destructive to normal skin physiology. This is generally influenced by several factors, 
including increased levels of inflammatory mediators, wound infection, hypoxia and poor nutrition. 
These are common issues occurring with age or the disease state of an individual. It is therefore 
critical that each phase of repair is supported by sufficient intracellular and extracellular signals to 
prevent inadequate or excessive activity at any key phase (5). Caring for acute and chronic wound 
sufferers is very time-consuming and costly; estimated to affect 500,000 Australians annually, leaving 
a multi-billion dollar burden on Australia’s health system (6). Optimisation of the wound healing 
environment is therefore essential to encourage accelerated repair, prevent infection and to reduce 
scarring. 
1.2 PHASES OF WOUND REPAIR 
1.2.1 Haemostasis 
Haemostasis is the first phase to occur upon onset of injury and prevents excessive blood loss (7). 
Commencing with a brief period of vasoconstriction, bleeding stops via the formation of a platelet 
plug, or clot. A clot is formed due to the binding of platelets to exposed collagen at the site of damage 
(8). Once bound, platelets change morphology and are termed ‘activated’, and must secrete a series of 
chemokines to increase platelet recruitment. This causes platelets to aggregate and a weak clot forms 
at the site of injury.  In addition, tissue factor expressed by cells surrounding the vessels, initiates the 
blood coagulation cascade for the formation of fibrin strands, as shown in Figure 1.2. Fibrin combines 
with the loosely arranged mass of platelets forming a tight plug (9) and is an important protein 
involved in repair. In addition to platelet plug fortification, it also provides a temporary matrix that 
promotes granulation tissue formation (10) and is shown to activate many cell types, including 
endothelial cells (11), smooth muscle cells (12), fibroblasts (13) and leukocytes (14). Once the clot 
has formed, the inflammatory phase can commence, initiated by the recruitment of phagocytes.  
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Figure 1.2: Haemostasis, the first phase of wound repair. Platelets aggregate at the site of injury 
forming a clot that is stabilised by fibrin strands (adapted from Beanes et al. 2003, (15)). 
1.2.2 Inflammation 
The inflammatory phase commonly develops two to five days post-injury and causes swelling, 
redness and pain at the wound site.  It is categorised into two main phases - early and late stage 
inflammation. Mast cell degranulation is an important event enhancing the early inflammatory 
response (16). Many of the mediators released via degranulation stimulate the hallmark effects of 
inflammation, such as vasodilation, vascular permeability, and activation and recruitment of 
circulating immune cells, primarily neutrophils (17). Chemical stimuli released by platelets and mast 
cells attract neutrophils to defend against microbial colonisation (18). Neutrophils form part of the 
body’s innate immunity and are capable of internalising pathogens for degradation in a process 
termed phagocytosis. Once a pathogen has been detected, the neutrophil surrounds and engulfs it. 
Inside the cell, pathogens are exposed to granules containing proteolytic and bactericidal agents, and 
consequently perish. In addition, neutrophils can kill pathogens by oxidative mechanisms, a process 
termed ‘respiratory burst’ (19). During phagocytosis, molecular oxygen is converted to reactive 
oxygen species (ROS), which can destroy pathogens within the cell (20). Neutrophils also have the 
ability to kill pathogens extracellularly via ROS generated by membrane NADPH oxidase and via the 
release of neutrophil extracellular traps, composed of a cytosolic protein complex (21).  
 
Skin Surface    Red Blood Cell    Platelet         Fibrin 
Injury Coagulation 
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Parallel to the influx of neutrophils, circulating monocytes enter the wound site and 
differentiate into mature tissue macrophages (22). Macrophages are multifunctional leukocytes, 
phagocytosing cellular debris, foreign materials and microbes (18). In addition, their role is to secrete 
requisite growth factors, as shown in Figure 1.3, that enable the transition into the proliferative and 
remodelling phases of repair. Unlike neutrophils, macrophages remain active at the site of injury for a 
longer time, forming part of late stage inflammation.   
 
 
 
 
 
 
Figure 1.3: Inflammation, the second phase of wound repair. Neutrophils and macrophages are 
recruited to the site of injury to clear cell debris and prevent infection (adapted from Beanes et al. 
2003, (15)). 
 
Although macrophages are essential in maintaining innate immunity their involvement in 
repair favours fibrosis, enhancing scar tissue formation in the final resolved wound (23). It has been 
shown, in C57BL/6 mice, that healing can be altered via the depletion of macrophages at different 
phases of repair. In that study, wounds were generated on the back of each mouse using a biopsy 
punch and macrophage depletion was induced transgenically (23). Macrophage depletion during the 
inflammatory phase significantly reduced granulation tissue formation and re-epithelialisation, while 
decreased scarring was observed. Macrophage depletion restricted to the proliferative phase caused 
severe haemorrhage at the wound tissue, preventing wound closure. In contrast, macrophage depletion 
during the remodelling phase did not significantly alter repair (23). This indicated that macrophages 
are critical in successful wound closure; however improved wound healing may be achieved by 
modulating their presence during the inflammatory phase in a controlled manner.  
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Circulating monocytes are additionally capable of differentiating in situ into dendritic cells. 
Although dendritic cells, macrophages and monocytes share phagocytic ability, dendritic cells are 
specialised cells that interconnect the innate and adaptive immune responses (24). The adaptive 
immune system is composed of two responses; humoral immunity mediated by antibodies produced 
by B lymphocytes, and cell-mediated immunity mediated by T lymphocytes. Dendritic cells 
phagocytose pathogens, degrading their proteins and presenting them to T lymphocytes. Stimulated T 
lymphocytes can be categorised into several subsets of specialised cells, however helper T cells are 
the most relevant in wound repair. Active helper T cells secrete cytokines that stimulate B 
lymphocytes to produce antibodies, binding to and marking pathogens for destruction via 
phagocytosis (25). Memory B cells, a B lymphocyte subtype, persist in the circulation and can rapidly 
stimulate antibody production when exposed to the same pathogen (24). When both the innate and 
adaptive immune systems are functioning efficiently, invading organisms are prevented from 
colonising the wound space.  For the wound healing cascade to advance into the proliferative phase, 
those inflammatory cells which were recruited in excess, must first be selectively killed via apoptosis 
(26).  
Apoptosis, or programmed cell death, is an energy-dependent biochemical mechanism 
designed to kill selective populations of cells without causing damage to surrounding tissue (27). 
Apoptosis is controlled by two pathway signals. An intrinsic mechanism commonly induced by cell 
stress, such as nutrient deprivation or hypoxia, and an extrinsic mechanism that is commonly induced 
by immune cells or cytokines (27). Once the cell commits to apoptosis a series of protease enzymes, 
called caspases, are activated and cleave intracellular proteins to cause cell death (27). Removal of 
dead cells is the final stage of programmed cell death, while uncleared cells can rapidly become 
necrotic, promoting inflammation (28). Dead cells are cleared via phagocytosis, predominantly by 
macrophages. Macrophages can target and recognise dead cells, largely apoptotic neutrophils, via a 
chemotactic gradient stimulating their migration to the apoptotic cell (28). In normal healing wounds, 
neutrophils undergo apoptosis after performing their functions. This is to prevent leakage of the 
neutrophil granule contents and oxygen metabolites that kill pathogens onto healthy tissue (26). A 
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defect in apoptosis can prolong wound closure and result in persistent inflammation, causing further 
recruitment of leukocytes (29). This can progress the wound into a chronic state, preventing cell 
proliferation for wound resolution. In normal healing wounds, the absence of neutrophils along with a 
decreased presence of macrophages at the wound site is indicative of the inflammatory phase ceasing 
and the proliferative phase commencing. 
1.2.3 Proliferation 
Proliferation is the third phase of wound healing. Several key processes, including fibroblast 
recruitment, granulation tissue formation, collagen deposition, angiogenesis and re-epithelialisation, 
occur simultaneously for wound closure (4). A variety of growth factors and proteins secreted by 
immune, endothelial and epidermal cells are responsible for these processes and are summarised in 
Table 1.1 below.  
Table 1.1 Growth factors and proteins essential for wound repair 
Growth 
factor 
Effect on repair Cell source Ref. 
PDGF Chemotactic for fibroblasts & 
smooth muscle cells. Promotes 
collagen synthesis 
Platelets, macrophages, endothelial 
cells, vascular smooth muscle cells & 
fibroblasts 
(30-32) 
EGF Mitogenic for keratinocytes, 
fibroblasts & endothelial cells 
Platelets & macrophages (18, 33) 
TGF-α Chemotactic & mitogenic for 
keratinocytes & fibroblasts 
Platelets, macrophages, fibroblasts & 
keratinocytes 
(33, 34) 
TGF-β Chemotactic for fibroblasts. 
Promotes collagen synthesis 
Platelets, macrophages, fibroblasts & 
keratinocytes 
(18, 33, 35) 
IGF-1 Mitogenic for fibroblasts & 
keratinocytes. Chemotactic for 
endothelial cells 
Platelets, macrophages & fibroblasts (33, 36) 
FGF Chemotactic for keratinocytes, 
fibroblasts & endothelial cells. 
Aids vessel formation 
Macrophages, mast cells & T-
lymphocytes 
(18, 32, 34) 
VEGF Mitogenic for endothelial cells Macrophages & keratinocytes (33) 
KGF Chemotactic & mitogenic for 
keratinocytes 
Fibroblasts (33, 34) 
Protein Effect on repair Cell source Ref. 
HIF Chemotactic & mitogenic for 
endothelial cells 
Hypoxic cells at wound site (37) 
Ang1 Endothelial cell migration, vessel 
formation & vessel stabilisation 
Pericytes (38, 39) 
Ang2 Endothelial cells (38, 39) 
PDGF: Platelet derived growth factor, EGF: Epidermal growth factor, TGF-α: Transforming growth factor alpha, 
TGF-β: Transforming growth factor beta, IGF-1: Insulin-like growth factor-1, FGF: Fibroblast growth factor, 
VEGF: Vascular endothelial growth factor, KGF: Keratinocyte growth factor, HIF: Hypoxia-inducible factor,  
Ang1: Angiopoietin 1, Ang2: Angiopoietin 2. 
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During the early proliferative phase, fibroblasts migrate to the wound centre and begin 
synthesising ECM components, forming granulation tissue. The matrix of early granulation tissue is 
composed of glycosaminoglycans and glycoproteins, predominantly hyaluronic acid and fibronectin. 
These proteins provide a ‘scaffold’ for the later fibrogenesis of type III collagen (40), as shown in 
Figure 1.4. Collagen deposition is critical in increasing the tensile strength of the wound and provides 
the required structure and support for the migration of endothelial and epithelial cells (41). In 
addition, ECM proteins bind many growth factors that can be released in a localised fashion, when the 
ECM is degraded and remodelled by matrix metalloproteinases (MMPs) (42). Granulation tissue 
formation must occur simultaneously with angiogenesis.  
 
 
 
 
 
 
Figure 1.4: Proliferation, the third phase of wound repair. Fibroblasts secrete ECM proteins 
enabling keratinocytes to migrate from the wound edge to commence gap closure (15).  
 
Angiogenesis is the growth of new blood vessels and restores the supply of oxygenated and 
nutrient-rich blood to newly formed tissue (43). Stimulated by growth factors and tissue hypoxia, 
endothelial cells migrate from pre-existing vessels through the granulation tissue and proliferate to 
create a branching network of tubular structures that mature to form new vessels (44). In parallel, 
pericytes migrate and proliferate over the diverging network of endothelial cells, stabilising new 
vessels and allow microvascular remodelling (31). Vessel branching occurs due to the local release of 
MMPs from fibroblasts, keratinocytes and endothelial cells. The MMPs digest components of the 
 
          Type III Collagen             Keratinocyte Migration                       Fibroblast 
13 
 
ECM surrounding endothelial cells and pericytes, allowing their distribution amongst the wound site 
in an organised manner (42, 45).  
Re-epithelialisation is the final process of the proliferation phase. Keratinocytes are recruited 
from both sides of the wound edge and from epithelial appendages, such as hair follicles, sweat glands 
and sebaceous glands and these cells migrate due to the stimulation of growth factors and lack of 
contact inhibition (41). Keratinocytes proliferate only at the wound edge and migrate over the 
granulation tissue, climbing over one another. The first cells reaching the wound site form the basal 
layer and keratinocytes continue this migration, layering on more cells. Migration continues until cells 
from both sides of the wound edge meet, at which point contact inhibition prevents further cell 
recruitment. Once the keratinocytes of the basal layer are anchored to the basement membrane, basal 
cells begin to divide and differentiate into the various strata constituting the normal epidermis, and the 
environmental barrier is reinstated (18, 41).  
In order to aid wound contraction, pre-existing fibroblasts either undergo apoptosis to limit 
scar tissue formation, or undergo a phenotypic differentiation into myofibroblasts.  Myofibroblasts 
share characteristics common to both fibroblasts and smooth muscle cells and can be defined as 
contractile non-muscle cells, due to their expression of alpha smooth muscle actin (α-SMA) (46). In a 
typical smooth muscle, cell contraction is rapid and short in duration, while myofibroblasts contract 
for an extended duration, causing permanent tissue retraction that is stabilised by ECM deposition to 
narrowing the wound gap (47). When the wound closes myofibroblasts undergo apoptosis, but if 
myofibroblasts persist fibrosis is promoted (48).  
1.2.4 Remodelling 
The final phase of wound repair is the remodelling phase. During this phase the granulation tissue 
matures to form a scar, capillaries remodel into larger vessels and the deposition rate of ECM proteins 
are reduced (41). In addition, the proportion of collagen types change. Type III collagen, deposited in 
a disorganised manner during the proliferative phase, is replaced by type I collagen that realigned and 
crosslinked, increasing the tensile strength of the tissue (18, 42) as shown in Figure 1.5.  
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The tensile strength of a freshly covered wound is equal to 25% of the original tissue. Although the 
tensile strength of the original tissue can never quite be regained, after many months of remodelling 
the tissue is restored to 80% of its original strength (7, 42). 
 
 
 
 
 
 
Figure 1.5: Remodelling, the final phase of wound repair. Type III collagen deposited during 
proliferation is replaced by type I collagen for increased tensile strength of the tissue (adapted from 
Beanes et al. 2003, (15)). 
1.3 FACTORS AFFECTING WOUND REPAIR 
  
The success of wound healing is influenced by a range of factors that can be characterised as either 
local or systemic. Local factors are those that directly influence healing and include oxygenation and 
infection, while systemic factors are represented by the health of an individual and include age, body 
type, nutrition, disease state and medication. Both local and systemic factors alter the efficiency of our 
body’s repair mechanisms (49).  
1.3.1 Oxygen 
Oxygen is important for cell metabolism and function.  It enables energy dependent processes 
including fibroblast proliferation, collagen synthesis and keratinocyte differentiation via the 
production of ATP (50). The role of oxygen is particularly important during inflammation (50).  
Neutrophils and macrophages arrive at the wound site and release large quantities of ROS and 
inflammatory cytokines as a result of their increased metabolic activity and oxygen uptake.  
 
     Type I Collagen 
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NADPH-oxidase, the enzyme responsible for the ‘respiratory bursts’ in neutrophils, is expressed at 
high levels in the cell membranes of inflammatory cells and facilitates the production of superoxide 
radical anions (51, 52). Although the generated ROS damage and kill invading pathogens they are 
also harmful to the proteins and DNA of healthy cells (53).  
Compared to immune cells, the quantity of ROS produced by other cell types is much lower.  
Low levels of ROS, particularly hydrogen peroxide (H2O2), also play a physiological role and 
function as cell signalling molecules. Hydrogen peroxide upregulates the production of vascular 
endothelial growth factor (VEGF) to promote angiogenesis (54) and has recently been shown to 
function as an important mediator for wound and neutrophil interaction by forming a H2O2 gradient 
that leads neutrophils to the wound site (55, 56). In addition, H2O2 stimulates the activation of EGF 
receptors (57) and stimulates TGFα production by fibroblasts (58).  
The lack of oxygen at the repair site causes tissue hypoxia due to the local disruption of the 
vasculature. As outlined in Table 1.1, hypoxia induces the release of hypoxia inducible factor (HIF) 
from oxygen deficient cells. This is a transcription factor that controls the expression of various 
angiogenic, metabolic and cell cycle genes and is responsible for increasing endothelial cell 
proliferation, migration, adhesion, sprouting and tube formation (59). However, sustained hypoxia is 
detrimental to healing. As stated above, the neutrophil killing ability is a highly oxidative mechanism 
and affects ROS production when oxygen levels are insufficient (60). A sustained hypoxic 
environment may explain the ability of bacteria to colonise a wound, delaying repair. 
It is clear that oxygen plays an important role in the wound healing process and stimulates the 
function and proliferation of key cells required for wound resolution. This is further enforced on the 
cellular level via the production of HIF to promote survival in low-oxygen conditions. It is also 
essential that an appropriate inflammatory phase transpires to ensure that the production of high 
quantities of ROS is a transient process, preserving healthy cells.  Healthy tissue with prolonged ROS 
exposure will become necrotic or apoptotic and prolong the inflammatory phase, leaving the wound 
open to infection. 
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1.3.2 Infection   
Once the skin is injured the microorganisms normally found on the skin’s surface obtain access to the 
underlying tissue. In the absence of an effective immune response microbial clearance is inadequate 
allowing infection. The state of infection can be categorised as contamination, colonisation, critical 
colonisation and wound infection (4, 61).  Contamination is defined as the presence of non-replicating 
bacteria within a wound, while colonisation is defined as the presence of replicating bacteria. Both 
contamination and colonisation do not initiate an immune response (62). In addition to the presence of 
replicating bacteria critical colonisation is usually associated with increased wound pain and the 
beginning of a local inflammatory response. Wound infection is associated with multiplication of 
bacteria causing a host immune response (4, 61, 62). Multiplying bacteria at the wound site can lead 
to the prolonged elevation of pro-inflammatory cytokines such as interlukin-1 (IL-1) and tumor 
necrosis factor-alpha (TNF-α), perpetuating the inflammatory phase by mediating the recruitment and 
activation of neutrophils and monocytes (63). Prolonged inflammation also leads to increased levels 
of MMPs that hinder the fibroblast’s ability to replace lost ECM (64). If this endures, the wound can 
enter a chronic state and fail to heal.    
1.3.3 Age 
Wounds in elderly patients require more time to heal than those of younger individuals, 
predominantly due to the effect of comorbidities that come with age. Older patients may have 
inadequate nutritional intake, altered hormonal responses, poor hydration and compromised immune, 
circulatory and respiratory systems, and an overall slower metabolism, affecting every phase of 
healing. Age related changes include increased secretion of inflammatory mediators, delayed 
infiltration and function of leukocytes, decreased secretion of growth factors and delayed re-
epithelialisation, angiogenesis, collagen deposition and remodelling (4, 65, 66). Additionally, the skin 
architecture is altered with age. There is a loss of elasticity and thinning of the dermis, making the 
elderly more susceptible to skin tears and damage. The effect of age on repair rate is clinically 
observable by age 60, and is statistically significant at age 70 (65). The difference in healing is 
especially apparent when comparing the elderly to an unborn foetus. 
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In the foetus, wounds heal by regeneration as opposed to tissue repair, resulting in scar-less 
healing (67). During regeneration, lost structure is replaced by the proliferation of similar cells; 
however postnatally humans have very limited capacity to heal by this method.  Wound regeneration 
in adults is only possible when damage to skin is superficial, leaving an intact tissue framework.  
There are vast differences in the healing response when comparing foetal regeneration with wound 
repair in adults and these are summarised in Table 1.2 below.  
When wounds damage the tissue framework, healing by regeneration is not possible in adults. 
Instead fibroblasts lay down granulation tissue, which matures to form a scar (67). Although the 
fibrous scar is not ideal it typically provides enough structural stability to re-enable function of 
damaged tissue. It is clear that age drastically alters repair mechanisms, however a greater disparity is 
evident when compounded with other factors that inhibit healing. 
Table 1.2 A comparison of foetal regeneration and adult wound repair (adapted from  
Leung et al. 2012, (68)). 
Effect on healing Foetal Adult 
Haemostasis Poor platelet aggregation Greater platelet aggregation 
Inflammation Minimal inflammatory response High levels of mast cell, neutrophil & 
macrophage recruitment 
Proliferation High hyaluronic acid expression 
Fast type III collagen deposition 
Absence of myofibroblasts 
Low hyaluronic acid expression 
Slow type III collagen deposition 
Presence of myofibroblasts 
Remodelling Low levels of collagen cross-linking High levels of collagen cross-linking 
Effect on growth  
factor secretion 
Decrease in FGF, PDGF & TGF-β 
Increase in VEGF 
Increase in FGF, PDGF & TGF-β  
Decrease in VEGF 
 
1.3.4 Obesity 
Obesity is a well-known health risk influenced by genetics, metabolism, food consumption and 
physical inactivity. The Australian Bureau of Statistics has revealed that as of 2015, 70.8% of men 
and 56.3% of women in Australia are overweight or obese (69). The body mass index (BMI) is a 
simple measure derived from the weight and height of an individual expressed in units of kg/m
2
. 
Individuals with a BMI above 30 are considered obese and risk a moderate decrease in life expectancy 
by 2 to 5 years, whilst life expectancy is significantly reduced by up to 13 years when a BMI above 40 
is maintained (70). Obesity also increases the risk of developing various chronic diseases.  
These include diabetes, hypertension, hypercholesterolemia, stroke, heart attack, osteoarthritis and 
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sleep apnoea, which can all impair wound healing. Obese individuals often present with wound 
complications which include infection, oedema and vascular insufficiency. Additional complications 
also arise in post-operative patients, such as hematoma (a swelling of clotted blood within the tissue), 
seroma formation (a collection of fluid below the skin), pressure ulcers, venous ulcers and wound 
dehiscence (a rupture of the wound along a surgical incision), which are often debilitating (71).   
Obesity is typically developed due to an imbalance in nutritional status. Consumption of large 
food portions high in calories, sugar and cholesterol are detrimental to physical health, which lead to 
metabolic disorders. Common micronutrient deficiencies include zinc, selenium, folate and vitamins 
A, B1, B12, C and D (72), some of which are required for successful wound closure. A table 
summarising these micronutrients (Table 1.3) can be found below.  
Table 1.3 The wound healing benefits of micronutrients 
Micronutrient Effect on repair Ref. 
Vitamin A Enhanced monocyte & macrophage recruitment, fibroblast proliferation & 
collagen synthesis. Assists collagen cross-linkage. Antioxidant. 
(73-78) 
Vitamin B1 Enhanced collagen deposition & maturation of granulation tissue (79, 80) 
Vitamin C Chemotactic for neutrophils. Cofactor for collagen & proteoglycan synthesis. 
Antioxidant. 
(4, 81, 
82) 
Vitamin E Antioxidant (83) 
Zinc Enhanced collagen synthesis, MMP activity & macrophage regulation  
& growth factor secretion. Antioxidant & antibacterial. 
(84-88) 
Selenium Antioxidant (85) 
 
1.3.5 Chronic Disease 
Many chronic diseases impact the body’s repair mechanisms. Among the most detrimental are 
cardiovascular conditions and diabetes. Cardiovascular conditions, which include coronary artery 
disease (CAD) and peripheral artery disease (PAD), hinder the blood flow supplying the wound site. 
CAD and PAD develop due to the build-up of cholesterol on the inner walls of blood vessels. 
Cholesterol can combine with fat, calcium, fibrous tissue and other substances in the blood to form a 
plaque. Over time the plaque enlarges, vessels harden and the arteries narrow. This process is termed 
atherosclerosis, and limits nutrient and oxygen delivery to wounded tissue, creating localised hypoxia 
(89). Low oxygen and nutrient levels at the wound site can severely hinder all phases of the wound 
healing cascade (90). Diabetes also encourages the formation of atherosclerotic plaques.  
19 
 
Diabetes is a chronic condition that prevents the body from producing or responding to the 
hormone insulin. This results in elevated levels of glucose in the blood (hyperglycemia), which can 
cause damage to major and minor vessels, promoting atherosclerosis. This often results in impaired 
wound repair typically attributed to poor oxygen delivery to the wound (91). Hyperglycemia can 
promote atherosclerosis via several methods, however the predominant method is via nonenzymatic 
glycosylation of proteins and lipids (92). Advanced glycation end products (AGEs) are proteins or 
lipids that have become glycated after exposure to sugar and cause intra- and extracellular 
dysfunction. Atherosclerosis promoting effects of AGES include collagen cross linking (93), 
enhanced ECM protein synthesis (94), trapping low-density lipoproteins (LDL) in the subendothelium 
(95), promoting inflammatory cytokine secretion (93), monocyte and macrophage chemotaxis (96), 
and increased permeability and oxidative stress of endothelial cells (97-99). In addition, 
hyperglycemia is responsible for nerve damage, called diabetic neuropathy.  
Diabetic neuropathy commonly affects the nerves of the feet and hands, causing numbness, 
tingling, discomfort, weakens and loss of sensation to the afflicted limb (100). Loss of pain and 
sensation and decreased blood supply to the body’s extremities enable the development of diabetic 
ulcers, which are prone to occurring in the feet. Lack of oxygen delivery to tissue can cause the 
breakdown of skin and necrosis, forming a hard-to-manage ulcer. These ulcers largely go unnoticed, 
due to lack of pain from peripheral nerve damage. Diabetic foot ulcers are estimated to occur in 15% 
of all diabetic patients and are the leading cause of non-traumatic amputation of the lower limb (101).  
Diabetes is a prominent cause of vascular insufficiency at the wound site, hindering  
the inflammatory phase of repair. Furthermore diabetes has also been shown to delay the  
proliferative phase. Diabetic wounds show upregulation of MMPs and decreased expression  
of key growth factors (102). Increased MMP activity enhances the breakdown of the ECM to  
prevent wound resolution, whilst differences in the cytokine profiles in the diabetic wound 
microenvironment include a reduction in PDGF, TGF-β and VEGF. Deficiencies in these  
growth factors decrease the rate of angiogenesis, fibroblast recruitment and collagen deposition. 
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Coupled with an overexpression of MMPs, wounds can enter a chronic state and have inadequate 
bacterial clearance or enhanced fibrosis (103-105) 
1.3.6 Medication 
Many medications affect the rate of wound healing, influencing clot formation, inflammatory cell 
recruitment, epithelial cell proliferation and the tensile strength of the repaired tissue. Common 
medications which have a significant impact on healing include glucocorticoid steroids, non-steroidal 
anti-inflammatory drugs and chemotherapeutic anti-cancer drugs (4). 
Glucocorticoid steroids are steroid hormones frequently used as anti-inflammatory agents for 
the treatment of autoimmune disorders, including multiple sclerosis, rheumatoid arthritis, psoriasis 
and eczema, as well as reducing pain, swelling and itching. These anti-inflammatory agents markedly 
affect most aspects of wound healing when used systemically. Glucocorticoid steroids have shown to 
delay the appearance of inflammatory cells, the deposition of ECM matrix proteins, angiogenesis, 
epithelial cell migration and wound contraction (106, 107). In some cases, wounds heal with 
incomplete granulation tissue, reducing the tensile strength of the wound (108).  
 Non-steroidal anti-inflammatory drugs (NSAIDs) include cyclooxygenase (COX) inhibiting 
drugs used to prevent the production of pro-inflammatory prostaglandins (PG). These drugs are 
commonly prescribed to temporarily alleviate arthritic and muscular pain by reducing inflammation 
and swelling (109). Similarly, systemic use of NSAIDs, e.g. ibuprofen, have demonstrated anti-
proliferative effects on wound healing, resulting in decreased or delayed platelet aggregation, 
fibroblast proliferation, angiogenesis, epithelialisation and wound contraction (110-114).  
 Other common medications affecting healing include anti-cancer drugs. Chemotherapy  
is a category of cancer treatment that utilises a drug regime to selectively kill malignant cells  
and tissue. Chemotherapeutics target rapidly dividing cells by inhibiting cellular metabolism,  
cell division and angiogenesis. However, many healthy cells and tissue throughout the body  
are also non-selectively targeted, including macrophages, fibroblasts and keratinocytes.  
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Inhibition of these cells delay clearance of bacteria, collagen synthesis, collagen deposition, re-
epithelialisation and decrease the tensile strength of the wound (115).  
 It is evident that the mechanisms of repair can be severely hindered via a range of local or 
systemic factors. Factors such as age, obesity, chronic disease, prescription medication, poor oxygen 
delivery and infection can all influence the transition of acute to chronic wounds, which typically 
require medical intervention. Intervention is possible via modulation of the inflammatory cascade, the 
wound microbiology and the levels of ROS at the site of repair.   
1.4 MODULATING WOUND REPAIR 
1.4.1 Inflammatory cascade 
The inflammatory cascade is a biological response initiated by harmful stimuli to the body. These 
stimuli include irritants, damaged cells and pathogens that the body is required to eradicate. As 
described in Section 1.2.2, inflammation is crucial for wound resolution, but is destructive if 
exacerbated. A schematic summarising the production of pro-inflammatory mediators is shown 
below. 
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Figure 1.6: The inflammatory pathways demonstrating pro-inflammatory mediator production. 
Arachidonic acid (AA), an ω-6 polyunsaturated fatty acid (PUFA), is released from the cell 
membrane when cleaved by phospholipase A2 (PLA2) and modified by 5-lipoxygenase (LOX) and 
cyclooxygenase (COX) into active mediators called eicosanoids, which include: leukotrienes (LT) 
prostaglandins (PG) and thromboxane A2 (TXA2). (Compiled from ref. (116-119)). 
 
As shown in Figure 1.6, pro-inflammatory LTs and PGs increase vascular permeability, 
leukocyte-endothelium adhesion and chemotaxis. Increased vascular permeability facilitates the 
migration of leukocytes, predominantly neutrophils, into the wound site from local vessels. This is 
supported by the upregulation of adhesion proteins expressed on the surface of both neutrophils and 
endothelial cells (116). Circulating neutrophils attach to the endothelium and migrate into the 
interstitium through gaps between adjacent endothelial cells (120). This process is amplified when 
newly recruited neutrophils secrete a potent chemoattractant, LTB4, which further recruits 
inflammatory cells (116).  Furthermore, recruited immune cells secrete pro-inflammatory cytokines 
enhancing the inflammatory cascade. Table 1.4 summarises the pro-inflammatory cytokines typically 
secreted by cells found in the wound microenvironment. 
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Table 1.4 Common pro-inflammatory cytokines released by cells during wound repair 
Cytokine Role in inflammation Cell source Ref. 
Tumor necrosis 
factor alpha  
(TNFα) 
Activates NF-κB to induce expression of 
pro-inflammatory genes including cytokines, 
chemokines & adhesion molecules 
Mast cells, neutrophils, 
macrophages & endothelial cells 
(121-
124) 
Interleukin-1α  
(IL-1α) 
Induces COX synthesis for PGE2 production 
& TNFα release from endothelial cells 
Mast cells, neutrophils, 
macrophages, monocytes, 
fibroblasts, keratinocytes & 
endothelial cells 
(125) 
Interleukin-1β  
(IL-1β) 
Induces gene expression & synthesis of 
cyclooxygenase type 2 (COX-2), PLA2 & 
inducible nitric oxide synthase (iNOS) for 
PGE2, platelet activating factor (PAF) & 
nitric oxide (NO) production respectively. 
Also increases the expression of adhesion 
molecules on endothelial cells to promote 
leukocyte infiltration 
Mast cells, neutrophils, 
macrophages, monocytes, 
fibroblasts, keratinocytes & 
endothelial cells 
(125-
127) 
Interleukin-6  
(IL-6) 
Stimulates acute phase protein production. 
Induces IL-8 & MCP-1 release from 
endothelial cells 
Neutrophils, monocytes, 
macrophages, T-cells & 
endothelial cells 
(128) 
Interleukin-8  
(IL-8) 
Induces neutrophil chemotaxis & respiratory 
burst 
Macrophages, epithelial cells & 
endothelial cells 
(129-
131) 
Monocyte 
chemoattractant 
protein -1 
(MCP-1) 
Induces monocyte, dendritic cell & natural 
killer cell chemotaxis 
Monocytes, macrophages, 
dendritic cells, fibroblasts, 
keratinocytes & endothelial cells 
(132, 
133) 
 
 
1.4.2 Anti-inflammatories     
Anti-inflammatories are agents designed to reduce the inflammatory response systemically or at 
targeted locations in the body by reducing immune cell infiltration, thus lowering pain and swelling. If 
the increased vessel permeability, neutrophil infiltration and pro-inflammatory mediator production 
persist, then chronic wound formation is encouraged, arresting wounds in the inflammatory phase 
(134). Therefore, anti-inflammatories possess the ability to assist the progression of wounds into the 
proliferative phase of repair.   
As highlighted above, in Section 1.3.6, anti-inflammatory drugs can severely hinder the 
healing cascade when prescribed to immunocompetent individuals (106-108, 110-114).  However, 
when inflammation is exacerbated, downregulation of the inflammatory response is favourable. The 
literature demonstrates that reduced wound inflammation is achievable via the use of various natural 
products and therapeutic agents. Examples can be found summarised in Table 1.5 below.   
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Table 1.5 Anti-inflammatory agents with chronic wound healing ability  
Product Class Origin Administrative 
Route 
Effect on repair Ref. 
Axaven® Flavonoid & saponin 
combination 
Plant Oral Reduced expression of 
MMPs & inflammatory 
cytokines: TNF-α, IL-6 
& IL-8 
(135) 
Neurotensin Neuropeptide Synthetic Topical dressing Reduced expression of 
MMPs & inflammatory 
cytokines: TNF-α, IL-1α, 
IL-1β & MCP-1 
(136, 
137) 
Doxycycline Tetracycline antibiotic Synthetic IV & oral Inhibition of MMPs & 
suppression of PLA2, 
TNF-α, IL-6 & IL-1β 
(138-142) 
Inflixmab Monoclonal antibody Synthetic IV Binds & inhibits TNF-α (143, 
144) 
Aloe vera 75 active constituents. 
Alprogen, bradykinase, 
salicylic acid, lupeol, 
β-sitosterol, & camper-
sterol believed to be anti-
inflammatory 
Plant Topical Inhibition of mast cell 
degranulation & PGE2 
production via COX-2 
(145-150) 
Curcumin Diarylheptanoid Plant Oral & Topical Inhibition of iNOS,  
NF-κB & the COX-2 & 
LOX pathways 
(151-153) 
Emu oil Saturated & unsaturated 
fatty acids, which include 
oleic acid, linoleic acid & 
linolenic acid 
Animal Oral & Topical Reduced expression of  
TNF-α 
(154-158) 
 
As noted in Table 1.5, commonality is found in these agents via their ability to reduce or 
inhibit the production of pro-inflammatory cytokines.  Although these agents can assist progression of 
the wound healing cascade they are not often first-line medicines. Over-inhibition of the inflammatory 
cascade can cause an equivalent deleterious effect on the wound microenvironment and an accurate 
preparation of these anti-inflammatory products is essential (4). Consequently, both an over- or under-
stimulated inflammatory response can suspend wound resolution and encourage colonisation by 
opportunistic microorganisms, thus further jeopardizing the closure of chronic wounds. 
1.4.3 Wound microbiology      
As mentioned in Section 1.3.2, unrestricted growth of microorganisms can hinder wound  
closure due to an exacerbated and prolonged inflammatory phase. Wound infection is a leading cause 
of chronic wound formation. The primary pathogens of concern are Staphylococcus aureus (S. 
aureus), Streptococcus pyogenes (S. pyogenes), Escherichia coli (E. coli), Proteus, Klebsiella, 
Pseudomonas aeruginosa (P. aeruginosa), Acinetobacter baumannii (A. baumannii) and 
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Stenotrophomonas maltophilia (S. maltophilia) (159). When a break in the skin occurs, these 
pathogens gain access to the underlying tissue, which provides a moist, warm and nutrient rich 
environment that supports microbial colonisation and proliferation. Wounds are primarily 
contaminated with microbes common to the normal skin flora, which include Staphylococcus 
epidermidis (S. epidermidis) and Proprionibacterium acnes (P. acnes), however when repair is 
delayed, the microbial flora of the wound alters and more invasive species are introduced (159, 160). 
Table 1.6, below summarises these bacteria. 
Table 1.6 Common bacteria found in acute and chronic wounds 
Species Gram Shape Metabolism Distribution Prevalence Ref. 
S. aureus +ve Coccus Facultatively 
anaerobic 
Skin Chronic wounds (161-165) 
S. epidermidis +ve Coccus Facultatively 
anaerobic 
Skin & mucosa Acute wounds (166) 
S. pyogenes +ve Coccus Aerobic Skin Chronic wounds (162) 
E. coli -ve Bacillus Facultatively 
anaerobic 
GIT Chronic wounds (163, 164, 
167) 
Proteus -ve Bacillus Facultatively 
anaerobic 
GIT, soil & water Chronic wounds (164, 165, 
168) 
Klebsiella -ve Bacillus Facultatively 
anaerobic 
GIT, soil, water & 
mucosa 
Chronic wounds (164, 169) 
P. aeruginosa -ve Bacillus Aerobic Soil, water & 
plants 
Chronic wounds (160, 161, 
163-165) 
A. baumannii -ve Cocco-
bacillus 
Aerobic Soil & water Chronic wounds (160, 170) 
S. maltophilia -ve Bacillus Aerobic Soil, water & 
plants 
Chronic wounds (160, 171) 
P. acnes +ve Bacillus Aerotolerant 
anaerobic 
Skin & GIT Acute wounds (172) 
 
If wounds remain chronic, infection is often polymicrobial, encouraging microbial synergy.  
Microbial synergy is a phenomenon in which aerobic and anaerobic microbes support the survival and 
proliferation of one another. This is accomplished via three mechanisms. Oxygen consumption by 
aerobic bacteria can induce tissue hypoxia, creating favourable conditions for anaerobic proliferation. 
Once established, anaerobes can inhibit phagocytosis of cohabiting microorganisms via the 
production of short chain fatty acids (SCFAs). These bacterial fatty acids are major by-products of 
anaerobic fermentation and have been shown to inhibit chemotaxis of neutrophils and phagocytosis of 
E. coli and S. aureus (173, 174). In addition, nutrient production from one microorganism may 
support growth and proliferation of another (159). Cohabiting is often seen in the case of S. aureus 
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and P. aeruginosa, which are the most common bacteria isolated from chronic wounds which prevent 
healing (161). In an immunocompromised host, an infection can progress into deeper tissue, become 
systemic and life threatening. In order to aid wound closure topical antimicrobials are available to 
assist in the treatment of severely infected wounds.  
1.4.4 Antimicrobials  
Antimicrobials are agents that kill or inhibit the growth of microorganisms. They can be characterised 
as disinfectants, antiseptics or antibiotics. Disinfectants refer to agents that destroy microbes on 
inanimate objects, while antiseptics, usually applied topically, prevent the growth and development of 
microorganisms without necessarily killing them. Antibiotics kill and stop the growth of bacteria and 
are used both topically and systemically. Many disinfectants and antiseptics have broad-spectrum 
antimicrobial activity, and can be characterised as bactericidal, fungicidal, virucidal or sporicidal 
when they kill microbes, and bacteriostatic, fungistatic, virustatic or sporistatic if they inhibit their 
growth (175).  
Certain microbes are very resilient at the wound site and intervention is often required to 
preserve life. Antiseptics, commonly impregnated in wound dressings, are advantageous over 
antibiotics as there is a reduced chance of resistance (176). Other ideal characteristics of antimicrobial 
agents include rapid bactericidal action, broad spectrum activity, minimal host cell toxicity and low 
cost (177). Numerous studies have shown that various antiseptics and antibiotics can facilitate wound 
closure, however their effect on wound healing is often overlooked. In clinical practice, antiseptics 
and antimicrobials are broadly used for wound care however a greater concern regarding their effect 
on human cells is required. Table 1.7 summarises these agents below. 
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Table 1.7 Commonly prescribed antiseptics and antimicrobials for clinically infected wounds 
Name Class Type Bacterial 
Spectrum 
Formulation(s) Advantages (A) / 
Disadvantages (D) 
Potential side effects Effect on repair Ref. 
Acetic acid Carboxylic acid Antiseptic Gram +ve & 
gram –ve 
0.25%, 0.5% & 
1% Solution 
(A): Inexpensive. 
(D): Limited clinical activity 
against biofilm. 
Skin irritation (pain & 
redness), haematuria & 
metabolic acidosis. 
Impaired function of 
neutrophils.  Fibroblast 
toxicity. Reduced re-
epithelialisation. 
(178-
181) 
Iodine (I) Halogen Antiseptic Gram +ve & 
gram -ve 
Povidone iodine: 
dressing, cream, 
1%, 5% & 10% 
ointment, 1% & 
10% solution 
(A): Resistance very rare. 
Inexpensive. Antifungal & 
antibacterial. 
(D): Iodine interacts with 
starches in dressings. 
Metabolic acidosis & 
hypersensitivity. 
Reduced MMP activity. 
Impaired proliferation 
& migration of fibro-
blasts. Reduced wound 
tensile strength. 
(182-
184) 
Antiseptic Gram +ve & 
gram -ve 
Cadexmer iodine: 
dressing, 0.9% 
ointment cream & 
solution 
(A): Antibacterial, antifungal 
& antiviral. 
(D): Undesirable interaction 
with sulphonamides. 
Stinging, erythema & 
hypersensitivity. 
No significant decrease 
in repair rate. Evidence 
of enhanced repair. 
(185-
188) 
Silver (Ag
+
) Transition metal Antiseptic Gram +ve & 
gram -ve 
Ionic silver (Ag
+
): 
dressing 
(A): Antibacterial, antiviral 
& Anti-inflammatory. 
(D): Inability to penetrate 
deep tissue. Bioaccumulation 
not well defined. Expensive. 
Skin staining. Impaired proliferation 
of fibroblasts. Reduced 
re-epithelialisation. 
 
(189-
192) 
Antiseptic Gram +ve & 
gram -ve 
Silver sulfadia-
zine: dressing & 
1% cream & 
ointment 
(A): Antibacterial, antifungal 
& antiviral. 
(D): Some pseudomonal 
resistance. 
Skin irritation (pain, 
burning & itching) & 
staining. 
Fibroblast toxicity. (193-
195) 
Chlorhexidine Biguanide Antiseptic Gram +ve & 
gram -ve 
4% foam, 2% & 
4% Solution & 
dressing 
 
(A): Inexpensive. Residual 
skin activity.  Alternate to (I) 
(D): Evidence of antibiotic 
resistance. 
Skin irritation (burning, 
itching, blistering & 
redness) & hyper-
sensitivity. 
Impaired proliferation 
of fibroblasts. 
(183, 
196-
199) 
Hexachloro-
phene 
Biguanide Antiseptic Gram +ve & 
gram -ve 
0.23% foam, 
2.5% gel & 3% 
solution 
(A): Residual skin activity 
(D): Evidence of antibiotic 
resistance. Expensive. 
Skin irritation (itching).  
Neurotoxicity & photo-
sensitivity. 
Not evaluated. (200-
202) 
Potassium 
permanganate 
Oxidising agent Antiseptic Gram +ve 0.01% Solution (A): Inexpensive. Antifungal 
& antibacterial. 
(D): Relatively weak agent 
Corrosive to skin (pain 
& redness), & causes 
staining. 
Reduction in exudate. (203, 
204) 
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Name Class Type Bacterial 
Spectrum 
Formulation(s) Advantages (A) / 
Disadvantages (D) 
Potential side effects Effect on repair Ref. 
Sodium 
hypochlorite 
(Dakin’s 
solution) 
Oxidising agent Antiseptic Gram +ve & 
gram -ve 
0.125%, 0.25% & 
0.5% Solution 
(A): Inexpensive. Antifungal, 
antibacterial. 
(D): Prolonged contact 
required for effect & 
inactivated by pus. 
Severe skin irritation 
(pain, burn & 
blistering). 
Blood clot lysis. Fibro-
blast, keratinocyte & 
endothelial cell toxicity. 
Impaired neutrophil 
migration. 
(205-
208) 
Hydrogen 
peroxide 
Oxidising agent Antiseptic Gram +ve & 
gram -ve 
1% cream, 1% & 
3% Solution 
(A): Inexpensive. Broad 
bactericidal activity. 
(D): Limited clinical studies. 
Skin irritation (redness 
& stinging). 
Impaired proliferation 
& migration of 
fibroblasts. 
(183, 
209) 
Cetrimide Cationic 
surfactant 
Antiseptic Gram +ve & 
gram -ve 
0.1% – 1%  
solution & 0.5% 
cream 
(A): Antibacterial & anti-
fungal. Residual skin 
activity. 
Skin irritation (redness 
& burning) & hyper-
sensitivity. 
Impaired formation & 
damage of granulation 
tissue. 
(198, 
199, 
210-
212) 
Chitosan Polysaccharide Antiseptic Gram -ve. 
Limited use on 
gram +ve 
0.01-1% cream 
2% gel & dressing 
(A): Antibacterial & anti-
fungal. 
(D): Only effective in an 
acidic medium 
None reported. Chance 
of allergy due to its 
source from the outer 
skeleton of shellfish. 
Enhanced granulation 
tissue formation & 
improved re-
epithelialisation. 
(213-
216) 
Bacitracin Cyclic 
polypeptide 
Antibiotic Gram +ve Ointment  
500 units/g 
(A): Inexpensive. Activity 
not impaired by pus or blood.  
(D): Evidence of antibiotic 
resistance. 
Skin irritation (rash, 
hives & itching) & 
hypersensitivity. 
Improved re-
epithelialisation. May 
inhibit contraction of 
wound. 
(217-
222) 
Fusidic acid Fusidane Antibiotic Gram +ve 250 mg tablet  
& 2% ointment, 
solution & cream 
(A): Penetrates both intact & 
damaged skin. 
(D): Staphylococci resistance 
Skin irritation (itching, 
(redness & hives) & 
hypersensitivity. 
Enhanced proliferation 
of fibroblasts & less 
collagen deposition. 
(223-
226) 
Gentamicin Aminoglycoside Antibiotic Gram +ve & 
gram -ve 
10 & 40 mg IV  
& IM injection, 
0.1% cream  & 
ointment 
(A): Inexpensive. Broad 
bactericidal activity. 
(D): Risk of systemic 
resistance. 
Discomfort at injection 
site (pain & redness), 
vomiting & fatigue. 
Improved re-
epithelialisation. 
(195, 
227-
229) 
Neomycin Aminoglycoside Antibiotic Gram -ve. 
Limited use on 
gram +ve 
500 mg tablet & 
0.5% ointment 
(A): Inexpensive. Low 
incidence of bacterial 
resistance. 
Muscle twitching, 
weakness & seizures. 
Hypersensitivity. 
Improved re-
epithelialisation. 
(222, 
230, 
231) 
Mafenide acetate Sulfonamide Antibiotic Gram -ve. 
Limited use on 
gram +ve 
5% solution  & 
8.5% cream 
 
(A): Broad bactericidal 
activity. Not impaired by pus 
or tissue exudates. 
(D): Expensive. 
Skin irritation (redness 
& burning) & hyper-
sensitivity. Evidence of 
systemic absorption. 
Inhibited re-
epithelialisation. 
(232, 
233) 
Table 1.7 (Continued) 
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Name Class Type Bacterial 
Spectrum 
Formulation(s) Advantages (A) / 
Disadvantages (D) 
Potential side effects Effect on repair Ref. 
Metronidazole Nitroimidazole Antibiotic Gram +ve 
& some -ve 
anaerobes 
250, 375, 500 mg 
tablet, 1% gel, 
0.75% cream 
(A): Antibiotic & anti-
protozoal.  
(D): Risk of antibiotic 
resistance. Metabolised to a 
carcinogen. Expensive. 
Skin irritation (redness 
& itching), nausea & 
peripheral neuropathy. 
Improved re-
epithelialisation. 
Delayed myofibroblast 
migration. 
(234-
238) 
Nitrofurazone Nitrofuran Antibiotic Gram +ve & 
gram -ve 
0.2% ointment, 
solution & cream 
(A): Broad bactericidal 
activity.  
(D): Risk of antibiotic 
resistance. 
Skin irritation (redness, 
itching, & swelling) & 
hypersensitivity. 
Facilitates formation of 
granulation tissue. 
(239-
241) 
Retapamulin Pleuromutilin Antibiotic Gram +ve 1% ointment (A): Low incidence of 
resistance.  
(D): Relatively expensive. 
Skin irritation (redness, 
burning & swelling) & 
hyper-sensitivity. 
Not evaluated. (242-
245) 
Table 1.7 (Continued) 
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It is evident in the literature that many methods are available to control the growth and 
proliferation of microbes. However, selectivity of these agents is crucial. It is clear that no single 
agent possess all the qualities of an ideal antimicrobial agent and many show counterintuitive qualities 
to repair mechanisms. Persistent microbial colonisation also ensures an active inflammatory response 
and thus the production of large quantities of ROS that are detrimental to host tissue.  
1.4.5 Antioxidants 
As described in Section 1.3.1 oxygen plays a vital role in the wound healing cascade. It’s essential for 
energy production and cell function, and it’s required for ROS production in host immunity. 
Therefore the wound healing cascade can be severely impaired in its absence. As noted, high levels of 
ROS are produced at the wound site with the primary intention of eliminating pathogens. In excess, 
ROS delay repair, but their amount is typically controlled by a series of cellular enzymes.  
Superoxide radical anions are the primary ROS produced from oxygen via a single electron reduction 
(51). To avoid tissue injury, excessively produced superoxide anions are dismutated to H2O2 by 
superoxide dismutase (SOD), which can be cleared by several pathways. SOD has three family 
members; SOD1 is located in the cytoplasm, SOD2 in the mitochondria and SOD3 is extracellular, 
and all together they form an important antioxidant defence in living cells. H2O2 is converted to water 
(H2O) via two electron reductions, catalysed by several enzyme families including: peroxiredoxins 
(PRDX), glutathione peroxidase (GPX) and catalase (246). This avoids the formation of hydroxyl 
radicals (•OH) resulting from a single electron reduction of H2O2. If dysfunction or overload of these 
enzymes occur, ROS species are able to accumulate and cause oxidative tissue injury.  
Due to the important antioxidant features of SOD its expression is particularly significant in wound 
repair. Consequently, when SOD is deficient, healing is impaired (247).  Furthermore, elevated 
expression of SOD and GPX in the wound microenvironment have been reported, validating their 
importance (248).  Although high levels of ROS can inhibit the ROS-scavenging ability of these 
enzymes (249-251).    
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Antioxidants help control oxidant stress at various locations in the body and their ability to 
prevent cardiovascular disease, cognitive impairment and cataracts is well recognised (252-257). 
However, investigating their potential on the wound healing environment is a novel area.  Antioxidant 
modulated repair may prevent chronic wound formation and increase both healing time and quality of 
repair via preventing oxidative host tissue injury that exacerbates the inflammatory phase and 
promotes scarring.  
A limited number of studies have demonstrated the effect of antioxidants on the wound 
healing microenvironment. Table 1.8 summarises their effect on healing and can be found below. 
Table 1.8 The effect of antioxidants on wound repair 
Name Class Effect on repair Ref. 
Curcumin Diarylheptanoid Shown to increase migration of macrophages & fibroblasts, 
enhance epithelialisation, collagen deposition & wound tensile 
strength, increase TGF-β and fibronectin expression and 
decrease the expression of pro-inflammatory cytokines & 
enzymes including: TNF-α, IL-β and MMPs.  Activity is a 
combination of its anti-inflammatory & antioxidant properties. 
(152, 
258, 
259) 
Lipoic acid Octanoic acid Shown to reduce cellular damage caused by lipid & DNA 
oxidation in patients undergoing hyperbaric oxygen therapy, 
upregulate α-SMA and VEGF expression & protect 
endothelial cells from oxidant injury. 
(260-
262) 
Uric acid 
analogue 
(6, 8-dithio-UA) 
Heterocyclic 
compound 
Formerly studied for its protection of neural cells against 
oxidative damage. Shown to improve migration & 
proliferation of fibroblasts, keratinocytes & endothelial cells & 
shown to increases SOD expression in mouse wound tissue.  
(263) 
 
Although very few studies have looked at the benefits of antioxidants in wound healing it is 
clear they show potential for aiding rapid repair of both acute and chronic wounds. It is also likely that 
antioxidant therapy could provide a more precise control of the wound microenvironment over anti-
inflammatory agents. Misjudging anti-inflammatory therapy is expected to severely impair healing 
due its action on host immunity. Although ROS are transiently essential for immune cell function, 
immune cells such as neutrophils and macrophages have multiple methods of eliminating bacteria and 
can switch between oxidative and proteolytic mechanisms (264, 265).  
1.5 MARINE OIL EXTRACT: CO2 OIL  
 
Studies over recent decades have discovered a link between inflammation and nutrition. In particular, 
the Mediterranean diet is advocated for protection against the development of chronic inflammatory 
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diseases (266). This led to the increased attention that marine oils receive today. Their benefit resides 
in their rich source of C 20 and C 22 carbon omega-3 PUFA’s, i.e. eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA), respectively. In particular, EPA’s role as a precursor for the synthesis 
of less inflammatory eicosanoids has profound implications for health and disease (267).  
It has been shown that EPA and DHA can assist in the treatment and prevention of 
inflammatory, cardiovascular and Alzheimer’s disease, and provide benefit in foetal development and 
ageing (268, 269). More recently, their potential for wound healing has been explored (270).   
Carbon dioxide (CO2) oil (Lyprinol
®
) is an omega-3 fatty acid-enriched product extracted 
from the New Zealand Green Lipped Mussel (NZGLM), Perna canaliculus. It is manufactured via 
supercritical fluid extraction with liquid CO2 and is a mixture of five main lipid classes, including: 
sterol esters, triglycerides, free fatty acids, sterols and polar lipids (271). CO2 oil’s bioactivity resides 
in its fatty acid class and is a potent source of both EPA and DHA (272-275). The literature 
demonstrates its ability to assist in various inflammatory conditions and are summarised in Table 1.9 
below.  
Table 1.9 The effect of CO2 oil on inflammatory disease 
Disorder Study Result Ref. 
Osteoarthritis 60 patients with symptomatic 
osteoarthritis of the knee & hip 
received 2 lyprinol® capsules, twice 
daily, for 4 or 8 weeks. 
Lyprinol® caused pain relief in 53% of 
patients assigned to a 4 week regime and 
80% of patients on an 8 week regime. 
(272) 
Rheumatoid 
arthritis 
Acute rear paw swelling was induced 
in female Wistar rats & orally 
administered CO2 oil assessed for its 
ability to assist in prophylactic & 
therapeutic models of rheumatoid 
arthritis. 
In the prophylactic model, CO2 oil (15 
mg/kg) outperformed aspirin (300 mg/kg) 
& ibuprofen (50 mg/kg) in reducing rear 
paw swelling. Similarly, In the therapeutic 
model CO2 oil (20 mg/kg) outperformed 
ibuprofen (40 mg/kg) & other marine oils 
(1850 mg/kg). 
(273) 
Inflammatory 
bowel disease 
C57BL/6 mice were gavaged daily 
for 13 days with Lyprinol® & 
consumed 2% dextran sulfate sodium 
(DSS), starting day 7, to create a 
model of inflammatory bowel 
disease. 
Body weight was recorded daily, colonic 
damage determined histologically. 
Lyprinol reduced body weight loss & crypt 
area loss when compared to standard fish 
oil.  
(274) 
Asthma 71 children, aged 6 to 13, received 
either 2 lyrpinol capsules, twice 
daily, or a placebo. Patients were 
maintained on beta-agonist therapy & 
inhaled corticosteroid. 
Lyprinol® improved the percentage of 
children reporting no trouble with their 
asthma at 12 weeks (97% vs 76%), with 
fewer mild & moderate asthma 
exacerbations occurring in the Lyprinol® 
treated group. 
(275) 
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CO2 oil exerts its therapeutic activity via modulation of the inflammatory cascade. As shown 
in Figure 1.7, PLA2 cleaves AA, an ω-6 PUFA, from the cell membrane of immune cells for the 
production of pro- inflammatory LTs and PGs. CO2 oil is able to reduce inflammation via utilising 
EPA, an ω-3 PUFA, as an alternative substrate to AA for the production of mediators with reduced 
affinity for eicosanoid receptors (271, 276, 277).  A comparison of the inflammatory mediators 
produced can be found in Figure 1.7 below. 
 
 
 
 
 
 
 
 
  
Figure 1.7: A comparison of the pro-inflammatory and less inflammatory pathways. Arachidonic 
acid metabolism by 5-lipoxygenase (5-LOX) and cyclooxygenase (COX) produces pro-inflammatory 
series 4 LTs and series 2 PGs. Alternatively, when eicosapentaenoic acid is utilised as a substrate for 
5-LOX and COX metabolism, the less inflammatory series-5 LTs and series-3 PGs are produced. 
(Compiled from ref. (271, 276)).  
 
CO2 oil may have potential for enhancing wound healing potential via its potent anti-
inflammatory properties. Existing anti-inflammatories, such as glucocorticoid steroids and NSAIDs 
are unsuitable for wound management, as they display deleterious effects on core healing processes, 
such as platelet aggregation, angiogenesis, epithelial cell migration, fibroblast proliferation and 
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wound contraction (106, 107, 110-114), as described in Section 1.3.6. In addition, glucocorticoid 
steroids can encourage diabetes (278), high blood pressure (279) and weight gain (280), whilst 
NSAIDs can induce stomach ulcers (281), dizziness (282) and hypersensitivity (283). In contrast, CO2 
oil has yet to display any side effects in the literature.  
Two functional forms of cyclooxygenase are found in the human body. The constitutive 
cyclooxygenase type-1 (COX-1) and the inducible cyclooxygenase type-2 (COX-2).  COX-1 
maintains the normal lining of the stomach and platelet function, whereas COX-2 is primarily present 
at the site of inflammation (284). Selective inhibition of COX-2 is therefore more desirable in wound 
healing. It has been shown that the stomach mucosa and aggregation of platelets is unaffected in CO2 
oil treated rats (273), indicating activity is directed more towards COX-2.   
CO2 oil therefore presents itself as a suitable candidate for the treatment of chronic wounds. It 
is more potent than other marine oils (273, 274) and the familiar over-the-counter anti-inflammatories, 
such as aspirin and ibuprofen (273), which are non-selective COX inhibitors. In addition, its anti-
inflammatory properties are elicited via the production of significantly less potent mediators acting as 
partial agonists (276), and not via complete inhibition of the inflammatory cascade (277).  
It is therefore likely that CO2 oil can permit better modulation of the inflammatory cascade when it is 
exacerbated and thereby aid in wound resolution.  
1.6 SHARK BILE STEROL: 5β-SCYMNOL 
 
As described in Section 1.4.5, free radicals have a dual function in the body and are both beneficial 
and destructive. In excess, free radicals cannot be readily destroyed before they react with important 
cellular macromolecules and their accumulation causes oxidative stress. Antioxidants are naturally 
found both intra- and extracellularly, however if overloaded, their free radical scavenging ability is 
compromised, necessitating an external supply through foods and supplements (285).  
 5β-scymnol sulfate ([24R]-3α,7α,12α,24,26-pentahydroxy-5β-cholestan-27-yl hydrogen 
sulfate)  is a naturally occurring C27 bile alcohol found in sharks and rays. It is one of the active 
constituents of ‘deep sea shark liver oil’, which is a Japanese traditional medicine consumed  
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orally and applied topically for the treatment of various conditions, including: liver disease, digestive 
system disorders, scalds, burns and acne (286). 5β-scymnol ([24R]-5β-cholestane-
3α,7α,12α,24,26,27-hexol ) is derived from the hydrolysis of 5β-scymnol sulfate and a comparison of 
their structures can be found in Figure 1.8.  
 
 
 
 
 
 
Figure 1.8: Chemical structures of 5β-scymnol and 5β-scymnol sulfate (287). 
 
5β-scymnol is a potent free radical scavenger, which is attributed to its aliphatic tri-alcohol 
moiety attached to its steroid backbone (288). It has also demonstrated other bioactivities with 
beneficial implications for health. Its biological effects are summarised in Table 1.10 below. 
Table 1.10 The biological effects of 5β-scymnol 
Effect Study Result Ref. 
Antioxidant 5β-scymnol’s •OH quenching ability 
was compared to 3 pycnogenol 
preparations, dimethyl sulfoxide, 
mannitol & Trolox in a •OH 
generating deoxyribose degradation 
system. 
5β-scymnol was more potent than the 
pycnogenol preparations, which are 
marketed as potent radical scavengers. 
5β-scymnol surpassed the •OH radical 
quenching ability of dimethyl sulfoxide, 
mannitol & Trolox. 
(288) 
Anti-
inflammatory 
The effect of 5β-scymnol on  
IL-1α mediated TNF-α release from 
UVB-irradiated human melanocyte 
derived cells was investigated in 
vitro. 
5β-scymnol inhibited TNF-α secretion 
from UVB exposed & IL-1α treated human 
epidermal melanocytes by 76% when 
compared to control. 
(289) 
Hepato-
protective 
An in vivo mouse acute 
hepatotoxicity model was induced by 
ip injection of high dose paracetamol 
(350 mg/kg). 
5β-scymnol at 20, 35 & 70 mg/kg 
significantly decreased the serum activity 
of 3 enzymatic markers of liver damage & 
remained hepatoprotective 4 hrs after 
paracetamol induce hepatotoxicity. 
(290) 
R1 = H, R2 = H = 5β-scymnol 
R1 = SO3H, R2 = H = C24R, C25S-5β-scymnol sulfate 
R1 = H, R2 = SO3H = C24R, C25R-5β-scymnol sulfate 
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Effect Study Result Ref. 
Anti-acne 10 females topically applied natural 
[24R] scymnol sulfate or synthetic 
[24R] 5β-scymnol to one side of their 
face, twice daily, for 28 days. 
Synthetic [24RS] racemic 5β-
scymnol was similarly applied & 
tested for 42 days. 
Each formulation reduced both sebum 
secretion & facial acne. 
Synthetic (24R) 5β-scymnol & natural 
(24R) scymnol sulfate were equipotent. 
The non-natural (24S) in the racemic 5β-
scymnol formulation had no adverse 
effects. 
(291) 
Peripheral 
artery disease 
An in vivo rat prophylactic peripheral 
arterial occlusion model was induced 
via iv injection of 5% lactic acid into 
the femoral artery. 
10 mg/kg 5β-Scymnol sulfate was 
orally administered 8 days prior to 
arterial occlusion & throughout the 
14 day trial. 
5β-Scymnol significantly inhibited lower 
limb lesion development. 
5β-Scymnol showed equipotency with 2 
clinically relevant antithrombotic drugs; 
Argatoroban & Ticlopidine. 
(292) 
 
As previously described, oxidative stress in the wound healing environment suspends repair 
processes due to local oxidative tissue damage.  It is therefore likely that 5β-scymnol can assist acute 
and chronic wounds due to its potent free radical scavenging ability, and prevent damage to essential 
cells that are crucial to well-organized repair. Its capacity to assist repair is further supported by its 
potential anti-inflammatory activity. Furthermore, other bile steroid compounds have been shown to 
enhance epithelial cell proliferation and migration in vitro and in vivo (293-296), which suggests  
5β-scymnol may benefit the wound healing environment beyond its known capabilities.  
1.7 NANOPARTICLE: ZINC OXIDE (ZnO) 
 
Nanoparticles are materials with three dimensions of 100 nm or less and exhibit novel properties that 
differentiate them from their bulk material (297). As a material approaches the nanoscale, its physical, 
chemical or biological activity changes as the surface area in relation to volume exponentially 
increases (298). Therefore, the size or scale of the particle can be classed as its most important 
feature. 
 Nanoparticles have many potential biomedical, environmental, industrial, agricultural and 
electronic applications. Their use in biology and medicine include drug and gene delivery (299), bio-
detection of pathogens (300) and proteins (301), separation and purification of molecules and cells 
(302), phagokinetic studies (303) and magnetic resonance image (MRI) contrast enhancement (304).  
Table 1.10 (Continued) 
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The biocompatibility of natural and synthetic biomaterials has also driven their use in 
prostheses (305), dentistry (306), cosmetics (307) and more recently tissue engineering (308) and 
wound healing (309).  In particular, both nanoceria and titania have demonstrated enhanced wound 
closure in murine wound repair models (310, 311).  
Cerium oxide (CeO2) was shown to increase the wound closure rate when applied topically to 
full thickness dermal wounds made on the shaved backs of C57BL/6 mice using a skin biopsy punch 
(310). Nanoceria (10 µL of a 10 µM solution) or vehicle (H2O) was applied topically, once daily, and 
wound size quantified from images taken on days 1, 3, 5, 8 and 13. Compared to vehicle control, 
nanoceria significantly decreased the wound size on each day and this was likely due to its ability to 
increase fibroblast, keratinocyte and vascular endothelial cell proliferation and migration in vitro.  
CeO2 has also shown •OH scavenging ability, which can confer protection to healthy tissue and 
accelerate repair (312).  
Titanium dioxide (TiO2) has also been trialled in a wound dressing composite, combined with 
the polysaccharide chitosan and the synthetic polymer polyvidone (311). Combining these 
constituents with 1% acetic acid formed a gel, which was moulded and dried into the dressing. Its 
effectiveness in wound healing was evaluated in adult male albino rats, which received 400 mm
2
 open 
excision wounds and dressed with the composite.  Wound size was quantified from images taken on 
days 0, 7, 11 and 16. Compared to control (gauze) and a chitosan only dressing, the TiO2 composite 
significantly increased the wound closure rate each day. The nanocomposite dressing showed 
antimicrobial activity against E. coli, S. aureus and P. aeruginosa in an agar disc diffusion assay in 
vitro. It is likely that this antimicrobial activity was predominantly due to chitosan’s addition in the 
nanocomposite, and not the TiO2 (213-216). Therefore, it is still unclear as to how the TiO2 
nanomaterial additionally assisted chitosan in wound repair.  
Zinc oxide (ZnO) is another nanoparticle with wound healing potential and is globally 
regarded as one of the most topically applied nano-sized compounds due to its approval by the Food 
and Drug Administration (FDA) for its inclusion into many sunscreen formulations (313).  
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It is advantageous over both ceria and titania due to its biodegradability in the body to zinc ions 
(Zn
2+
). As outlined in Table 1.3, zinc is an essential micronutrient displaying antioxidant and 
antimicrobial activity and is involved in collagen synthesis, MMP function, and macrophage 
regulation (84-88). These are significant properties promoting rapid repair and have therefore 
attracted its incorporation into wound healing studies.  
The ability of zinc to enhance wound repair remains inconclusive. Early studies are 
contradictory (314-318) and the size of the material was uncertified. It has recently been shown that 
NPs of the same material but of dissimilar size can vary greatly in their cytotoxicity, and it is therefore 
a crucial detail when characterising a material for in vivo application (319-321).  A table summarising 
zinc’s recent wound healing applications is shown below. 
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Table 1.11 The effects of zinc in wound healing 
Formulation Study Effect on repair Year Ref. 
ZnO The wounds of 40 patients presenting with poor healing soft-tissue 
injuries of the hand & lower limb were treated with ZnO tape. 
All patients’ wounds successfully healed with a median time of 10 
days 
1988 (322) 
ZnO & ZnSO4 ZnO & ZnSO4 were infused into a 100% cotton gauze compress &  
a glutaraldehyde cross-linked bovine collagen sponge. 
4 Yorkshire female piglets received 400 µm partial thickness wounds on 
their backs. 
ZnO (25 g/L) & ZnSO4 (2, 20 & 200 g/L) infused dressings were applied. 
Wounds were excised 64 hrs post treatment. 
Haematoxylin & eosin (H&E) stained sections showed that ZnO 
significantly increased re-epithelialisation of wounds by 33% in 
gauze & by 76% in the collagen sponge compared to control. 
ZnSO4 did not enhance re-epithelialisation.  
1991 (314) 
ZnO 2 cm x 2cm full thickness wounds were created either side of the dorsal 
midline on 18 New Zealand female rabbits. 
ZnO (ZnO® pomade, Turkey) or tripeptide-copper complex (lamin® 2% 
gel, USA) was applied topically, daily for 21 days. 
Wound margins were traced on days 0, 7, 14, & 21 & a skin specimen 
was obtained, using a 4 mm biopsy punch, from the wound to the left of 
the dorsal midline for histological analysis. 
ZnO treated wounds were significantly smaller than non-treated 
control rabbits on days 7, 14 & 21. 
H&E stained sections revealed the average neutrophil count in the 
control group was significantly lower than in the ZnO group on day 
7 but not on days 14 & 21. 
2006 (323) 
ZnO Full thickness skin excisions were created on both ears on 10 albino  
New Zealand female rabbits. 4 wounds 1 cm in diameter were created on 
the ears of the first 5 animals (group 1), whilst 3 wounds 1.5 cm in 
diameter were created on the ears of the remaining animals (group 2). 
40% ZnO ointment or vehicle (vaseline & lanolin) was applied daily for 
3 or 6 weeks in group 1 & 2 rabbits respectively.  
Wounds were photographed weekly & excised at week 3 (group 1) & 6 
(group 2) for histological analysis. Blood samples were collected from 
group 2 & non-operated rabbits. 
ZnO did not enhance wound closure rate in group1 & 2 rabbits. 
Serum zinc concentration was not significantly different between 
ZnO treated & non-treated rabbits. 
  
2010 (324) 
Zn
2+
 4 cm
2
 excisional dorsal cephalad & caudad wounds were created on 172 
weight matched albino rats. The rats were divided into 4 groups & 
received no treatment (group 1), a daily oral ZnSO4 supplement (group 
2), bi-daily topically applied honey (group 3) or a combination of the 
ZnSO4 supplement & honey (group 4).  
Wounds were photographed every 2
nd
 day for 3 weeks. All animals were 
culled at day 21 for histological analysis. Blood samples were collected 
from each rat. 
H&E stained sections revealed a significant increase in the wound 
tensile strength of group 4 treated rats when compared to group 1 & 
group 2. 
The wound tensile strength of group 2 treated rats was greater than 
those in group 3. 
Group 2, 3 & 4 treated rats enhanced collagen deposition, re-
epithelialisation & angiogenesis when compared to control. 
An 85% increase in zinc plasma concentration was detected in 
2011 (84) 
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Formulation Study Effect on repair Year Ref. 
group 2 & 4 rats when compared to control. 
ZnO 10 cm
2
 partial thickness burns were formed on the shaved backs of 20 
adult weight matched New Zealand rabbits using a heated probe. 
The rabbits were divided into 2 groups & treated with either a 20% ZnO 
or 1 % silver sulfadiazine (SSD) ointment. 
The burns were photographed every 3rd day & excised at 6 weeks for 
histological analysis. 
H&E & Masson trichrome stained sections revealed that the 20% 
ZnO ointment significantly enhanced the 50% & 80% re-
epithelialisation time when compared to the clinically relevant 1% 
SSD formulation. 
The thickness of both the epidermis & dermis was significantly 
wider in SSD treated burns when compared to the 20% ZnO 
ointment treated group. 
2012 (325) 
ZnO ZnO infused β-chitin composite hydrogel bandages were fabricated, 
characterised & evaluated for their wound healing potential. 
1.5 cm
2
 partial thickness skin wounds were created on the shaved backs 
of 30 weight matched Sprague Dawley rates aged 4-6 weeks old. 
Rats were dressed with a ZnO composite bandage (0.025% ZnO or 0.1% 
ZnO), a β-chitin hydrogel control bandage, an alginate calcium sodium 
dressing (Kaltostat®) or kept bare.  
Dressings were replaced & the wounds photographed weekly for 3 
weeks. Wounds were excised at weeks 1 & 3 for histological analysis. 
Picro-Sirius Red stained sections revealed that the β-chitin control 
& the ZnO nanocomposite groups significantly enhanced collagen 
deposition and wound closure when compared to Kaltostat® & bare 
wounds at week 3. 
H&E staining revealed complete re-epithelialisation in ZnO 
nanocomposite treated groups only. 
 
2013 (326) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.11 (Continued) 
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It is clear there is moderate evidence supporting zinc’s wound healing potential, particularly as a metal 
oxide. Several studies suggest ZnO enhances repair by improving re-epithelialisation, collagen deposition 
and wound tensile strength (84, 314, 325, 326). However, the material size is disregarded in each study. 
This gap in the literature requires attention in order to determine if ZnO can enhance repair in a size-
dependent manner. It is likely that as ZnO approaches the nanoscale, its effect on repair will differ due to 
its changing physical, chemical and biological properties. In addition, zinc, as both an ion and metal 
oxide, shows significant anti-inflammatory (327-330) and anti-microbial activity (326, 331, 332), further 
emphasizing its potential to assist in wound repair. 
1.8 SUMMARY 
 
Wound repair is a highly ordered process essential to an organism’s survival. It is reliant on the precise 
interaction of numerous cell types under the stimulation of growth factors and cytokines. Many local and 
systemic factors can negatively impact the wound closure rate and promote scar tissue formation. Medical 
intervention is often required to assist repair of non-healing wounds by limiting microbial colonisation, 
exacerbated inflammation and oxidant stress.  CO2 oil and 5β-scymnol are novel marine products with the 
potential to decrease inflammation and oxidant damage at the wound site. ZnO has also demonstrated 
many beneficial properties for wound healing, most notable is its ability to enhance re-epithelialisation. 
These products singularly or in combination may provide relief for the half-million Australians who 
suffer from debilitating and severe wounds annually.  
1.9 PROJECT OUTLINE 
 
The MNPs used within our laboratory have been comprehensively studied for their anti-inflammatory and 
antioxidant activity (271, 273, 276, 287-291, 333, 334). This includes the NZGLM-derived CO2 oil, as 
discussed in Section 1.5, and the shark bile sterol 5β-scymnol, as discussed in Section 1.6. DME oil, also 
derived from the NZGLM, is a novel product that differs from CO2 oil via its extraction method, while its 
anti-inflammatory properties in relation to CO2 oil are unknown. Our laboratory has also extensively 
characterised and investigated the effects of ZnO NPs for their cytotoxicity and uptake by  
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human monocytes and macrophages (319, 335-337). Furthermore, the ZnO NPs have demonstrated 
immunomodulatory activity (338), and inhibitory action on mast cell activation (339). It is therefore 
evident that both the MNPs and ZnO NPs have the potential to modulate the inflammatory phase of 
healing.  
As discussed in Sections 1.2.2, 1.4.1 and 1.4.2, the inflammatory phase of healing is integral to 
acute wound repair, however persistent localised inflammation can result in chronic wounds, where 
inflammation impacts upon the proliferation and migration of keratinocytes and fibroblasts in the 
proliferative phase. It is therefore necessary to assess the MNPs and ZnO NPs for their cytotoxicity and 
ability to modulate the growth of these cells. It is also essential to identify whether the MNPs or ZnO NPs 
are beneficial or deleterious to one or both of the inflammatory and proliferative phases.  
The literature additionally supports ZnO’s ability to enhance in vivo re-epithelialisation (314, 325, 
326), however the underlying mechanism and particle size dependence of this effect remains unclear. 
Although there are many factors influencing the repair process, as outlined in Section 1.3, it is only by 
optimisation of the core wound healing phases that faster healing times can be attained. Both the 
inflammatory and proliferative phases of healing are fundamental to successful wound resolution, and of 
equal or even greater importance is the quality of the newly resolved tissue.  
Although ZnO is reported to enhance in vivo re-epithelialisation, many processes are required to 
permit the migration and proliferation of keratinocytes from the wound edge. An integral process that 
facilitates wound re-epithelialisation is the deposition of a supportive collagen framework by fibroblasts. 
Although faster healing times may be promoted via a rapid deposition of collagen, the quality of the final 
resolved wound may be compromised due to enhanced scar tissue formation. It is therefore essential to 
explore the effects of MNPs and ZnO NPs on fibroblast activity. These in vitro studies are additionally 
important to ascertain which materials are likely to demonstrate the greatest wound healing potential  
in vivo. 
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To date, no studies have been conducted to determine the effects of the MNPs on in vitro or in 
vivo models of wound repair. Furthermore, and as discussed above, ZnO’s effect on healing also requires 
further investigation. Therefore, the MNPs and ZnO NPs were investigated in this PhD project in models 
of the inflammatory and proliferative phases of healing.  
1.9.1 Hypothesis 
The two underlying hypotheses of this PhD project are that: 
1. The MNPs and ZnO NPs will successfully modulate inflammation and the  
re-epithelialisation phase of proliferation in vitro.  
2. The in vitro active materials will accelerate wound healing in vivo.  
1.9.2 Aims 
These hypotheses were addressed through the following aims: 
1. To determine the in vitro anti-inflammatory activities of CO2 oil, DME oil,  
5β-scymnol and ZnO nanoparticles by their potential to inhibit the formation of pro-
inflammatory products of the lipoxygenase and cyclooxygenase pathways. 
2. To determine if CO2 oil, DME oil, 5β-scymnol and ZnO nanoparticles enhance  
in vitro re-epithelialisation by their potential to accelerate the gap-fill time of a scratched 
monolayer of either keratinocytes or fibroblasts. 
3. To determine if the in vitro active treatments enhance in vivo wound repair 
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CHAPTER 2: MATERIALS AND METHODS 
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2.1 INTRODUCTION 
 
All chemicals and reagents were of the highest quality and obtained from reputable distributors.  
2.2 CELL CULTURE  
2.2.1 HaCaT cells 
Human, adult, low Calcium, high Temperature skin keratinocytes (HaCaT), kindly provided 
by Professor Peter Parsons, QIMR, Brisbane, Australia, were thawed from liquid nitrogen and 
cultured aseptically in RPMI-1640 media supplemented with 5% (v/v) foetal bovine serum (FBS) 
(SAFC Biosciences, Australia) and 1% (v/v) Penicillin-Streptomycin-Glutamine (Invitrogen, 
Australia) in 25cm
2
 culture flasks (Cellstar, Australia). Cells were grown to near confluence (≈80%) 
and subcultured at a 1:4 ratio into 75 cm
2
 flasks (Cellstar, Australia). The media was discarded in 
confluent flasks and the cells were washed in 5 mL of phosphate buffered saline (PBS) (Sigma, 
Australia) followed by 4 mL of 0.05% (w/v) trypsin/ethylenediaminetetraacetic acid (EDTA) 
(Invitrogen, Australia) for 2-6 mins to detach the adherent cells. To neutralize the trypsin 8 mL of 
supplemented media was added to the cells, which were then centrifuged at 300 x gravity (g) for 5 
mins. The supernatant was discarded and the cells resuspended in 1 mL of supplemented media.  
A 25 µL aliquot of the cell suspension was diluted with 25 µL of 0.4% (w/v) Trypan Blue (Sigma, 
Australia) and a 10 µL sample of the mixture placed on a cover-slipped haemocytometer (Leica, 
Germany). Cells were counted at 100X magnification using a light microscope (Leitz-Diaplan, 
Germany) and resuspended to 5 x 10
5
 cells/mL before being seeded into 24 well plates for 
experimentation. To maintain the cell culture, 2 x 10
5
 cells were seeded into a 75 cm
2
 flasks with 12 
mL of supplemented media. Media was replenished every 2-3 days. 
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Figure 2.1: HaCaT cells grown in culture (photo: C. Aloe. 2016). 
2.2.2 Primary human epidermal keratinocytes 
Human epidermal keratinocytes (HEK) were purchased from Lonza (Australia). Cells were 
removed from liquid nitrogen, thawed aseptically and cultured under sterile conditions in keratinocyte 
growth media-Gold™ (KGM-Gold) (Lonza, Australia) in 25cm2 culture flasks (Cellstar, Australia). 
Cells were grown to near confluence (≈80%), and subcultured at a 1:4 ratio into 75cm2 culture flasks 
(Cellstar, Australia). The media was discarded in confluent flasks and the cells were washed in 5 mL 
of 30 mM HEPES-buffered saline solution (Lonza, Australia), followed by 4 mL of 0.25 % 
Trypsin/EDTA (Lonza, Australia) for 2-6 mins to detach adherent cells. To neutralize trypsin, 8 mL 
of trypsin neutralizing solution (Lonza, Australia) was added to the cells, which were then centrifuged 
at 200 x g for 5 mins. The supernatant was discarded and the cells resuspended in 1 mL of  
KGM-Gold. The cells were counted and resuspended as outlined in Section 2.2.1, and seeded into 24 
well plates for experimentation. To maintain the cell culture, 3 x 10
5
 cells were seeded into 75cm
2
 
culture flasks with 10 mL of KGM-Gold. Media was replaced on alternate days, and the volume of 
media added to the flasks was increased each time by 2 mL until confluency was achieved and the 
cells were ready for experimental use or subculture.    
 
 
 
50 µM 
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Figure 2.2: HEK cells grown in culture (photo: C. Aloe, 2015) 
2.2.3 Primary human dermal fibroblasts 
Human dermal fibroblasts (HDF) were purchased from Lonza (Australia). Cells were 
removed from liquid nitrogen, thawed aseptically and cultured under sterile conditions in fibroblast 
growth media (FGM) supplemented with a SingleQuots™ kit (Lonza, Australia) in 25cm2 culture 
flasks (Cellstar, Australia). Cells were grown to near confluence (≈80%) and subcultured at a 1:4 ratio 
into 75cm
2
 culture flasks (Cellstar, Australia). The media was discarded in confluent flasks and the 
cells were washed in 5 mL of 30 mM HEPES-buffered saline solution (Lonza, Australia), followed by 
4 mL of 0.25% Trypsin/EDTA (Lonza, Australia) for 2-6 mins to detach adherent cells. Eight 
millilitres of trypsin neutralizing solution (Lonza, Australia) was added to the cells to neutralize 
trypsin, after which the cells were centrifuged at 200 x g for 5 mins. The supernatant was discarded 
and the cells resuspended in 1 mL of supplemented FGM. The cells were counted and resuspended as 
outlined in Section 2.2.1, and seeded into 24 well plates for experimentation. To maintain the culture, 
3 x 10
5
 cells were seeded into 75cm
2
 culture flasks with 10 mL of supplemented FGM. Media was 
replaced on alternate days, and the volume of media added to the flasks was increased each time by  
2 mL until confluency was achieved and the cells were ready for experimental use or subculture.    
 
 
 
50 µM 
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Figure 2.3: HDF cells grown in culture (photo: C. Aloe, 2015). 
2.2.4 Freezing cells 
Cells where washed in PBS, trypsinised, centrifuged and diluted with Trypan Blue  
(Sigma, Australia) and counted using a haemocytometer (Leica, Germany). The cells (5 x 10
6
) were 
resuspended in 1 mL of freeze mix buffer (10% DMSO, 10% FBS, 80% supplemented media) and 
split into 2 mL cryotubes. Cryotubes were placed in a freezing container (Thermo Fisher Scientific, 
Australia), holding isopropanol, and kept at -80°C for 24 hrs prior to transfer into liquid nitrogen for 
long term storage. 
2.3 MARINE NATURAL PRODUCT PREPARATION 
 
The natural products, CO2 oil, DME oil and 5β-scymnol, were supplied by MacLab Australia Pty. 
Ltd. and weighed and suspended in absolute alcohol at a final concentration of 20 mg/mL. MNPs 
were sonicated for 30 mins for both sterilization and to assist marine oil dispersion. Stock solutions 
were made fresh prior to experimental use and working solutions were created by aliquoting the 
appropriate amount of stock solution into the culture media to achieve the desired MNP concentration, 
whilst keeping a consistent volume of solvent (0.5% v/v).  
 
50 µM 
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2.4 NANOPARTICLE PREPARATION 
 
The particulates utilized in this study were supplied by Micronisers Pty. Ltd. (Melbourne, Australia).  
ZnO 30nm with and without a surfactant dispersant (Orotan 731 DP, a sodium polyacrylate), ZnO 
80nm, ZnO 200nm and TiO2 anatase (25nm) were weighed and suspended in Milli-Q water at a final 
concentration of 20 mg/mL. These materials have been characterised for their physiochemical 
properties, as previously reported (319). The ZnO 30nm NPs (with the particle size and surface area 
shown in Table 1.7), were identical in properties to the OECD standard reference nanomaterial, NM-
112. The TiO2 anatase (25nm) is equivalent to the OECD standard reference nanomaterial, NM-105 
(P25 Aeroxide, with 75% of the NPs in the anatase form and 25% in the rutile form of TiO2. The 
particulates were sonicated for 30 mins for sterilization and to disperse the particles in solution. The 
stock solutions were left to rest at room temperature (RT) for 24 hrs for use the following day.  
Prior to immediate use, the stock solutions were vortexed for 30 secs and the tubes were inverted  
10-20 times until particles were resuspended. Nanoparticle working solutions were created by 
aliquoting the appropriate amount of stock solution into culture media to achieve the desired NP 
concentration for experimentation. Zinc chloride (ZnCl2) (Sigma, Australia), was used as a zinc ion 
control in culture media and was treated as above.  
Table 2.1 Particulates investigated in this study (adapted from Shen et al. 2013, (336)). 
Particle Disk Centrifuge 
Agglomerate Size    
(mean [peak half-
width]) 
Agglomerate 
Surface Area 
(m
2
/g) 
Primary 
Particle Size 
(nm) 
Primary Particle 
Surface Area 
(m
2
/g) 
ZnO 30 1.33 µm [0.68 – 1.98 
µm] 
0.80 DLS: 36  6 
(TEM: 25  7) 
30 
ZnO 80 1.32 µm [0.65 – 1.32 
µm] 
0.81 DLS: 83  8 13 
ZnO 200 1.29 µm [0.88 – 1.69 
µm] 
0.83 DLS: 200-500 3 
sZnO 30 75 nm [50 – 100 nm] 14.27 * * 
TiO2 
Anatase 
111 nm [55 – 209 nm] 13.62 DLS: 25  3 60 
Disk centrifuge analysis was used to measure agglomerate size of ZnO and TiO2 nanoparticles after 24 hr 
exposure to cell culture media with 10% serum. Primary particle size was determined by dynamic light 
scattering (DLS) or transmission electron microscopy (TEM) for each particle in a dispersed solution in water. 
Surface areas were calculated assuming nominally spherical particles and particle agglomerates. *Primary 
particle size for surfactant-dispersed nanoparticle is the same as for pristine material. 
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2.5 HYDROLYSIS OF MARINE OILS 
 
The following procedure was adapted from McPhee et al. 2007, (276). The CO2 and DME oil samples 
(100 mg) were refluxed with 2 mL of 1 M potassium hydroxide (KOH) in 95% ethanol for 1 hr. The 
solution was cooled, 5 mL of H2O was added and the mixture extracted with 3 x 5 mL of hexane-
diethyl ether (1:1, v/v).  The solvent extract was washed with 5 mL of H2O, dried over anhydrous 
sodium sulfate (Na2SO4) and the non-saponifiable materials recovered upon solvent removal by rotary 
evaporation. The aqueous layer was acidified with 6 M hydrochloric acid (HCl) and extracted with 3 x 
5 mL of hexane-diethyl ether (1:1, v/v). The free fatty acids were recovered upon washing with H2O, 
drying over anhydrous Na2SO4 and removal of solvent by evaporation. 
2.6 THIN LAYER CHROMATOGRAPHY   
 
The following procedure was adapted from McPhee et al. 2007, (276). Individual lipid classes from 
CO2 and DME oil samples were identified using thin layer chromatography (TLC).  Ten microliter 
samples of 10 mg/mL solutions were applied to a silica plate using a Camag Linomat 5 automated 
spray-on applicator (Camag, Australia), with a 100 µL syringe set at a band length of 8 mm and a 
dosage rate of 150 nL/s. The plate was developed in a Camag High-Performance Thin-Layer 
Chromatography (HPTLC) horizontal twin trough chamber (Camag, Australia). The chamber was 
charged with petroleum spirit-diethyl ether-acetic acid (70:30:1 v/v/v) and the mobile phase allowed 
to travel to a distance of 8 cm from the application position.  
 The TLC plate was air-dried for 5 mins, sprayed with copper sulfate charring reagent and 
transferred upright into a DANI 8150 gas chromatograph oven (DANI Instruments, Italy). The oven 
was programmed to increase the heat of the chamber from 30°C to 160°C, increasing the temperature 
by 10°C/min. The lipids were visualised as charred bands against the white background of the silica 
plate. 
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2.7 NEUTROPHIL 5-LIPOXYGENASE INHIBITION 
2.7.1 Porcine blood collection 
A 500 mL Schott bottle (Sigma, Australia) was filled with 60 mL of 6% Dextran T500 
(Sigma, Australia) and 60 mL of 4.5% EDTA (Sigma Australia) (Appendix 1), pH 7.4. The following 
day fresh porcine blood was collected from the Australian Food Group abattoir (Laverton, Australia), 
filling the bottle to a marked 420 mL level. The bottle was mixed gently by inversion and returned 
immediately to the laboratory.  
2.7.2 Neutrophil isolation 
The 500 mL Schott bottle was allowed to stand in a 37°C water bath for 30 mins to encourage 
dextran bound red blood cells to sediment. The white blood cell rich supernatant was removed and 
centrifuged at 1500 x g for 10 mins to isolate the buffy coat. The buffy coat was removed and 
transferred onto a dual layer Percoll gradient (GE Healthcare, Australia) with specific gravities of 
1.089 and 1.093 g/dL for the top and bottom layers, respectively (Appendix 1). The gradient was 
centrifuged at 600 x g for 30 mins and the neutrophils collected from the interface between the two 
Percoll layers.  The neutrophils were washed in Dulbecco’s salt solution (Appendix 1), pH 7.4  
and centrifuged at 600 x g for 10 mins. Contaminating red blood cells were lysed with 5 mL of 0.83% 
ammonium chloride (NH4Cl) for 6 mins at 37°C and washed again in Dulbecco’s salt  
solution. Neutrophils were then resuspended in Hank’s balanced salt solution (Sigma, Australia) at 
11.2 x 10
6
 cells/mL. 
2.7.3 Inhibition assay 
Ten microliter samples of working solution of CO2 oil, DME oil, 5β-scymnol, ZnO 30nm or 
vehicle were added to glass culture tubes containing 1.39 mL of Hanks buffer (Sigma, Australia), pH 
7.4. The samples were equilibrated at 37°C for 5 mins, prior to incubation with 0.5 mL of freshly 
isolated porcine neutrophils for 5 mins. Fifty microliters of arachidonic acid substrate (2.5 µM final 
concentration) was then added to each tube and after a further 5 mins the reaction was initiated via the 
addition of calcium ionophore (50 µL, 2.5 µM final concentration). After 5 mins the reaction was 
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stopped by the addition of 176.5 µL of 167 mM citric acid containing the internal standard PGB2 
(Appendix 1).  
2.7.4 Eicosanoid extraction  
Eicosanoid metabolites were extracted into chloroform by the addition of 5 mL  
of chloroform-methanol (7:3 v/v) to the cell suspension. The suspension was mixed and centrifuged  
at 800 x g for 10 mins to create a distinct organic and aqueous phase. The lower chloroform phase 
was transferred to 5 mL Wasserman tubes and evaporated to dryness under nitrogen.  
The eicosanoid metabolites were then reconstituted in 120 µL of LTB4 mobile phase 
(methanol/H2O/acetic acid, 1520:680:1.6, v/v/v, pH 3.0). 
2.7.5 High performance liquid chromatography (HPLC) 
Leukotriene B4 (LTB4) and associated trans-isomers were resolved by reverse-phase HPLC. 
The HPLC system consisted of a Waters 717 Autosampler, a Waters 600E Multi Solvent Delivery 
System and a Waters 996 photodiode array detector (Waters, USA). A Waters C18 Symmetry
®
 
column (5 µm, 3.9 x 150mm) and a flow rate of 1 mL/min with an injection volume of 25 µL were 
used for all separations. Samples were loaded into a carousel made for automatic injection.  
Run time per sample was 30 mins and the metabolites were detected at 270 nm. The data was collated 
and analysed using the Waters Millennium Software, version 3.2 and the metabolite peak heights 
were ratioed against their respective internal standard peak height. 
2.8 CYCLOOXYGENASE INHIBITION  
 
Inhibition of two cyclooxygenase isoenzymes (COX-1 and COX-2) in the presence of  CO2 oil,  
DME oil, 5β-scymnol or ZnO 30nm was determined utilizing the COX (ovine) inhibitor screening 
assay kit (Cayman, Australia, Cat. No. 560101). 
2.8.1 Inhibition assay 
Ten microliter aliquots of COX-1 or COX-2 (ready as supplied) were added to glass  
culture tubes containing 950 µL of reaction buffer and 10 µL heme (ready as supplied).  
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The enzyme was equilibrated in a shaking water bath set to 37°C for 5 mins prior to incubation with 
20 µL of working solution of CO2 oil, DME oil, 5β-scymnol, ZnO 30nm or vehicle for an additional 5 
mins. PGH2 production was initiated by the addition of arachidonic acid substrate (10 µL, 100 µM 
final concentration) and after 2 mins the reaction was stopped with 50 µL HCl (0.1 M final 
concentration). All tubes were removed from the water bath and 100 µL saturated stannous chloride 
(SnCl2) solution was added to each tube to reduce PGH2 to the more stable prostaglandin, PGF2α. 
Background tubes were created by inactivating a 10 µL aliquot of either COX-1 or COX-2 in boiling 
water for 3 mins and carrying out the reaction steps as described above. 
2.8.2 Prostaglandin quantification  
PGF2α was quantified via enzyme immunoassay (EIA) using a broadly specific antiserum that 
binds to all major PG compounds. The assay is based on the competition between PGs and a PG-
acetylcholinesterase (AChE) conjugate (PG tracer) for a limited amount of PG antiserum. As the 
concentration of the PG tracer is held constant while the concentration of PGF2α varies, the amount of 
PG tracer that is able to bind to the PG antiserum is inversely proportional to the concentration of PG 
in the well, absorbance measured at 405 nm. A 96 well plate pre-coated with capture antibody was 
provided with the COX (ovine) inhibitor screening assay kit and a sample plate layout of the EIA is 
shown Appendix 2. EIA analysis was performed utilising the Cayman ELISA (Competitive) Analysis 
Tools spreadsheet (Cayman Chemical Company, USA).  
2.9 CYTOTOXICITY ASSAY  
 
A cell proliferation colorimetric assay kit was utilised to determine the sensitivity of HaCaT, HEK 
and HDF cells to the MNPs and NPs. HaCaT, HEK and HDF cells were cultured, detached, 
centrifuged and counted as described in Sections 2.2.1, 2.2.2 and 2.2.3 respectively. Cells (3 x 10
5
) 
were seeded into 24 well plates and allowed to incubate at 37°C, 5% CO2 for 24 hrs. Cells were then 
exposed to a dose range of either MNPs or NPs, and HaCaT cells were incubated for a further 23.5 
hrs, whilst the primary cells were incubated for an additional 23 hrs. The supernatant in each well was 
then discarded and replenished with 300 µL of the appropriate cell culture media.  
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An aliquot (60 µL) of  3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium (MTS) (Promega, Australia) was added to each well and incubated at 37°C, 5% CO2 
for 30 mins for HaCaT cells, or 1 hour when added to primary keratinocytes or fibroblasts. The 
absorbance of each well was measured after the appropriate incubation period at 490 nm using a 
CLARIOstar high performance microplate reader (BMG LABTECH, USA). Cell viability is 
determined in this assay as MTS (a tetrazolium compound) is reduced enzymatically to the coloured 
formazan product, which is directly proportional to the number of living cells in the well. Cell 
viability data was expressed as the percentage of viable cells in untreated vehicle control incubations. 
2.10 SCRATCH REPAIR 
 
The following protocol was adapted from Liang et al. 2007, (340). In vitro scratch closure was 
assessed in HaCaT, HEK, and HDF cells. Cells were cultured, detached, centrifuged and counted as 
described in Sections 2.2.1, 2.2.2 and 2.2.3, respectively and 5 x 10
5
 cells/well were seeded into 24 
well plates and incubated for 48 hrs at 37°C, 5% CO2 to achieve confluency (≈90 %). A horizontal 
scratch was made across the centre of each well using a p10 pipette tip (LabAdvantage, USA) and the 
wells washed with 500 µL of PBS to remove non-adhering cells. The wells were then replenished 
with the appropriate cell culture media containing MNPs or NPs at known concentrations and 
incubated for an additional 10 hrs. The gap closure time was assessed by photo analysis of images 
captured on an inverted light microscope at 0, 4, 8 and 10 hrs. Between 4 to 6 images were captured 
of each scratch at each time point, and a reference grid was drawn beneath each well to ensure images 
were taken at the same position. Enhanced or delayed repair was evident when comparing MNP or NP 
exposed cells to non-treated vehicle controls using ImageJ (described in Section 2.15). An example of 
the images captured and the method of analysis are shown below.  
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Figure 2.4: Scratch assay demonstrating an in vitro model of re-epithelialisation in HaCaT cells. 
HaCaT cells were grown to confluence in a 24 well culture plate and a horizontal scratch was made 
across the centre of each well using a p10 pipette tip, forming a gap in the monolayer. HaCaT cells 
were incubated for 10 hrs and images were captured at 4 time points (0, 4, 8 and 10 hrs). Scratch 
closure was assessed by quantifying the remaining gap size at each time point using ImageJ.  
 
2.11 CELL ADHESION ASSAY  
 
The ZnO 30nm and sZnO 30nm NPs were investigated for their potential to mediate adherence of 
HaCaT cells in 24 well plates. 5 x 10
5
 cells were seeded into each well and immediately dosed with a 
concentration range of either ZnO 30nm or sZnO 30nm NPs, and incubated for 90 mins at 37°C, 5% 
CO2. Non-adherent cells were washed off with 1 mL of PBS (Sigma, Australia), and the adherent cells 
were detached with 150 µL TrypLE
TM
 1X (Life Technologies, USA) and counted as described in 
Section 2.2.1. Adherence of HaCaT cells was also assessed utilising the MTS reagent assay, in which 
5 x 10
5
 cells were seeded per well and incubated, as described above. The cell suspension containing 
non-adherent cells was aspirated, the wells washed with 1 mL of PBS and replenished with 300 µL of 
supplemented media. A 60 µL aliquot of MTS (Promega, Australia) was then added and incubated at 
37°C, 5% CO2 for 1 hour and absorbance was measured as outlined in 2.9. 
 
 
0 hr 4 hr 8 hr 10 hr 
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2.12 FLOW CYTOMETRY 
 
2.12.1 Sample preparation 
The HaCaT cells were cultured, detached, centrifuged and counted, as described in Section 
2.2.1, and 5 x 10
5
 cells/well were seeded into 24 well plates and incubated at 37°C, 5% CO2 for 24 
hrs. HaCaT cells were then treated with either ZnO 30nm, sZnO 30nm, ZnCl2 or TiO2 25nm and 
incubated for either 4 or 10 hrs. At the end of each incubation the cells were washed with 2 mL of 
PBS (Sigma, Australia) and detached with 150 µL TrypLE
TM
 1X (Life Technologies, USA). Cells 
were then fixed with 1 mL 80% ethanol and transferred to flow cytometry tubes for overnight storage 
at -20°C. 
2.12.2 Ki-67 staining 
Samples were removed from -20°C and centrifuged at 200 x g for 10 mins. The supernatants 
were discarded and the cells washed twice with 2 mL of staining buffer (PBS with 1% FBS) and 
centrifuged, as described above, between washes. Cells were resuspended in 270 µL of staining buffer 
and 30 µL of a 1:50 dilution of unconjugated anti-Ki-67 antibody (Sigma, USA, Cat. No. 
SAB4501880) was added to make a final dilution of 1:500 in each tube. Tubes were mixed gently and 
incubated for 30 mins at RT. Cells were washed twice and resuspended in 270 µL of staining buffer 
and 30 µL of a 1:50 dilution of secondary polyclonal antibody-PE (Sapphire, Australia, Cat. No. 120-
70070) was added to make a final dilution of 1:500 in each tube. Tubes were mixed gently and 
incubated at RT in the dark for 30 mins. Cells were washed twice and resuspended in 300 µL of 
staining buffer prior to for flow cytometric analysis. In addition, an isotype control (BD Biosciences, 
Australia, Cat. No. 558595) was utilised to measure the level of non-specific background signal 
caused by the Ki-67 antibody. 
2.12.3 Integrin β1 staining 
Samples were removed from -20°C and centrifuged at 200 x g for 10 mins. The supernatants 
were discarded and the cells washed twice with 2 mL of staining buffer (PBS with 1% FBS) and 
centrifuged, as above, between washes. Cells were resuspended in 20 µL of phycoerythrin (PE) 
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conjugated anti-CD29 antibody (BD Biosciences, Australia, Cat. No. 556049) as per manufacturer 
recommendations. Tubes were mixed gently and incubated at RT in the dark for 30 mins. Cells were 
washed twice with staining buffer and the supernatant aspirated. Cells were again washed twice and 
resuspended in 300 µL of staining buffer for flow cytometric analysis. In addition, an isotype control 
(BD Biosciences, Australia, Cat. No. 558595) was utilised to measure the level of non-specific 
background signal caused by the CD29 antibody. 
2.12.4 Flow cytometric analysis 
Ki-67 and CD29 expression in treated HaCaT cells was measured using a FACSCanto II 
Flow cytometry system (BD Biosciences, USA). The upper limit setting of 10,000 events, or maximal 
events after 3 mins per tube, was used. The events of each sample tube were exported from the BD 
FACSDiva
TM
 software and imported into an Excel spreadsheet for analysis.  
2.13 IN VIVO WOUND REPAIR 
 
The in vivo animal study was conducted after approval was obtained from the RMIT Animal Ethics 
Committee (Project approval AEC# 1428). Documentation of this approval is shown in Appendix 3. 
The methodology of the in vivo wound repair model was adapted from Chigurupati et al. 2013, (310).  
2.13.1 Experimental animals 
Seven-week-old female C57BL/6 mice were delivered from the Animal Resources Centre 
(Murdoch, Western Australia) and acclimatized for 1 week at the RMIT University animal facility 
(RMIT, Bundoora), where they were housed in cages in groups of 4. Following the wound procedure, 
mice were housed individually to prevent neighbouring mice from interfering with wound repair.  
2.13.2 Nanoparticle solution preparation 
Nanoparticles used for in vivo experimentation were weighed and suspended in Milli-Q  
water at a final concentration of 20 mg/mL. The mixtures were sonicated for 30 mins for both 
sterilization and to disperse the particles in solution. The stock solutions were left to rest at RT for 24 
hrs for use on the following day. Just prior to use, the stock solutions were vortexed for 30 seconds 
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and tubes inverted 10-20 times until particles were resuspended. Nanoparticle working solutions were 
then made up by aliquoting the appropriate amount of stock solution into saline to achieve the desired 
NP concentration for wound application. 
2.13.3 Wound repair model 
Eight-week-old female mice were transported to the RMIT Animal Facility (RAF) procedure 
room, weighed and housed individually in appropriately labelled cages. Mice were sedated using the 
inhalation anesthetic isoflurane (Appendix 4), and their backs were shaved and wiped with 70% 
ethanol to create a clean area to perform a punch hole biopsy. Mice were injected subcutaneously in 
the flank with  0.05 mg/kg buprenorphine to provide analgesia upon awakening from anaesthesia. 
Stiefel biopsy punches, 5 mm, (Stiefel Australia), were used to create a circular incision on the centre 
of their shaved backs, minimizing their ability to scratch the wound site. Mice were returned to their 
cages following the application of either ZnO 30 nm, sZnO 30 nm, ZnO 200 nm or TiO2 25nm  
(20 µL of a 0.5 µg/mL suspension)  or vehicle (saline) and placed upon a heat pad to aid recovery 
from surgery.  
2.13.4 Monitoring 
Mice were stringently monitored following each procedure. They were monitored each hour 
for the first 4 hrs following punch hole biopsy for alertness, activity, posture, breathing pace, 
appearance of the wound and other key clinical observations ensuring the mice were in no discomfort 
and an excellent state of health (Appendix 5). Mice were then monitored twice-daily over the course 
of the experimental period. In addition, mouse wounds were photographed daily, commencing on day 
3, to track the progress of the healing wounds. The photos were taken from the same distance, in the 
same room and under the same lighting conditions each day.  
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2.14 HISTOLOGY 
 
2.14.1 Tissue preparation and processing for paraffin embedding and sectioning 
Mice were humanely culled by CO2 euthanasia (Appendix 6) on days 7 and 14 of the 14 day 
experimental period. Once culled, the wounds were dissected and placed into a 10% neutral buffered 
formalin (NBF) solution for 3 days prior to tissue processing. Processing was conducted using the 
rodent program on the tissue processor (Leica ASP200 S, Australia). The tissue was then embedded in 
paraffin using the Shandon Histocentre Embedder (Thermo Trace, USA). A Leica rotary microtome 
(Leica RM 2235, Australia) was used to cut the paraffin embedded tissue at a 3 µm thickness. 
Sections were transferred to superfrost ultra plus microscope slides (Menzel, Australia), dried in a 
60°C oven for 1 hour, and stored in slide storage boxes to protect the sections from sunlight and dust 
until required for staining.    
2.14.2 Haematoxylin and Eosin (H&E) 
Formalin-fixed paraffin-embedded sections were stained with H&E to assess the tissue 
morphology and leukocyte infiltration of each section. Sections were dewaxed, hydrated through 
descending graded alcohols, rinsed and stained by Mayer’s haematoxylin (Grale, Australia) for 1.5-3 
mins. Sections where then rinsed and placed in 1% aqueous eosin (Grale, Australia) for 2 mins, the 
slides dehydrated through ascending graded alcohols, cleared in xylene and mounted with DPX 
(Merck, Australia), as outlined in Appendix 7. 
2.14.3 Picro-Sirius Red 
Formalin-fixed paraffin-embedded sections were stained with Picro-Sirius Red to determine 
total collagen deposition and prevalence of collagen type I and III in each section. Sections were 
dewaxed, hydrated through descending graded alcohols, washed in water and stained in Picro-Sirius 
Red (Abcam, USA) for 1 hour. Sections were then washed in two changes of acidified water, 
dehydrated in three changes of 100% ethanol, cleared in xylene and mounted with DPX (Merck, 
Australia), as outlined in Appendix 8. Brightfield images were captured using an Olympus BX53 light 
microscope with a top mounted Olympus DP73 digital camera (Olympus, Australia). Real-time 
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polarization was achieved utilizing an Olympus U-ANT nosepiece analyser and an Olympus U-POT 
drop in polarizer (Olympus, Japan). 
2.14.4 Immunohistochemistry (IHC) 
Formalin-fixed paraffin-embedded sections were stained with antibodies (Santa Cruz 
Biotechnology, USA) to demonstrate cell proliferation (Ki-67 antibody [M-19]: sc-7846), epidermal 
remodelling (Cytokeratin-14 antibody [CK-14]: sc-17104) and vascular remodelling (Smooth Muscle 
Actin B4 antibody [SMA B4]: sc-53142). Sections were dewaxed, hydrated through descending 
graded alcohols, rinsed in cold water and transferred into a staining dish containing pre-heated Tris-
EDTA antigen retrieval buffer (Appendix 9). The staining dish was placed in a water bath set to 
100°C and incubated for 20 mins. Sections were then rinsed in cold water and washed in PBS 
containing 0.4% Triton X-100 (PBS-T) for 10 mins using two 5 min washes. The sections were then 
blocked in 5% bovine serum albumin (BSA) in PBS-T for 30 mins and incubated overnight at 4˚C in 
primary antibody (1:50), diluted in 1% BSA PBS-T. On the following day, the sections were washed 
in PBS-T, blocked with 1.0% H2O2 for 15 mins and washed again. The appropriate horseradish 
peroxidase (HRP) conjugated secondary antibody (sc-3851 or sc-3697) was added to the sections 
(1:50), diluted in 1% BSA PBS-T and allowed to incubate for 1 hour at RT. Sections were then 
washed a final time in PBS-T, incubated in SIGMAFAST™ 3,3’Diaminobenzidine (DAB) substrate 
(Sigma, Australia, Cat. No. D4293), dehydrated through ascending graded alcohols, cleared in xylene 
and mounted with DPX (Merck, Australia), as outlined in Appendix 9. Brightfield images were 
captured using an Olympus BX41 light microscope with a top mounted Olympus DP72 digital camera 
(Olympus, Australia). 
2.15 IMAGE ANALYSIS 
 
Image analysis was performed using ImageJ (Version 1.47) developed by Wayne Rasband at the 
National Institute of Health (New York, USA) to quantitate in vitro cell re-epithelialisation of HaCaT, 
HEK and HDF cells and to measure parameters of wound repair in C57BL/6 mice in vivo. 
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Scratch assay images of MNP and NP treated cells were analysed using the ‘polygon tool’, 
which enables contouring of the leading edge of re-epithelialising cell cultures. This technique was 
also utilised to measure the change in wound area from punch biopsy wound images and to measure 
the epidermal layer thickness of H&E stained tissue sections.   
Total collagen deposition of each Picro Sirius Red stained section was assessed via converting 
a brightfield image to greyscale, isolating the red-stained collagen using thresholding, and measuring 
the thresholded area. Similarly, differentiating type I and type III collagen was achieved by removing 
the dark blue-black background of polarized images and thresholding for either the green (type III) or 
yellow-orange birefringence (type I). Once either subtype was solely present, the image was 
converted to greyscale and the collagen content was measured. 
Sections stained via IHC were analysed using the ‘grid’ and ‘cell counter’ tools, and 
positively-stained cells or proteins were counted manually. This method was also employed to count 
leukocytes in H&E stained sections.   
2.16 STATISTICAL ANALYSIS 
 
Statistical analysis was performed to assess the significant difference between treatment types and 
treatment concentrations. Nonparametric unpaired T-tests were used to compare two data sets where 
appropriate and One-way or Two-way ANOVA with Bonferroni’s post-hoc analysis, was used where 
appropriate for multiple comparisons. All statistical analysis was performed using GraphPad Prism 
version 6 for windows (GraphPad Software, La Jolla, USA). 
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CHAPTER 3: WOUND HEALING POTENTIAL 
OF MARINE NATURAL PRODUCTS 
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3.1 INTRODUCTION 
 
In Sections 1.1 and 1.2, wound repair was described as a highly specialised process consisting of four 
main phases essential to the survival of localised tissue and the whole organism. The inflammatory 
and proliferative phases of repair can influence both the rate of wound resolution and the skin 
physiology of newly resolved tissue and its subsequent remodelling. This is due to the nature of 
inflammatory cells, which are recruited to remove cell debris and eliminate foreign pathogens. These 
inflammatory cells also increase their rate of localised growth factor secretion and the production of 
pro-inflammatory mediators, such as LTB4 and PGH2 in the wound microenvironment, as outlined in 
Tables 1.1 and 1.4, and Figure 1.6. 
 Growth factors such as PDGF and TGF-β stimulate chemotaxis of fibroblasts and promote 
collagen synthesis during the proliferative phase to facilitate re-epithelialisation and restoration of a 
physical barrier, thereby protecting the body from the external environment (18, 30-33, 35). If 
inflammation is exacerbated, wound repair is inhibited and localised tissue damage is enhanced, 
preventing wound closure. This is typically due to microbial colonisation and enhanced ROS 
production by neutrophils (52), which further advances inflammatory cell recruitment and the 
production of pro-inflammatory cytokines, such as TNF-α and IL-1 (63). If the inflammatory phase 
does not resolve in a timely manner, simultaneous production and destruction of tissue occurs, and 
scar tissue formation is encouraged, which negatively impacts both the tensile strength and 
morphology of remodelled skin. Therefore three MNPs were selected for their potential to mediate the 
inflammatory response in healing wounds. 
3.1.1 Green-lipped mussel oils 
 In recent decades, the anti-inflammatory properties of marine oils have attracted high levels 
of attention due to their beneficial implications for human health. Marine oils contain a high source of 
EPA and DHA, which have the potential to mitigate excessive production of pro-inflammatory 
mediators (267).  
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 The CO2 oil is an omega-3 fatty acid enriched product extracted from the New Zealand green 
lipped mussel, Perna canaliculus. It is manufactured via supercritical fluid extraction (SFE) with 
liquid CO2 and contains a mixture of five main lipid classes, including: sterol esters, triglycerides, free 
fatty acids, sterols and polar lipids (271). The CO2 oil is a potent source of both EPA and DHA, and 
its activity resides in the fatty acid class. The literature has demonstrated its ability to assist in treating 
various inflammatory conditions, including osteoarthritis, rheumatoid arthritis, inflammatory bowel 
disease and asthma (272-275), and thus it shows great potential to be an inflammatory mediator in a 
wound healing application. The DME oil is also derived from Perna canaliculus, and differs from 
CO2 oil via its extraction method. DME can be readily liquefied when compressed to produce an 
effective extraction solvent that displays a number of advantages over traditional extractants, such as 
liquid CO2.  For example, DME can extract both polar and non-polar lipids from liquid and dry 
preparations, indicating that differences in the lipid profiles of CO2 and DME extracted mussel oils 
may arise. However, the comparative bioactivity of DME oil to CO2 oil is unknown. 
3.1.2 5β-scymnol 
 5β-scymnol is a naturally occurring bile sterol found in sharks and rays as 5β-scymnol sulfate, 
which is the active component of the Japanese traditional medicine ‘deep sea shark liver oil’, that has 
been shown to assist in the treatment and management of various ailments when applied topically 
(286). Recent studies with 5β-scymnol have shown that it possesses potent antioxidant ability, 
protection against liver and peripheral artery disease, anti-acne properties, and potential for anti-
inflammatory activity, as summarized in Table 1.10. While 5β-scymnol’s chemical structure and 
corresponding antioxidant activity has been well studied (287, 288, 334), its anti-inflammatory 
potential requires further investigation. Both of these biological properties are of particular 
significance for efficient wound repair.  
Excessive inflammation prevents wound progression into the proliferative phase of repair, 
inhibiting wound closure and facilitating microbial colonisation. Therefore, effective modulation  
of the inflammatory response with CO2 oil, DME oil or 5β-scymnol would appear to be favourable for 
wound resolution.     
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 In this Chapter, all of the experimental studies investigating the results investigating the 
MNPs’ effects on inflammation and proliferation are presented and examined in detail. The aims of 
these studies reported were to determine the in vitro anti-inflammatory activity of CO2 oil, DME oil 
and 5β-scymnol, and to elucidate their effect and toxicity on representative cells of the proliferation 
phase, specifically keratinocytes and fibroblasts.  
3.2 MATERIALS AND METHODS 
 
A thorough explanation of the materials and methodology for the experimental procedures used to 
generate the results presented in this chapter are shown in Chapter 2. The following is a brief 
summary of the specific protocols used in the studies described in Chapter 3. 
3.2.1 Marine natural product preparation  
The CO2 oil, DME oil and 5β-scymnol samples were supplied by MacLab Australia Pty. Ltd. 
(Melbourne, Australia), and were weighed and suspended in absolute alcohol at a final concentration 
of 20 mg/mL. The MNPs were sonicated for 30 mins for both sterilization and to assist in marine oil 
dispersion in solution, as described in Section 2.3. 
3.2.2 Thin layer chromatography 
The lipid compositions of the CO2 and DME oils were determined using normal phase thin 
layer chromatography, as described in Section 2.6. In addition, a sample of each marine oil was 
hydrolysed, as outlined in Section 2.5, and resolved on a silica plate to further assess the composition 
of both marine oils.   
3.2.3 Neutrophil 5-lipoxygenase inhibition 
The effect of CO2 oil, DME oil and 5β-scymnol on the inhibition of LTB4 from porcine 
neutrophils was determined via co-incubating the MNPs with freshly isolated neutrophils and AA 
substrate, along with calcium ionophore to stimulate the production of inflammatory eicosanoids, as 
described in Section 2.7.3. The eicosanoids were extracted from the reaction mixture as outlined in 
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Section 2.7.4, and LTB4 production was quantitated reverse phase HPLC, as described in Section 
2.7.5.  
3.2.4 Cyclooxygenase inhibition 
The effect of CO2 oil, DME oil and 5β-scymnol on PGH2 formation in a cell free system was 
determined by co-incubating the MNPs with either COX-1 or COX-2 and the AA substrate, as 
described in Section 2.8.1. PGH2 was reduced to the more stable prostaglandin, PGF2α and quantified 
via EIA as outlined in 2.8.2. 
3.2.5 Cytotoxicity assay 
The effect of CO2 oil, DME oil and 5β-scymnol on the viability of HaCaT and HDF cells was 
determined after 24 hrs of exposure to a concentration range of 0.1-300 µg/mL. The cells were 
cultured as described in Sections 2.2.1 and 2.2.3 and seeded as outlined in Section 2.9. The 
tetrazolium compound MTS was added to the wells containing vehicle or MNP-treated cells, and 
converted to the coloured formazan product in viable cells.  
3.2.6 Scratch repair 
The effect of CO2 oil, DME oil and 5β-scymnol on in vitro cell re-epithelialisation and gap 
closure of a fibroblast monolayer was assessed at concentrations of 0.1, 1.0 and 10 µg/mL. The cells 
were cultured as described in Sections 2.2.1 and 2.2.3, and seeded as outlined in Section 2.10. Cell 
monolayers of immortalised keratinocytes and primary human fibroblasts were scratched with a p10 
pipette tip, then treated with the MNPs of interest and imaged over a 10 hour time course, in order to 
compare the gap closure rate of vehicle-treated versus MNP-treated cells. 
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3.3 RESULTS 
 
3.3.1 CO2 oil comprises more triglycerides and less polar lipids than DME oil 
The CO2 oil is manufactured via SFE with liquid CO2 from freeze-dried stabilized NZGLM powder 
and contains a mixture of five main lipid classes, including: sterol esters, triglycerides, free fatty 
acids, sterols and polar lipids. DME oil is also derived from Perna canaliculus, but differs to the CO2 
oil via the use of DME in the solvent extraction method. Due to the polarity differences of these two 
solvents, the lipid profile of the two oils differ (Figure 3.1), especially in the triglyceride and polar 
lipid components. The CO2 oil contains more triglycerides and less polar lipids than DME oil, which 
was evident upon hydrolysis of the triglycerides leading to a noticeably larger free fatty acid (FFA) 
band in the CO2 oil. Although seasonal variation can occur, the relative percentage of the five lipid 
classes do not vary more than 10%. The CO2 oil profile is very similar to our previously published 
report on this extract (276).  
 
 
 
 
 
 
Figure 3.1: Thin layer chromatography demonstrating the lipid profiles of CO2 oil and DME oil. 
The CO2 and DME oil lipid profiles were compared to determine if a different extraction method 
altered the lipid composition of the marine oils obtained from the NZGLM, Perna canaliculus. The 
same amount of material was loaded in each track. It is evident that CO2 oil comprises a greater 
triglyceride and smaller polar lipid band when compared to DME oil. This is further confirmed via 
KOH hydrolysis of the triglyceride component in each sample, which showed a greater quantity of 
FFA in the CO2 oil. 
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3.3.2 CO2 and DME oils inhibit the formation of the 5-lipoxygenase pathway end product 
LTB4 
LTB4 production was stimulated in porcine neutrophils via co-incubation with AA and calcium 
ionophore and measured using reverse-phase HPLC. Anti-inflammatory activity of CO2 and DME oil 
was assessed by their potential to inhibit the production of LTB4, a pro-inflammatory end product of 
AA metabolism in the 5-LOX pathway.  Both CO2 and DME oils significantly inhibited LTB4 
production, in a dose-dependent manner, at 25 and 50 µg/mL when compared to vehicle control 
(Figure 3.2). 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: The effect of CO2 oil and DME oil on LTB4 production in porcine neutrophils. 
Porcine neutrophils were incubated in the absence and presence of CO2 oil or DME oil, AA and 
calcium ionophore to determine their potential at inhibiting LTB4 production via the 5-LOX pathway. 
LTB4 was quantified using reverse phase HPLC and ratioed to an internal standard (PGB2).   
Mean % control + SEM are shown. One-way ANOVA with Bonferroni’s post-hoc analysis was 
conducted (***P<0.001, n= 3 experiments in triplicate). 
 
*** 
*** 
*** *** 
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3.3.3 5β-scymnol does not inhibit the formation of the 5-lipoxygenase pathway end  
product LTB4  
Anti-inflammatory activity of 5β-scymnol was assessed by its potential to inhibit the production of 
LTB4, a pro-inflammatory end product of AA metabolism in the 5-LOX pathway. While 5β-scymnol 
did not significantly decrease LTB4 production, the trend towards increased LTB4 production at the 
higher concentrations was not statistically significant (Figure 3.3).  
 
 
 
 
  
 
 
 
 
 
 
 
Figure 3.3: The effect of 5β-scymnol on LTB4 production in porcine neutrophils. Porcine 
neutrophils were incubated in the absence and presence of 5β-scymnol, AA and calcium ionophore to 
determine 5β-scymnol’s potential at inhibiting LTB4 production via the 5-LOX pathway. LTB4 was 
quantified using reverse phase HPLC and ratioed to an internal standard (PGB2). The CO2 oil at  
50 µg/mL was utilised as a positive control. Mean % control + SEM are shown. One-way ANOVA 
with Bonferroni’s post-hoc analysis was conducted (***P<0.001, n= 3 experiments in triplicate). 
 
 
*** 
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3.3.4 CO2 and DME oils inhibit the formation of the cyclooxygenase pathway  
intermediate PGH2 
PGH2 production following the co-incubation of COX-1 or COX-2 with AA was measured via EIA. 
Anti-inflammatory activity of CO2 and DME oils were assessed by their potential to inhibit the 
production of PGH2, a pro-inflammatory intermediate of AA metabolism in the COX pathway.  
The CO2 oil significantly inhibited COX-1 and COX-2 at both 25 and 50 µg/mL. Similarly, DME oil 
also significantly inhibited COX-1 and COX-2 at both 25 µg/mL and 50 µg/mL (Figure 3.4). 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: The effect of CO2 oil and DME oil on PGH2 production by purified COX enzymes. 
COX-1 and COX-2 isoenzymes were incubated in the absence and presence of CO2 oil and AA to 
determine the potential of CO2 oil and DME oil to inhibit PGH2 production via the COX pathway. 
PGH2 was converted to the more stable prostaglandin F2α (PGF2α) and quantified via EIA. The control 
is an untreated reaction, whilst indomethacin and NS-398, known COX-1 and CoOx-2 inhibitors 
respectively, were used as positive controls at their IC50. Mean % control + SEM are shown. The 
control sample produced 2.5 + 0.2 µg/mL of PGF2α, in the COX-1 reaction, whilst 1.0 + 0.2 µg/mL of 
PGF2α was produced in the COX-2 reaction. One-way ANOVA with Bonferroni’s post-hoc analysis 
was conducted (**p<0.01, ***p<0.001, n= 3 experiments in duplicate). 
  
*** 
*** ** 
*** *** *** 
** ** 
*** 
*** 
 71 
 
3.3.5 5β-scymnol inhibits the formation of the cyclooxygenase pathway intermediate PGH2  
Anti-inflammatory activity of 5β-scymnol was assessed by its potential to inhibit the production of 
PGH2, a pro-inflammatory intermediate of AA metabolism in the cyclooxygenase pathway.  
5β-scymnol exhibited a dose-dependent inhibition of PGH2 production, via both COX-1 and COX-2 
at 0.2 and 2.0 µM (Figure 3.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: The effect of 5β-scymnol on PGH2 production by purified COX enzymes. COX-1 and 
COX-2 isoenzymes were incubated in the absence and presence of 5β-scymnol and AA to determine 
5β-scymnol’s potential at inhibiting PGH2 production via the COX pathway. The control is an 
untreated reaction, whilst indomethacin and NS-398, known COX-1 and COX-2 inhibitors 
respectively, were utilised as positive controls at their IC50. Mean % control + SEM are shown 
(control values as shown in Figure 3.4). One-way ANOVA with Bonferroni’s post-hoc analysis was 
conducted (*p<0.05, **p<0.01, ***p<0.001, n=3 experiments in duplicate). 
 
 
  
** 
* 
** 
*** ** 
* 
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3.3.6 CO2 oil, DME oil and 5β-scymnol show equipotent dose-dependent cytotoxicity in 
HaCaT cells  
The viability of HaCaT cells exposed in vitro for 24 hours to CO2 oil, DME oil and 5β-scymnol, was 
assessed over a broad concentration range to determine the appropriate sub-cytotoxic dose range for 
use in the scratch proliferation assay. The MNPs were not miscible in water and were therefore 
prepared in ethanol, as outlined in Section 2.3. Two solvent vehicles were originally considered for 
this study, i.e. ethanol and dipropylene glycol (DPG), with the least cytotoxic solvent to HaCaT cells 
selected for subsequent experiments. A significant decrease in cell viability was evident when HaCaT 
cells were treated with DPG at 0.5% v/v or ethanol at 1% v/v. As ethanol demonstrated a lower 
toxicity to HaCaT cells (Figure 3.6), it was the solvent vehicle selected for use with the treatments. 
HaCaT cells, treated with CO2 oil, DME oil and 5β-scymnol showed a significant decrease in cell 
viability at concentrations of 100 µg/mL or above (Figure 3.7). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Dose-dependent cytotoxicity of ethanol and DPG on HaCaT cells after 24 hrs.  
Mean % viability + SEM are shown, using the MTS cell viability assay. Two-way ANOVA with 
Bonferroni’s post-hoc analysis was conducted (*P<0.05, **p<0.01 and ***p<0.001, n= 2 experiments 
in triplicate). 
 
 
 
* 
*** 
*** 
* 
** 
*** 
*** 
*** 
*** 
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Figure 3.7: Dose-dependent cytotoxicity of CO2 oil, DME oil and 5β-scymnol on HaCaT cells 
after 24 hrs.  Mean % viability + SEM are shown, using the MTS cell viability assay. Two-way 
ANOVA with Bonferroni’s post-hoc analysis was conducted (*P<0.05 and ***p<0.001, n= 3 
experiments in triplicate). 
 
 
3.3.7 CO2 oil, DME oil and 5β-scymnol do not enhance HaCaT cell re-epithelialisation in vitro 
The effect of CO2 oil, DME oil and 5β-scymnol on the re-epithelialisation of HaCaT cells was 
evaluated utilising the scratch repair assay. HaCaT cells were incubated with non-cytotoxic doses 
(0.1, 1.0 and 10 µg/mL) of the MNPs for 10 hrs, as pre-determined in the cytotoxicity assay. Images 
captured at 0, 4, 8 and 10 hrs were assessed using ImageJ to quantify the remaining gap size at each 
time point. The CO2 and DME oils significantly impaired the re-epithelialisation of HaCaT cells at the 
highest concentration of 10 µg/mL, whilst 5β-scymnol did not significantly enhance nor impair gap 
closure (Figure 3.8). 
 
* 
*** 
*** 
*** 
*** 
*** 
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Figure 3.8: The effect of CO2 oil, DME oil and 5β-scymnol on HaCaT cell re-epithelialisation in 
vitro. HaCaT cells were grown to confluence in a 24 well culture plate and a horizontal scratch was 
made across the centre of each well using a p10 pipette tip, forming a gap in the monolayer. HaCaT 
cells were incubated in the absence and presence of CO2 oil, DME oil or 5β-scymnol for 10 hrs. 
Images were captured at 0, 4, 8 and 10 hrs and scratch closure was assessed by quantifying the 
reaming gap size at each time point using ImageJ. Mean % repair of control + SEM are shown.  
Two-way ANOVA with Bonferroni’s post-hoc analysis was conducted (***p<0.001, n= 3 
experiments in triplicate). 
 
 
 
*** *** *** 
*** 
*** *** 
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3.3.8 CO2 oil, DME oil and 5β-scymnol show equipotent dose-dependent cytotoxicity  
in HDF cells 
The viability of HDF cells exposed for 24 hours to CO2 oil, DME oil and 5β-scymnol was also 
assessed in vitro to determine the appropriate dose range to use in the scratch proliferation assay.  
A significant decrease in cell viability was evident when HDF cells were treated with the MNPs  
at 300 µg/mL (Figure 3.9). 
 
 
 
 
 
 
Figure 3.9: Dose-dependent cytotoxicity of CO2 oil, DME oil and 5β-scymnol on HDF cells after 
24 hrs. Mean % viability + SEM are shown. Two-way ANOVA with Bonferroni’s post-hoc analysis 
was conducted (***p<0.001, n= 3 experiments in triplicate). 
 
3.3.9 CO2 oil, DME oil and 5β-scymnol do not enhance HDF cell gap closure in vitro 
The effect of CO2 oil, DME oil and 5β-scymnol on the gap closure in HDF cultures was evaluated 
utilising the scratch repair assay. Images captured at 0, 4, 8 and 10 hrs analysed for exposure 
concentrations of 0.01, 0.1, 1.0 and 10 µg/mL. The CO2 oil significantly impaired the gap closure  
of a HDF monolayer at the highest concentration of 10 µg/mL at each timepoint (Figure 3.10).  
By comparison, DME oil only significantly inhibited gap closure at this dose at the 8 hr time point 
and 5β0scymnol only significantly inhibited repair at the same high dose at the 4 hr timepoint.   
 
*** 
*** 
*** 
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Figure 3.10: The effect of CO2 oil, DME oil and 5β-scymnol on the gap closure of a HDF cell 
monolayer in vitro. HDF cells were grown to confluence, scratched and imaged as described in 
Figure 3.8. Mean % repair of control + SEM are shown. Two-way ANOVA with Bonferroni’s  
post-hoc analysis was conducted (*p<0.05 and **p<0.01, n= 3 experiments in triplicate). 
 
 
 
 
*** *** *** 
* 
 
*** 
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3.4 DISCUSSION 
 
3.4.1 The lipid profile of Perna canaliculus derived marine oil is extraction solvent dependent 
Both CO2 and DME oils are derived from the NZGLM, Perna canaliculus and are manufactured via 
SFE. Supercritical fluid extraction facilitates the separation of individual components to achieve 
isolation and purification of a biologically active fraction. A fluid is termed supercritical when held at 
or above its critical temperature and pressure (341). The fluid adopts properties midway between a 
gas and a liquid and can readily penetrate porous and fibrous solids to allow the selective extraction of 
lipids from food products (341). Using supercritical fluids of CO2 and DME, enables the production of 
CO2 and DME oils from freeze dried stabilized mussel powder that are lipid rich extracts containing a 
mixture five main lipid classes (273). These are: sterol esters, triglycerides, free fatty acids, sterols 
and polar lipids (as shown in Figure 3.1). It was evident that CO2 oil contains more triglycerides and 
less polar lipids, such as phospholipids than the DME oil. This is largely due to the respective 
polarities of the extracting solvents, i.e CO2 is a non-polar molecule that facilitates the extraction of 
non-polar triglycerides. Comparatively, DME is slightly more polar, enabling it to better extract 
phospholipids and other polar lipids at the expense of the non-polar triglycerides. The CO2 oil’s 
bioactivity resides in its fatty acid class (271), and therefore the lipid profiles of the oils were further 
examined upon KOH hydrolysis of their triglyceride component to FFA. Figure 3.1 shows a markedly 
larger FFA band in the hydrolysed CO2 oil sample when compared to hydrolysed DME oil, which is 
consistent with hydrolysis of the larger triglyceride component observed in the non-hydrolysed CO2 
sample compared to the DME oil. The literature demonstrates that the anti-inflammatory activity of 
marine oils is largely derived from their omega-3 PUFA content (271, 277, 342). It is therefore likely 
that CO2 oil may exhibit better anti-inflammatory activity. To ascertain whether this difference in the 
lipid composition corresponded to a change in anti-inflammatory activity, both oils were tested for 
their ability to inhibit production of inflammatory metabolites of the 5-LOX and COX pathways, 
which help to evaluate their potential to modulate the inflammatory phase of wound healing.  
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3.4.2 CO2 and DME oils inhibit formation of the 5-LOX pathway end product LTB4  
and COX pathway intermediate PGH2 
During the inflammatory phase of repair, AA is cleaved via PLA2 from the phospholipid membrane 
of inflammatory cells, such as mast cells, neutrophils and macrophages, for subsequent production of 
inflammatory eicosanoids. The endogenous substrate AA is modified via 5-LOX for the production of 
the 4-series LTs and via COX for the production of the 2-series PGs. LTB4 is a potent chemoattractant 
of neutrophils and macrophages that can induce and prolong inflammation, leading to delayed repair 
and excessive scarring (116, 343, 344). Similarly, the COX pathway end products, PGD2 and PGE2, 
can promote inflammation at the site of repair, and they are known to function by increasing the 
permeability of the localised vasculature to accelerate immune cell infiltration (116).  
The anti-inflammatory activity of these marine oils were therefore assessed by their potential to 
inhibit the formation of LTB4 and PGH2, the latter being a precursor of PGD2 and PGE2. 
In this study, both CO2 and DME oils significantly inhibited LTB4 production in a  
dose-dependent manner when compared to the vehicle control. Both CO2 and DME oils significantly 
reduced LTB4 production with the concentration for 50% inhibition (IC50) at approximately 23 µg/mL 
(Figure 3.2).  
It has been shown that the ω-3 PUFAs present in the NZGLM oils, including EPA, are 
utilised as alternative substrates to AA in the 5-LOX pathway. This is due to EPA competing with AA 
for modification by 5-LOX to produce eicosapentaenoate metabolites, which shifts eicosanoid 
synthesis towards less pro-inflammatory species (271). This is demonstrated by the significant 
reduction in the pro-inflammatory AA metabolite LTB4 when porcine neutrophils are co-incubated 
with the EPA rich oils. Furthermore, both oils exhibited an equivalent level of activity, suggesting that 
the key differences in their lipid profiles has not produced a difference in their bioactivity on 5-LOX.   
In addition, both marine oils demonstrated an inhibition of COX pathway production of the 
intermediate PGH2. The COX pathway is responsible for prostanoid formation and includes 
production of prostaglandins, prostacyclins and thromboxanes, which have integral roles in the body. 
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These roles include: regulation of inflammation and modulation of platelet activation and aggregation 
(116), which are elicited via the production of prostanoids from two functional forms of COX, termed 
isoenzymes. These are COX-1 and COX-2, and although both isoenzymes produce PGs that promote 
inflammation, COX-1 also produces PGs that activate platelets and protect the stomach and intestinal 
lining (116, 284).  
In this study both CO2 and DME oils significantly inhibited PGH2 production in a  
dose-dependent manner when compared to the vehicle control. Both marine oils were tested in a cell 
free system for their ability to modulate PGH2 production by purified ovine COX-1 and -2 enzymes. 
The CO2 oil significantly reduced PGH2 production from COX-1 and COX-2, with IC50 values of 
approximately 43 and 46 µg/mL, respectively (Figure 3.4). Similarly, DME oil significantly reduced 
PGH2 production from COX-1 and COX-2, with IC50 values of approximately 50 and 60 µg/mL, 
respectively. The activities of the marine oils were also compared to indomethacin, a known COX-1 
inhibitor and NS-398, a specific inhibitor COX-2, which showed that the oils were able to act in an 
equivalent manner to inhibit PGH2 production, but with lower potency, when compared to the known 
COX inhibitors at their IC50 of 0.2µM. 
The literature shows that the NZGLM oils are able to modulate the production of pro-
inflammatory PGs via the COX pathway by utilising EPA as a competitive substrate inhibitor instead 
of AA (276). This is analogous to EPA’s role in reducing pro-inflammatory metabolite production via 
5-LOX. Our research group also reported the presence of a novel family of ω-3 PUFAs in NZGLM 
oil extracts, which are also competitive substrates for both COX and LOX pathways to produce less 
inflammatory metabolites than the AA-derived products (271). Both oils caused a similar level of 
COX-1 and -2 inhibition, without desirable preference for either isoenzyme, suggesting that their lipid 
composition has not influenced their COX modulating activity. In a previous study completed by the 
RMIT Natural Products Research Group, CO2 oil was evaluated for its potential to inhibit  
COX-1 and -2 metabolite production. It was shown that at 100 µg/mL CO2 oil inhibited both 
isoenzymes by 80%, which corresponds with its ability to inhibit PGH2 in a dose-dependent manner 
(276).  
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Although the marine oils may assist in acute wound repair, their time of application is critical. 
As discussed in Section 1.2.2, inflammation is required to prevent microbial colonisation and for the 
removal of cell debris. Inflammatory cells additionally secrete a series of growth factors that facilitate 
collagen deposition and re-epithelialisation, as shown in Table 1.1. Therefore, premature inhibition of 
this phase may reduce both the rate of wound closure and quality of the resolved wound. However, 
the inflammatory response must still subside for the wound healing cascade to advance to the 
proliferative phase (345). Therefore, the potent anti-inflammatory activity of the marine oils may 
accelerate the transition between these phases. Furthermore, the oils show potential for the 
management of inflammation in chronic wounds.  
3.4.3 5β-scymnol does not inhibit the formation of the 5-LOX pathway end product LTB4  
but inhibits formation of the COX pathway intermediate PGH2 
In addition, the MNP 5β-scymnol was assessed for its 5-LOX and COX modulating activity.  
5β-scymnol did not inhibit LTB4 production at the concentration range tested (Figure 3.3). However, a 
trend was observed towards enhanced LTB4 production when porcine neutrophils were co-incubated 
with 5β-scymnol at a concentration above 6.25 µM. It is possible that 5β-scymnol’s detergent activity 
elicited this effect via a biological surfactant related mechanism and may have partially compromised 
the integrity of the phospholipid membranes of the porcine neutrophils to facilitate AA release and 
provide additional substrate for 5-LOX metabolism.  
 5β-scymnol was also tested for its ability to inhibit the production of PGH2 from pure ovine 
COX-1 and -2 enzymes in a cell free system. 5β-scymnol significantly reduced PGH2 production, 
from COX-1, by 32 + 3% at 2 µM, whilst PGH2 production was significantly reduced, from COX-2, 
by 29 + 4% and 41 + 4% at 0.2 and 2 µM, respectively (Figure 3.5). Furthermore, 5β-scymnol at  
2 µM, matched the activity of the specific COX-2 inhibitor, NS-398, at its IC50, i.e. 5β-scymnol was 
therefore 10-fold less potent.   
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Although both marine oils also inhibited PGH2 production, their mode of action differs to that of 5β-
scymnol. The chemical structure of 5β-scymnol is markedly different to the PUFAs,  
as it features an aliphatic tri-alcohol moiety attached to a steroid backbone (288). Therefore, it cannot 
act as a substrate inhibitor of COX and must inhibit PGH2 production by an alternate mechansim. 
While it is well established that steroidal compounds are able to reduce PG production by modulating 
expression of COX or inhibiting PLA2, 5β-scymnol’s effect was seen using pure COX enzymes in a 
cell free system. As a direct inhibitory effect of steroidal agents on the active site of COX has not 
been reported in the literature, 5β-scymnol’s mechanism of action is unknown.  
 It was also evident that 5β-scymnol potentially favours inhibition of COX-2 over COX-1 by 
30% at 2µM (approximately 1.0 µg/mL). As briefly introduced above, COX-1 plays an important role 
in homeostatic function of the gastrointestinal tract and facilitates the activation and aggregation of 
platelets (116), and is also vital in mediating normal kidney function (346). By contrast, COX-2 is 
mainly induced in response to inflammatory stimuli, which led to the notion that selective COX-2 
inhibition can reduce production of pro-inflammatory mediators without sacrificing the homeostatic 
functions of COX-1-derived end products. This bioactivity is potentially favourable in a wound 
healing application, however, as discussed in Section 3.4.2, the time of application is integral to the 
success of an anti-inflammatory agent.  
3.4.4 CO2 oil, DME oil and 5β-scymnol do not enhance HaCaT cell re-epithelialisation  
or HDF cell gap closure in vitro 
Considering the wound healing process is a multi-faceted biological response assessing the MNPs’ 
effects on other key phases of repair was essential in this study. As stated in Section 1.2.3, the 
proliferative phase of repair necessitates fibroblast recruitment, granulation tissue formation, collagen 
deposition and re-epithelialisation (4). These processes are dependent on proliferation and migration 
of keratinocytes and fibroblasts.  
 The MNPs were therefore initially assessed for their cytotoxicity to human keratinocytes 
(HaCaT cells) and fibroblasts (HDF). Figures 3.7 and 3.9 demonstrate that these MNPs have a similar 
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dose response relationship on cell viability and show that HaCaT cells are 3-fold more sensitive to the 
MNPs than fibroblasts. This was shown via a significant loss in HaCaT cell viability following 
exposure to 100 µg/mL, whilst no significant loss in HDF cell viability was evident until 300 µg/mL 
of MNPs. Considering the anti-inflammatory effects of these MNPs were observed at much lower 
concentrations, it is reasonable to conclude that the MNPs have the potential to modulate the 
inflammatory phase of healing without impairing the viability of cells essential to the proliferative 
phase. In addition to their effects on cell viability, the MNPs were investigated for their potential to 
modulate the re-epithelialisation of keratinocytes and proliferation of fibroblasts, which was simulated 
in the scratch repair assay.   
 A gap was created in HaCaT and HDF cell monolayers, and the closure rate evaluated in the 
presence of the MNPs. It was evident that the MNPs had no effect on the gap closure rate of HaCaT 
or HDF cells at concentrations of 1.0 µg/mL or less. However, impaired scratch closure was observed 
in HaCaT cell cultures at 10 µg/mL for both CO2 and DME oil at all timepoints (Figure 3.8). In 
contrast, gap closure in HDF cultures was significantly impaired at all timepoints by CO2 oil with 
DME oil significantly inhibiting gap closure at 8 hrs only (Figure 3.10).  While 5β-scymnol at  
10 µg/mL significantly reduced gap closure in HDF cultures at 4 hours, this effect was transient and 
gap closure was the same as controls at 8 hrs. Furthermore, 5β-scymnol had no effect on HaCaT cell 
re-epithelialisation.  
  This demonstrates that HaCaT and HDF cells are more sensitive to the marine oils than  
5β-scymnol exposure. Although the MNPs do not impair the viability of HaCaT and HDF cells until 
exposed to 10-fold higher doses, it is clear that other metabolic pathways responsible for cell 
migration or proliferation are potentially hindered at much lower concentrations. Reduced 
keratinocyte and fibroblast activity at the wound site can impair remodelling by reducing the tensile 
strength of the final resolved wound (41), and these results  suggest that the marine oils should not be 
applied topically to wounds at concentrations exceeding 10 µg/mL. This lower dose would have 
reduced 5-LOX and COX modulating activity and therefore limits their overall wound healing 
potential.  
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3.5 CONCLUSION  
 
Many anti-inflammatory drugs developed thus far by the pharmaceutical industry display undesirable 
toxicity and associated adverse effects. Natural products that display high efficacy and potency 
combined with minimal side effects are therefore increasingly sought after as alternatives. 
Advancements in the development of wound healing remedies are gradual, due to the complex 
processes involved in each phase of wound healing. The inflammatory phase of healing is integral, but 
when exacerbated it can enhance immune cell infiltration, causing damage to host tissue and 
significantly delaying repair. The 5-LOX and COX pathways are important targets for immune 
response modulation and the NZGLM oils were shown to successfully inhibit the production of pro-
inflammatory eicosanoids from both pathways. Both marine oils demonstrated equipotent bioactivity, 
although their lipid profiles and extracting solvents differed. Furthermore, the MNPs tested did not 
enhance the re-epithelialisation of HaCaT cells and gap closure of HDF cultures, but instead they 
inhibited these processes at concentration which were 10-fold less than those which cause a loss in 
cell viability. Consequently, their potential to interfere with migratory or proliferative pathways at 
subcytotoxic concentrations demonstrates that their application as topical wound healing agents may 
be limited. Finally, 5β-scymnol did not alter gap closure in scratched keratinocyte or fibroblast 
monolayer cultures. However, 5β-scymnol also demonstrated direct inhibition of COX, by an 
unknown mechanism, which requires further investigation. 
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CHAPTER 4: WOUND HEALING POTENTIAL 
OF ZnO NANOPARTICLES 
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4.1 INTRODUCTION 
 
The four central phases of wound repair are haemostasis, inflammation, proliferation and remodelling, 
as discussed in Sections 1.2 and 3.1.  It is possible to modulate the inflammatory phase of repair via 
the inhibition of two key inflammatory pathways, as discussed in Chapter 3. Excessive inflammation 
is a leading cause of non-healing wounds and inhibits the sequence of events responsible for wound 
closure. These events include: fibroblast recruitment, collagen deposition and re-epithelialisation and 
encompass the proliferative phase of repair (347).    
Although excessive inflammation is detrimental, the proliferative phase is reliant on the 
secretion of growth factors from inflammatory cells. During the early proliferative phase fibroblasts 
migrate to the wound edge, under the influence of PDGF (30-32), TGFα (33, 34), TGFβ (18, 33, 35) 
and FGF (18, 32, 34), to commence synthesis of ECM components that provide a scaffold for the 
deposition of type III collagen (40). The collagen layer facilitates the migration of keratinocytes in a 
well-organised fashion to initiate closure of the wound. If fibroblast and keratinocyte proliferation and 
migration are inadequate, then wound closure is delayed or inhibited and, as a consequence, the 
healing tissue will display poor morphology. Due to the increasing use of NPs in wound management, 
and the long-standing use of bulk ZnO in skin rash creams, several ZnO NPs were selected for 
investigation of their potential to mediate the proliferative phase in healing wounds.  
4.1.1 ZnO NPs 
Nanoparticles are materials with three dimensions of the order of 100 nm or less which 
exhibit novel properties that differentiate them from their bulk material (297). As a material 
approaches the nanoscale its physical, chemical or biological characteristics may vary. Therefore, the 
size of a particle can be classed as one of its most important features. Nanoparticles have many 
applications and are utilised in a growing number of medical fields (299-304). This includes their use 
in wound management, whereby nanosilver is utilised in dressings for its rapid action and broad 
spectrum antibacterial activity (348). This has generated interest in the wound healing potential of 
other nanomaterials.   
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ZnO is globally regarded as one of the most topically applied compounds due to its approval 
by the FDA and other regulating agencies for its use in many sunscreen formulations (313). In recent 
decades, it has also attracted interest as a wound healing agent. There are limited studies evaluating 
the application of zinc, as an ion or compound, to healing wounds and the results of these studies 
remain inconclusive (84, 314, 322-326). However, a few of these studies have reported the wound 
healing benefits of ZnO. For example, ZnO has been shown to successfully enhance repair by 
improving re-epithelialisation, collagen deposition and the tensile strength of the final resolved wound 
(84, 314, 325, 326). However, the material’s particle size is usually not considered in these studies. 
Therefore, ZnO was investigated in this study at three different particle sizes (30, 80 and 200nm) to 
evaluate whether there is a size-dependent effect on the proliferative phase of wound repair.  
It has been shown that NPs readily agglomerate in solution (336, 349). This is due to the high 
surface energy of nanomaterials, which possess a high surface area to volume ratio. Therefore, a 
surfactant-dispersed variant of ZnO 30nm (termed “sZnO 30nm”) was also utilised to compare the 
effect of agglomeration state.  Furthermore, ZnCl2 and TiO2 25nm were utilised as a zinc ion control 
and a non-zinc NP material control, respectively. Additionally, the NP which most positively 
influenced in vitro re-epithelialisation was also investigated for its ability to modulate the 5-LOX and 
COX inflammatory pathways. 
 In this Chapter, all the experimental studies investigating the effect of ZnO NPs on the 
proliferative phase of healing are presented and examined in detail. The aims of these studies were to 
determine the NP’s effect on an in vitro model of re-epithelialisation and to explore its anti-
inflammatory activity.  
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4.2 MATERIALS AND METHODS 
 
A thorough explanation of the materials and methodology for the experimental procedures used to 
generate the results presented in this chapter are shown in Chapter 2. The following is a brief 
summary of the specific protocols used in the experiments described in Chapter 4.  
4.2.1 Nanoparticle preparation 
The nano-sized and bulk particulates were supplied by Micronisers Pty. Ltd. (Melbourne, 
Australia), and weighed and suspended in Milli-Q H2O at a final concentration of 20 mg/mL. The 
particulates were sonicated for 30 mins for both sterilization and to disperse the particles in solution 
prior to use, as utilised as outlined in Section 2.4. 
4.2.2 Cytotoxicity assay 
 The effect of ZnO 30nm, ZnO 80nm, ZnO 200nm, sZnO 30nm, ZnCl2 and TiO2 25nm on the 
viability of HaCaT, HEK and HDF cells was determined after 24 hrs of exposure to a concentration 
range from 0.01 up to 100 µg/mL. The cells were cultured as described in Sections 2.2.1, 2.2.2 and 
2.2.3, and seeded as outlined in Section 2.9. The tetrazolium compound MTS was added to the wells 
containing vehicle or particulate-treated cells, and converted to the coloured formazan product in 
viable cells.  
4.2.3 Scratch repair 
 The effect of ZnO 30nm, ZnO 80nm, ZnO 200nm, sZnO 30nm, ZnCl2 and TiO2 25nm on  
in vitro cell re-epithelialisation and gap closure of a fibroblast monolayer was assessed at a 
concentration range of 0.01 – 10 µg/mL. The cells were cultured as described in Sections 2.2.1, 2.2.2 
and 2.2.3, and seeded as outlined in Section 2.10. Monolayers of HaCaT, HEK, and HDF cells were 
scratched with a p10 pipette tip, then treated with the particulates of interest and imaged over a  
10 hr time course, in order to compare the gap closure rate of vehicle-treated versus particulate-treated 
cells. 
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4.2.4 Cell adhesion assay 
The effect of ZnO 30nm and sZnO 30nm on their potential to mediate adherence of HaCaT 
cells was evaluated. The cells were cultured as described in Section 2.2.1, and seeded as outlined in 
Section 2.11. The cells were treated with the NPs and incubated for 90 mins. The adherent and  
non-adherent cells were then quantified via either Trypan Blue Exclusion or MTS assay, as described 
in Section 2.11. 
4.2.5 Flow cytometry  
 The effect of ZnO 30nm, sZnO 30nm, ZnCl2 and TiO2 25nm on the expression of the 
proliferation marker Ki-67, and the adhesion and migration marker CD29, was evaluated in HaCaT 
cells. The cells were cultured as described in Section 2.2.1 and seeded as outlined in Section 2.12.  
The cells were treated with the NPs and incubated for either 4 or 10 hrs, at which point they were 
collected and fixed (as described in Section 2.12.1) and then stained for Ki-67 and CD20 marker 
expression (as outlined in Sections 2.12.2 and 2.12.3). 
4.2.6 Neutrophil 5-lipoxygenase inhibition 
The effect of ZnO 30nm on the inhibition of LTB4 from porcine neutrophils was determined 
via co-incubating the NP with freshly isolated neutrophils and AA substrate along with calcium 
ionophore to stimulate the production of inflammatory eicosanoids, as described in Section 2.7.3.  
The eicosanoids were extracted from the reaction mixture (as outlined in Section 2.7.4), and the LTB4 
production was quantitated via reverse phase HPLC (as described in Section 2.7.5).  
4.2.7 Cyclooxygenase inhibition 
The effect of ZnO 30nm on PGH2 formation in a cell free system, was determined by  
co-incubating the NP with either COX-1 or COX-2 and the AA substrate, as described in Section 
2.8.1. PGH2 was then reduced to the more stable PGF2α, which was quantitated via EIA, as outlined in 
Section 2.8.2. 
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4.3 RESULTS 
 
4.3.1 ZnO NPs show dose- and particle size-dependent cytotoxicity in HaCaT cells 
The viability of HaCaT cells exposed for 24 hrs to the ZnO NPs was assessed in vitro to investigate 
the effect of NP size on cytotoxicity. Furthermore, sZnO 30nm, ZnCl2 and TiO2 25nm were evaluated 
as controls for NP dispersion, free zinc ions in solution, and as a non-zinc NP material, respectively. 
As shown in Figure 4.1, a significant decrease in cell viability was evident when the HaCaT cells 
were treated with 10 µg/mL of ZnO 80nm, ZnO 30nm and ZnO 200nm. All test materials 
significantly decreased cell viability at 100 µg/mL with TiO2 25nm being by far the least cytotoxic.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Dose- and particle size-dependent cytotoxicity of the ZnO NPs to HaCaT cells after 
24 hrs.  HaCaT cells were incubated with ZnO 30nm, ZnO 80nm, ZnO 200nm, sZnO 30nm, ZnCl2 
and TiO2 25nm. Mean % viability + SEM are shown. Two-way ANOVA with Bonferroni’s post-hoc 
analysis was conducted (*P<0.05 and ***p<0.001, n= 3 experiments in triplicate). 
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4.3.2 ZnO NPs enhance HaCaT cell re-epithelialisation in vitro in a dose- and particle  
size-dependent manner  
The effect of the ZnO NP materials on the re-epithelialisation of HaCaT cells was assessed in vitro, 
along with the control materials. The cell viability data (Figure 4.1) indicated that some cytotoxicity 
would occur only at the highest concentrations investigated (i.e. 10 µg/mL) during the shorter 10 hr 
incubation period. The materials were evaluated at 0.01, 0.1, 1.0 and 10 µg/mL and images were 
captured at 0, 4, 8 and 10 hrs. Re-epithelialisation was assessed by quantifying the required gap-fill 
time using ImageJ, which revealed that after 10 hrs, the scratched and untreated HaCaT cell 
monolayers had repaired the gap by 60 + 2%. Remarkably, the ZnO NPs enhanced scratch closure in a 
dose- and particle size-dependent manner. The smaller ZnO 30nm NPs had the greatest effect on  
re-epithelialisation at 0.1 µg/mL, which significantly stimulated repair by nearly 40% at both  
8 and 10 hrs. At this same optimal dose, the ZnO 80nm NPs were intermediately effective with a  
25% enhancement, whilst the ZnO 200nm bulk particulate was the least effective with only a  
10% enhancement (Figure 4.2). Furthermore, both the ZnCl2 and TiO2 significantly enhanced repair 
by 20% and 30% respectively, as shown in Figure 4.3, at the same dose of 0.1 µg/mL. Interestingly, 
the surfactant dispersal of the ZnO 30nm NPs removed its bioactivity, as sZnO 30nm was ineffective.  
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Figure 4.2: The effect of ZnO 30nm, ZnO 80nm and ZnO 200nm on HaCaT cell  
re-epithelialisation in vitro. HaCaT cell monolayers were scratched and incubated with the materials 
for 10 hrs. Images were captured at 0, 4, 8 and 10 hrs and assessed with ImageJ to quantify the  
gap size at each time point. Mean % repair of control + SEM are shown. Two-way ANOVA with 
Bonferroni’s post-hoc analysis was conducted (*P<0.05 and ***p<0.001, n= 3 experiments in 
triplicate). 
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Figure 4.3: The effect of sZnO 30nm, ZnCl2 and TiO2 25nm on HaCaT cell  
re-epithelialisation in vitro. HaCaT cell monolayers were scratched and incubated with treatments as 
detailed in Figure 4.2. Mean % repair of control + SEM are shown. Two-way ANOVA  
with Bonferroni’s post-hoc analysis was conducted (*P<0.05, **p<0.01 and ***p<0.001,  
n= 3 experiments in triplicate). 
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4.3.3 ZnO NPs show dose- and particle size-dependent cytotoxicity in HEK cells in vitro 
The effect of ZnO NPs on keratinocyte cytotoxicity was further assessed in primary human cells  
in vitro. Furthermore, sZnO 30nm, ZnCl2 and TiO2 25nm were additionally evaluated, as outlined  
in Section 4.3.1. The primary keratinocytes were more sensitive than HaCaT cells, as shown by a 
significant decrease in cell viability when HEK cells were treated with ZnO 30nm at 3 µg/mL, and 
ZnO 80nm and ZnO 200nm at 10 µg/mL (Figure 4.4). Similarly, ZnCl2 was cytotoxic at 10 µg/mL, 
whilst sZnO 30nm and TiO2 25nm did not affect HEK viability at the concentration range tested.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Dose- and particle size-dependent cytotoxicity of ZnO NPs to HEK cells after 24 hrs.  
HEK cells were incubated with ZnO 30nm, ZnO 80nm, ZnO 200nm, sZnO 30nm, ZnCl2 and  
TiO2 25nm. Mean % viability + SEM are shown. Two-way ANOVA with Bonferroni’s  
post-hoc analysis was conducted (**P<0.01 and ***p<0.001, n=3 experiments in triplicate using 
HEK cells from 1 human donor). 
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4.3.4 ZnO NPs enhance HEK re-epithelialisation in vitro in a dose- and particle  
size-dependent manner 
The effect of the ZnO materials on keratinocyte re-epithelialisation in vitro was further assessed in 
primary cells, along with the control materials. The cell viability data (Figure 4.4) indicated that 
cytotoxicity would not be occurring at the highest concentration investigated (i.e. 1.0 µg/mL) during 
the shorter 10 hr incubation period. The materials were evaluated at 0.01, 0.1 and 1.0 µg/mL and the 
treated wells were again imaged at 0, 4, and 10 hrs and re-epithelialisation was assessed by 
quantifying the required gap-fill time using ImageJ, which showed that scratched and untreated HEK 
monolayers had repaired the gap by 50 + 4% after 10 hrs (Figure 4.5). As with HaCaT cells,  
the ZnO 30nm NPs markedly enhanced repair by 45% at an optimal dose of 0.1 µg/mL. The other 
materials were compared with ZnO 30nm NPs at this same dose (Figure 4.6). Unlike HaCaT cells, 
there was a lack of effect from ZnO 80nm and ZnO 200nm materials by 10 hrs. Similar to HaCaT 
cells, the sZnO 30nm NPs were again ineffective, whilst both ZnCl2 and the TiO2 NPs were shown to 
significantly enhance repair at the same optimal dose by 25 to 30%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: The effect of the ZnO 30nm NP on HEK re-epithelialisation in vitro. HEK 
monolayers were scratched and incubated with the materials for 10 hrs. Images captured at 0, 4 and 10 
hrs, were assessed with ImageJ to quantify the gap size at each time point. Mean % repair of control + 
SEM are shown. Two-way ANOVA with Bonferroni’s post-hoc analysis was conducted (*p<0.05, 
and ***p<0.001, n=3 from 2 separate experiments in triplicate using HEK cells from 3 human 
donors). 
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Figure 4.6: A comparison of the effects of the materials on HEK re-epithelialisation in vitro. 
HEK monolayers were scratched and incubated with a 0.1 µg/mL dose of the materials for 10 hrs and 
images were captured and assessed as described in Figure 4.5. Two-way ANOVA with Bonferroni’s 
post-hoc analysis was conducted (*p<0.05, *p<0.01 and ***p<0.001, n=3 from 2 separate 
experiments in triplicate using HEK cells from 3 human donors). 
 
 
4.3.5 ZnO NPs show equipotent dose-dependent cytotoxicity in HDF cells  
The cytotoxicity profile of the ZnO NPs was assessed in HDF cells as a comparison for their effects in 
keratinocytes. Furthermore, sZnO 30nm, ZnCl2 and TiO2 25nm were additionally evaluated, as 
outlined in Section 4.3.1. The variously sized ZnO materials, i.e. ZnO 30nm, ZnO 80nm and  
ZnO 200nm, demonstrated similar cytotoxicity profiles in HDF cells, with similar sensitivity to that of 
the primary keratinocytes, except for ZnO 200, which was more cytotoxic in HEK cells. The other 
materials, sZnO 30, ZnCl2 and TiO2, were well tolerated by HDF cells at 10 µg/mL. 
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Figure 4.7: Dose- and particle size-dependent cytotoxicity of ZnO NPs to HDF cells after 24 hrs. 
HDF were incubated with ZnO 30nm, ZnO 80nm, ZnO 200nm, sZnO 30nm, ZnCl2 and TiO2 25nm. 
Mean % viability + SEM are shown. Two-way ANOVA with Bonferroni’s post-hoc analysis  
was conducted (*p<0.05, **P<0.01 and ***p<0.00, n=3 experiments in triplicate using HDF cells 
from 1 human donor). 
 
 
4.3.6 ZnO NPs do not enhance HDF cell gap closure in vitro 
The effect of the ZnO NPs on gap closure in HDF cultures was also investigated in vitro at 0.01, 0.1, 
1.0 and 10 µg/mL. Furthermore, sZnO 30nm, ZnCl2 and TiO2 25nm were additionally evaluated. The 
cell viability data (Figure 4.7) indicated that HDF cells would not be affected over the 10 hr 
incubation period by doses of 1.0 µg/mL. However, the highest dose of 10 µg/mL for the ZnO 
materials was cytotoxic, and this was reflected in the lack of gap closure in scratched HDF 
monolayers. Scratched and untreated HDF monolayers had repaired the gap by 50 + 3% after 10 hrs. 
Analysis of the images captured at 0, 4, 8 and 10 hrs (Figure 4.8) revealed that none of the treatments 
had a stimulatory effect on the repair of scratched fibroblast monolayers.  
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Figure 4.8: The effect of ZnO 30nm, ZnO 80nm, ZnO 200nm, sZnO 30nm, ZnCl2 and  
TiO2 25nm on the gap closure of a HDF monolayer in vitro. HDF monolayers were scratched and 
incubated with the materials for 10 hrs and images were captured and assessed as described in  
Figure 4.5. Mean % repair of control + SEM are shown. Two-way ANOVA with Bonferroni’s  
post-hoc analysis was conducted (*p<0.05, **P<0.01 and ***p<0.001, n=2 experiments in triplicate 
using HDF cells from 2 human donors). 
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4.3.7 ZnO NPs do not moderate the expression of the cell proliferation marker Ki-67 
As ZnO 30nm NPs were the most potent in enhancing re-epithelialisation, their effect on cell 
proliferation was investigated as a potential mode of action. The cell proliferation marker Ki-67 is 
expressed during all active phases of the cell cycle. It was therefore hypothesized that the ZnO NPs 
enhance re-epithelialisation by inducing cell proliferation and Ki-57 expression in the keratinocytes. 
In order to create a negative control for this experiment two methods were employed to downregulate 
Ki-67 expression. Firstly, the cells were serum starved to reduce the rate of cell division; and 
secondly, contact inhibition was induced to arrest cell growth. As shown in Figure 4.9, serum 
starvation for 24 hrs significantly reduced HaCaT cell proliferation by 50%. Consequently, Ki-67 
expression was evaluated by flow cytometry in these serum starved cells after 24 hrs, along with 
contact-inhibited confluent cell monolayers, which were formed by plating 4x the regular HaCaT cell 
seeding density 24 hrs prior to sampling. As shown in Figure 4.10, staining with a 1:500 dilution of 
Ki-67 antibody revealed a significant reduction in the expression dude 
of this marker in the confluent cell monolayer and this was therefore chosen as the appropriate 
negative control to use in subsequent experiments. Ki-67 expression was next evaluated in cells 
exposed to ZnO 30nm, sZnO 30nm, TiO2 25nm for 4 or 10 hrs at 0.01, 0.1 and 1.0 µg/mL, in order to 
replicate the scratch repair analysis times. As shown in Figures 4.11 and 4.12, Ki-67 expression was 
not altered in cells exposed to various zinc-containing materials. However Ki-67 expression was 
moderately upregulated in HaCaT cells exposed to a 1.0 µg/mL dose of TiO2 25nm NPs at the 4 hr 
time point only (Figure 4.12). 
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Figure 4.9: The effect of serum depletion on HaCaT cell proliferation. HaCaT cells were 
incubated with reduced serum cell culture media for 18, 24 or 48 hrs to impair cell division, which 
was evaluated utilising the MTS assay. Control wells represent cells exposed to normal 5% (v/v) FBS 
in RPMI media. Mean % control + SEM are shown. One-way ANOVA with Bonferroni’s  
post-hoc analysis was conducted (*p<0.05, **p<0.01 and ***p<0.001, n=2 experiments in triplicate). 
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Figure 4.10: The effect of serum starvation and contact inhibition on Ki-67 expression.  
HaCaT cells were plated in either serum depleted media for 24 hrs or grown into a confluent cell 
monolayer and stained with PE anti-human Ki-67 antibody at a 1:500, 1:1000 and 1:10000 dilution  
for flow cytometric analysis. Mean % control + SEM are shown. One-way ANOVA with 
Bonferroni’s post-hoc analysis was conducted (*p<0.05, n=2 experiments in duplicate). 
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Figure 4.11: The effect of the ZnO 30nm and sZnO 30nm NPs on Ki-67 expression in HaCaT 
cells. HaCaT cells were plated in a 24 well culture plate and exposed to either ZnO 30nm or sZnO 
30nm NPs for 4 or 10 hrs. Confluent cell monolayers were utilised as a negative control  
to downregulate Ki-67 expression. The cells were stained with PE anti-human Ki-67 antibody at a 
1:500 dilution for flow cytometric analysis. Mean % control + SEM are shown. One-way ANOVA 
with Bonferroni’s post-hoc analysis was conducted (***p<0.001, n=3 experiments in duplicate). 
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Figure 4.12: The effect of ZnCl2 and the TiO2 25nm NP on Ki-67 expression in HaCaT cells. 
HaCaT cells were plated in a 24 well culture plate and exposed to either ZnCl2 or TiO2 25nm NPs and 
Ki-67 expression measured as described in Figure 4.11. Mean % control + SEM are shown.  
One-way ANOVA with Bonferroni’s post-hoc analysis was conducted (**p<0.01 and ***p<0.001, 
n=3 experiments in duplicate). 
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4.3.8 ZnO NPs do not alter HaCaT cell adhesion in vitro 
As ZnO 30nm NPs were the most potent in enhancing re-epithelialisation, their effect on cell adhesion 
was investigated as a potential contribution to the mode of action. The effect of ZnO 30nm and sZnO 
30nm NPs on the adherence of keratinocytes was evaluated in vitro. The time taken for half of a 
plated HaCaT cell population to achieve adherence was determined via aspirating the non-adherent 
cells from specific wells at 30 min intervals, and then counting the reaming adherent cells using a 
haemocytometer via the Trypan Blue Exclusion method, as outlined in Section 2.2.1. As shown in 
Figure 4.13, it was determined that approximately 90 mins was required for the adherence of 50% of 
the HaCaT cells in each well. To determine whether ZnO 30nm or sZnO30nm affect the rate of cell 
adherence, the HaCaT cells were co-plated with the ZnO NPs at the optimal re-epithelialisation dose 
of 0.1 µg/mL and incubated for 90 mins. The influence of NPs on the cell adherence was assessed via 
two methods: using the Trypan Blue Exclusion method on adherent cells after detachment; using 
MTS assay to measure the number of living cells adhered to the surface of each well.  As shown in 
Figures 4.14 and 4.15, no difference in the rate of cell attachment was found following exposure to 
ZnO 30nm and sZnO 30nm NPs when compared to control well, when evaluated with Trypan Blue. 
Furthermore, this observation was confirmed when the viable adherent cell number was assessed by 
the MTS assay (Figure 4.16 and 4.17).  
 
 
 
 
 
 
 
Figure 4.13: Rate of HaCaT cell adhesion. HaCaT cells (5 x 10
5
) were seeded into 24 well culture 
plates. At 30 min intervals non-adherent cells were aspirated and the remaining adherent  
cells were detached and stained with Trypan Blue for counting with a haemocytometer.  
Mean % cell adherence + SEM are shown (n=3 experiments in triplicate). 
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Figure 4.14: The effect of the ZnO 30nm NP on HaCaT cell adherence and cell viability  
when evaluated by the Trypan Blue Exclusion method. HaCaT cells were co-seeded with the  
ZnO 30nm NPs into 24 well culture plates. At 90 mins, the wells were washed and the adherent  
cells detached and stained with Trypan blue for counting with a haemocytometer. Mean % cell 
adherence + SEM are shown (n=2 experiments in triplicate). 
 
 
 
 
 
 
 
 
 
 
Figure 4.15: The effect of the sZnO 30nm NP on HaCaT cell adherence and cell viability  
when evaluated by the Trypan Blue Exclusion method. HaCaT cells were co-seeded  
with the sZnO 30nm NPs into 24 well culture plates and processed as described in Figure 4.14.  
Mean % cell adherence + SEM are shown (n=2 experiments in triplicate).  
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Figure 4.16: The effect of the ZnO 30nm NP on HaCaT cell adherence when evaluated  
by the MTS assay. HaCaT cells were co-seeded with the ZnO 30nm NPs into 24 well culture plates.  
At 90 mins, the unattached cells were removed to separate plates and the viable cell number for both 
the adherent and non-adherent populations were measured by the MTS assay. Mean % cell adherence 
or detachment + SEM are shown (n=2 experiments in triplicate). 
 
 
 
 
 
 
 
 
 
 
Figure 4.17: The effect of the sZnO 30nm NP on HaCaT cell adherence when evaluated  
by the MTS assay. HaCaT cells were co-seeded with the ZnO 30nm NPs into 24 well culture  
plate and adherent and non-adherent cell populations processed as described in Figure 4.16.  
Mean % cell adherence or detachment + SEM are shown (n=2 experiments in triplicate). 
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4.3.9 ZnO NPs do not moderate the expression of the cell adhesion and migration marker 
CD29  
To further investigate the effect of ZnO 30nm on cell behaviour, the expression of the cell adhesion 
and migration marker CD29 was measured via flow cytometry in ZnO treated HaCaT cells. This 
protein plays a crucial role in cell-cell and cell-matrix interactions, in order to facilitate keratinocyte 
migration. It was therefore hypothesized that the ZnO NPs may inhibit expression of this marker, thus 
reducing adhesion and promote HaCaT cell migration that would assist the keratinocyte re-
epithelialisation process. The cells were exposed to ZnO 30nm, sZnO 30nm, ZnCl2 and TiO2 25nm 
for 4 or 10 hrs at 0.1 and 1.0 µg/mL, in order to replicate the scratch repair analysis times. Contacted-
inhibited confluent cell monolayers were utilised as a positive control, and was seen to significantly 
reduce CD29 expression at both 4 and 10 hr timepoints (Figures 4.18 and 4.19). However, CD29 
expression was not altered in any of the exposed cells.   
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Figure 4.18: The effect of the ZnO 30nm and sZnO 30nm NPs on CD29 expression in HaCaT 
cells. HaCaT cells were plated in a 24 well culture plate and exposed to either ZnO 30nm  
or sZnO 30nm NPs for 4 or 10 hrs. Confluent cell monolayers were utilised as a positive control  
to downregulate CD29 expression. The cells were stained with PE anti-human CD29 antibody  
for flow cytometric analysis. Mean % control + SEM are shown. One-way ANOVA with 
Bonferroni’s post-hoc analysis was conducted (*p<0.05 and **p<0.01, n=2 experiments in duplicate). 
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Figure 4.19: The effect of ZnCl2 and the TiO2 25nm NP on CD29 expression in HaCaT cells. 
HaCaT cells were plated in a 24 well culture plate and exposed to either ZnCl2 or TiO2 25nm NPs  
and CD29 measured as described in Figure 4.18. Mean % control + SEM are shown.  
One-way ANOVA with Bonferroni’s post-hoc analysis was conducted (*p<0.05 and **p<0.01,  
n=2 experiments in duplicate). 
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4.3.10 ZnO NPs inhibit the formation of the 5-lipoxygenase pathway end product LTB4 
The anti-inflammatory activity of ZnO 30nm NPs was assessed by its potential to inhibit the 
production of LTB4, a pro-inflammatory end product of AA metabolism in the 5-LOX pathway.  
As shown in Figure 4.20, the ZnO 30nm NPs significantly inhibited LTB4 production in a  
dose-dependent manner (*p<0.05 and **p<0.01 respectively).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20: The effect of the ZnO 30nm NP on LTB4 production in porcine neutrophils.  
Porcine neutrophils were incubated in the absence and presence of ZnO 30nm NPs, AA and calcium 
ionophore to determine its potential at inhibiting LTB4 production via the 5-LOX pathway.  
LTB4 was quantified using reverse phase HPLC and ratioed to an internal standard (PGB2).  CO2 oil  
at 50 µg/mL (as shown in Figure 3.2) was utilised as a positive control. Mean % control + SEM  
are shown. One-way ANOVA with Bonferroni’s post-hoc analysis was conducted  
(*p<0.05 and **p<0.01, n=3 experiments in triplicate). 
 
 
 
***
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4.3.11 ZnO NPs inhibit the formation of the COX-2 pathway intermediate PGH2 
PGH2 production was stimulated via the co-incubation of COX-1 or COX-2 with AA and measured 
via EIA. Anti-inflammatory activity of ZnO 30nm NPs was assessed by its potential to inhibit the 
production of PGH2, a pro-inflammatory intermediate of AA metabolism in the COX pathway. 
Although the ZnO 30nm NPs did not significantly inhibit PGH2 production by COX-1 it did 
significantly inhibit COX-2 at 0.1 µg/mL and at 1.0 µg/mL (*p<0.05), as shown in Figure 4.21.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21: The effect of the ZnO 30nm NP on PGH2 production by purified COX enzymes. 
COX-1 and COX-2 isoenzymes were incubated in the absence and presence of the ZnO 30nm NPs 
and AA to determine its potential at inhibiting PGH2 production via the COX pathway. PGH2 was 
converted to the more stable prostaglandin F2α (PGF2α) and quantified via EIA. The control is an 
untreated reaction, whilst indomethacin and NS-398, known COX-1 and COX-2 inhibitors 
respectively, were utilised as positive controls at their IC50.  Mean percentage control + SEM are 
shown (control vales as shown in Figure 3.4). One-way ANOVA with Bonferroni’s post-hoc analysis 
was conducted (*p<0.05 and **p<0.01, n=3 experiments in duplicate). 
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4.4 DISCUSSION 
 
4.4.1 ZnO NPs show dose- and particle size-dependent cytotoxicity in HaCaT cells 
The effect of ZnO NPs on HaCaT cell cytotoxicity was investigated to discern whether there is a NP 
size effect on the viability of epidermal keratinocytes, which are integral to in vivo wound  
re-epithelialisation. Decreased cell viability was observed in ZnO treated cells after 24 hrs at doses 
from 10 µg/mL. A particle size-dependent effect was observed, as the ZnO 200nm particulates were 
the most cytotoxic, followed by the ZnO 30nm NPs and the ZnO 80nm NPs. In contrast, our 
laboratory has reported a different particle-size dependent cytotoxicity profile in THP-1 monocytes 
and macrophages, whereby the ZnO 30nm NPs were the most cytotoxic followed by ZnO 80nm NPs 
and the ZnO 200nm particulate was the least cytotoxic (336). This demonstrates that the profile of 
cytotoxicity for ZnO particulates is both particle size- and cell type-dependent. This is likely due to 
the functional differences between the epidermal cells and cells of the immune system. Epidermal 
keratinocytes are highly specialised epithelial cells that provide a protective barrier to guard the body 
against microorganisms, viruses, parasites, heat and water loss (2, 350). In contrast, monocytes and 
macrophages are phagocytic cells that are adept at engulfing cell debris, microbes and foreign 
materials (18). Therefore, it is likely that the rate of particulate uptake is different between these cell 
types for the different sized materials.  
 In section 4.1.1, it was stated that the ZnO NPs readily agglomerate in solution and the 
agglomeration is dependent on their primary particle sizes, and dispersion as previously reported by 
our laboratory (336). The surfactant-dispersed sZnO 30nm NPs were less cytotoxic to keratinocytes 
than the ZnO 30nm NPs (Figure 4.1), indicating that particle agglomeration influences cytotoxicity 
and is another important parameter when assessing the effects of NPs in an in vitro system. 
Furthermore, ZnCl2 was also less cytotoxic than the ZnO NPs. ZnCl2 is a water-soluble compound, 
which dissociates to form free zinc ions in solution. However, our laboratory has recently shown that 
ZnCl2 forms a range of poorly soluble carbonate and phosphate nano-particulate species when added 
to mammalian cell culture media (335). Consequently, it is therefore difficult to discern between the 
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cytotoxicity attributed to the free zinc ions verses those of the zinc precipitates. Additionally, the 
cytotoxicity of TiO2 25nm NPs to HaCaT cells were assessed and utilised as a non-zinc NP material 
control in this study. These TiO2 NPs were well tolerated by the cells at both 10 and 100 µg/ml when 
compared to the other materials. This is likely due to a large difference in solubility, as ZnO NPs are 
highly water soluble while TiO2 is insoluble (351).  
4.4.2 ZnO NPs enhance in vitro re-epithelialisation of HaCaT cells in a dose- and  
particle size-dependent manner 
The ZnO NPs were evaluated in an in vitro system of keratinocyte re-epithelialisation by measuring 
the required gap-fill time of scratched HaCaT cell monolayer cultures over a 10 hr period.  
As discussed in Sections 1.7 and 4.1.1, enhanced re-epithelialisation has been observed in ZnO treated 
wounds in vivo (314, 325, 326).  However, the underlying mechanism and particle size dependence of 
this effect was unclear. The cell viability profile (Figure 4.1) was utilised to establish a suitable dose 
range in order to assess ZnO effect on re-epithelialisation in HaCaT cells. Notably, the ZnO NPs 
enhanced in vitro re-epithelialisation in a dose- and particle size-dependent manner, with ZnO 30nm 
being the most potent (Figure 4.2), followed by ZnO 80nm and ZnO 200nm. This effect had a 
biphasic dose-response profile as it was optimal at 0.1 µg/mL for all materials, but was less effective 
at higher and lower doses. Interestingly, surfactant-dispersed ZnO 30nm variant, sZnO 30, did not 
alter the scratch closure time (Figure 4.3), indicating that particle agglomeration greatly influences the 
ZnO NP enhancement of re-epithelialisation. Furthermore, ZnCl2 also enhanced in vitro repair. 
Although it is unknown whether ZnCl2 elicited its effect as a free ion or as an insoluble zinc 
precipitate, it has been shown that zinc ions can similarly enhance re-epithelialisation in keratinocyte 
cultures (352). As outlined in Sections 4.1.1 and 4.4.1, TiO2 25nm NPs were utilised in this study as a 
non-zinc NP material control. Interestingly, TiO2 NPs also enhanced in vitro re-epithelialisation to a 
similar extent as seen with the ZnO 30nm NPs. Although these two NPs contain different materials, 
they do share a mutual characteristic, i.e both materials exhibit a similar primary particle size. This 
suggests that the enhanced re-epithelialisation observed in HaCaT cells may not be nanomaterial 
specific but a size dependent effect, although agglomeration size is also important. 
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4.4.3 ZnO NPs show dose- and particle size-dependent cytotoxicity in HEK cells 
In order to confirm whether the effects seen in the immortalised HaCaT cell line also occurred in 
primary cells in general, human epidermal keratinocytes from three human donors were also studied. 
The effect of ZnO NPs on primary keratinocyte viability was investigated to determine a suitable dose 
range for evaluating their effect on in vitro re-epithelialisation. The primary cells were 10-fold more 
sensitive than HaCaT cells to the cytotoxic effects of ZnO NPs. HEK cell viability was markedly 
reduced at 10 µg/mL, with ZnO 30nm also decreasing viability at 3.0 µg/mL (Figure 4.4). In contrast, 
the ZnO 80nm and ZnO 200nm materials both appeared to enhance the cell viability at 3.0 µg/mL. 
This may have been due to either the materials enhancing cell proliferation, or increasing the 
activation and metabolism of MTS by the cell’s mitochondria. However, considering the steep loss in 
viability between 3.0 and 10 µg/mL, the latter explanation is more likely. Furthermore, out laboratory 
has previously reported a relationship in mitochondrial superoxide generation with increasing 
concentrations of ZnO NPs in THP-1 monocytes and macrophages (336). This effect has also been 
observed in keratinocyte cultures (353). Although ROS in moderate levels can regulate cellular 
signalling, in excess they lead to cell death via apoptosis, which alters mitochondrial metabolism 
(354). It is therefore likely that this effect was produced as a result of a near cytotoxic dose or an 
adaptive metabolic response to increased intracellular Zn
2+
 caused by the ZnO NPs. There was also a 
trend towards this effect occurring to a smaller degree in ZnO 30nm NP treated cells at 1.0 µg/mL, 
and also in ZnCl2 treated cells at 3.0 µg/mL, prior to a significant loss in cell viability at the next 
highest dose. As shown in HaCaT cells, the sodium polyacrylate coating on the sZnO 30nm NPs 
appeared to confer cytoprotection. Similarly, TiO2 25nm NPs did not affect the viability of HEK at 
the concentration range tested, as was the case with HaCaT cells.  
4.4.4 ZnO NPs enhance in vitro re-epithelialisation of HEK in a dose- and particle  
size-dependent manner 
Primary keratinocytes were also investigated in order to demonstrate the reproducibility of the in vitro 
model, and to verify that the observation of re-epithelialisation enhancing effects of ZnO NPs was not 
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an artefact of the immortalised cell line. ZnO 30nm NPs were evaluated at 0.01, 0.1, and 1.0 µg/mL, 
which was below the cytotoxic concentration (Figure 4.4), whilst the other materials were evaluated at 
the optimal dose of 0.1 µg/mL only. These doses also enabled a direct comparison to the doses used in 
HaCaT cell experiment. As shown in Figure 4.5, the ZnO NPs enhanced repair in a biphasic  
dose-dependent manner, whilst Figure 4.6 shows that this effect is particle size-dependent. Analogous 
to the effect seen with HaCaT cells, ZnO 30nm NPs had the greatest effect on re-epithelialisation and 
stimulated gap closure at 0.1 µg/mL, and was marginally more potent in the primary cells than in the 
immortalised cells. Furthermore, sZnO 30nm NPs had no effect on re-epithelialisation, as was shown 
in HaCaT cells, which further supports the agglomeration dependency of this effect. Additionally, 
both ZnCl2 and TiO2 25nm also enhanced repair of HEK cells, in a similar manner to the HaCaT cells 
(Figure 4.6), further supporting the general nanomaterial effects in the immortalised cells. 
Although both the HaCaT and HEK cells originate from the skin epithelium, there are critical 
differences in their genetic composition. This is largely due to the nature of transformed cells, 
whereby immortalization is achieved via the specific mutation and regulation of genes that induce 
apoptosis (355). The p53 protein is a multifunctional tumor suppressor protein, which becomes 
activated in response to cell stress. Its activation can initiate cell cycle arrest, cellular senescence or 
apoptosis, which is an important process of deleting damaged cells that avoids local inflammation. A 
p53 mutation, such that is found in the HaCaT cell line, grants these cells a high capacity to 
differentiate, proliferate and resist apoptosis (350, 355). Interestingly, the ZnO 30nm NPs had a 
greater effect in the HEK cells, which exhibit normal p53 expression.  
 It has been shown in the literature that the rate of ZnO NP uptake is cell-cycle dependent 
(356). The cell cycle is divided into 4 distinct phases: G1 (gap 1 checkpoint), S (DNA replication), G2 
(gap 2 checkpoint) and M (mitosis). The p53 protein functions in the checkpoint control phases, and 
can arrest damaged cells in G1 or in G2, and activate the expression of genes to initiate apoptosis. 
Cellular uptake of  ZnO NPs is greatest during the G2/M phase, followed by the S phase and then the 
G0/G1 phase (356). Due to the p53 mutation in HaCaT cells, both cell division and NP uptake is 
quicker in these cells compared to primary cells. However, this has not equated to faster  
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re-epithelialisation in HaCaT cells. Therefore, this suggests that the NPs are not enhancing re-
epithelialisation by mediating the cell cycle process. 
4.4.5 ZnO NPs show dose- and particle size-dependent cytotoxicity in HDF cells 
Although re-epithelialisation is reliant on the proliferation and migration of keratinocytes in vitro, the 
role of fibroblasts is integral in facilitating re-epithelialisation in vivo. Fibroblasts are responsible for 
the deposition of collagen at the wound site. Collagen is the most abundant protein in the ECM and 
provides the structural support to enable re-epithelialisation and wound closure (4). Therefore, 
assessing the toxicity of the ZnO NPs to the fibroblasts, particularly at the concentration which 
exhibited the greatest potential for enhanced repair of keratinocytes, was essential. As shown in 
Figure 4.7, no loss in viability was observed at the optimal re-epithelialisation dose of 0.1 µg/mL.  
An adaptive metabolic response was seen in HDF cells exposed to ZnO 200nm, with the possible 
mechansim as suggested in Section 4.4.4. As observed in the keratinocyte cultures, TiO2 25nm was 
the least toxic material. Which is likely due to the large difference in the solubility of ZnO and TiO2 
NPs in aqueous environments, which is also outlined in Section 4.4.1 (351). 
4.4.6 ZnO NPs do not enhance HDF cell gap closure in vitro  
To compare the effects of the ZnO NPs on HDF cells the same in vitro scratch closure system was 
used. It was essential to determine whether the ZnO NPs had no effect, stimulated, or inhibited the 
growth of fibroblasts at 0.1 µg/mL, which was known to be the optimal stimulatory dose for 
keratinocyte re-epithelialisation. As shown in Figure 4.8, the materials did not enhance the repair of a 
scratched fibroblast monolayer over the concentration range tested. Although ZnO significantly 
inhibited HDF gap closure at 10 µg/mL, due to cytotoxicity, closure was not impaired at 0.1 µg/mL. 
This was an important observation as stimulation to fibroblast migration or proliferation at the wound 
site may promote excessive collagen deposition and scarring, whilst inhibition may promote poor 
tensile strength of the final resolved wound (4). These results indicate that the stimulatory effect of the 
ZnO 30nm NPs is cell type dependent.  
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4.4.7 ZnO NPs do not mediate the expression of the cell proliferation marker Ki-67 in vitro 
To help determine a mechanism of action responsible for ZnO’s effect in the keratinocytes two 
possible scenarios were investigated. Firstly, was that the NPs were possibly influencing cell 
proliferation, whilst the second scenario investigated the rate of keratinocyte adhesion (discussed in 
Section 4.4.8). 
It was hypothesized that enhanced proliferation enabled quicker re-epithelialisation by 
increasing the number of cells in the culture well. Hence, the expression of Ki-67 was investigated in 
HaCaT cells, as this protein is strictly correlated with proliferation and is expressed during all active 
phases of the cell cycle (357). Staining of the HaCaT cells with anti-Ki-67 antibody revealed that the 
zinc materials had no effect on Ki-67 expression at the 4 or 10 hr timepoints (Figures 4.11 and 4.12). 
However, it was possible to down-regulate Ki-67 expression in contact-inhibited cells in confluent 
cultures. This demonstrated that regulation of this proliferation marker was still possible in the 
immortalised HaCaT cells, even though they possess a p53 mutation that inhibits cell cycle arrest 
(355). This data suggests that either the mechanism of action was not via cell proliferation, or that  
Ki-67 expression was increased prior to the 4 hr endpoint and had returned to basal levels before the 
first sampling timepoint. Interestingly, the 1.0 µg/mL dose of TiO2 25nm NPs was able to 
significantly increase Ki-67 expression in the HaCaT cells at 4 hrs (Figure 4.12). However, 
considering that the TiO2 25nm NPs were most effective at 0.1 µg/mL, it is improbable that 
proliferation alone caused its stimulatory effect on re-epithelialisation. Furthermore, this data implies 
that Ki-67 expression, and consequently proliferation, may not be dependent upon the solubility of the 
NPs, as TiO2 is relatively insoluble when compared to ZnO (351). 
4.4.8 ZnO NPs do not mediate cell attachment or expression of the adhesion marker CD29 in 
vitro 
The second strategy employed to help establish ZnO’s mechansim of action investigated its ability to 
mediate cell adhesion. Cell adhesion is the binding of a cell to a surface via cell adhesion molecules, 
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such as integrins, selectins and cadherins (358). A change in the expression of cell adhesion markers 
can therefore change the mobility of the cell to a migratory or stationary state.  
It was therefore hypothesized that the ZnO NPs enhanced re-epithelialisation by reducing the 
binding force of the cells to the culture plate, to encourage keratinocyte migration. This was 
investigated by two methods in the HaCaT cells. Firstly, via assessing the rate of cell attachment in 
cells co-plated with ZnO NPs, and secondly, via assessing the expression of the adhesion and 
migration marker CD29.    
HaCaT cells were co-plated with the ZnO NPs for 90 mins, which had been previously 
established to result in 50% cell adherence in control wells. The independent methods of Trypan Blue 
Exclusion and MTS assay were utilised to measure the number of viable cells attached in culture and 
evaluate whether the NPs altered cell attachment following the 90 min incubation. It was hypothesised 
that if altered cell adherence was responsible, it would be lower in the affected ZnO 30nm NP treated 
cells, and unchanged in the sZnO 30nm NP treated well. As shown in Figures 4.14-4.17, the ZnO NPs 
did not alter the rate of cell attachment when assessed by either method. 
Adhesion and migration of ZnO NP exposed keratinocytes was further investigated via  
flow cytometry. It has been demonstrated that β1 integrin (CD29) is important for adhesion and 
terminal differentiation of keratinocytes both in vitro and in vivo. (359-361). Furthermore, β1 integrin-
deficient cultured keratinocytes have shown poor cell adhesion, reduced proliferation and impaired 
cell migration when assessed via flow cytometry (361). The cell adhesion and migration marker CD29 
was therefore utilised to assess integrin β1 expression in HaCaT cells exposed to ZnO 30nm, sZnO 
30nm, ZnCl2 and TiO2 25nm NPs for 4 or 10 hrs. Staining the cells with anti-CD29 antibody revealed 
that these materials did not alter the expression of this marker (Figures 4.18 and 4.19). As expected, 
CD29 expression was downregulated in contact-inhibited cells. This is likely due to the spatial 
characteristics of the confluent cell monolayer, whereby adherent keratinocytes either loose adhesion, 
form multi-layers, completely detach, or die, to accommodate newly dividing cells. 
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This result suggests that the ZnO NPs do not meditate the expression of this particular 
adhesion marker. Alternatively, the expression of CD29 may have been transient and had returned to 
basal levels at 4 and 10 hrs. However, there is still the possibility that the NPs may modulate the 
expression of other adhesion markers, such as selectins, cell adhesion molecules (CAMs), or 
cadherins.  
4.4.9 ZnO NPs inhibit the formation of the 5-LOX pathway end product LTB4  
and the COX-2 pathway intermediate PGH2  
Additionally, the ZnO NPs were evaluated for their ability to mediate the inflammatory phase of 
wound repair. The 5-LOX and COX pathways, which were discussed in Section 1.4, are essential 
pathways of inflammation that result in the production of inflammatory metabolites, known as the LT 
and PGs, respectively. The leukotriene LTB4 is primarily responsible for chemotaxis of leukocytes, 
whilst the prostaglandin PGE2, a PGH2 metabolite, causes vasodilation and increases localised 
vascular permeability at the site of injury (116). When combined, these processes allow entry of large 
quantities of immune cells to the wound site for the removal of cell debris and pathogenic material. 
Upon resolution of the inflammatory phase, immune cells are required to either return to the 
circulation or undergo apoptosis to prevent damage to host tissue (26). As discussed in Section 1.2.2, 
if inflammation is persistent, wound closure is delayed and fibrosis is promoted. Various studies have 
shown that the ZnO NPs possess anti-inflammatory activity (330, 362, 363). Furthermore, our 
laboratory has shown ZnO’s immunomodulatory activity of human monocytes and macrophages 
(319), lung epithelial cells (338) and of murine mast cells (339). The anti-inflammatory activity of the 
ZnO NPs was therefore assessed by their potential to inhibit formation of LTB4 from porcine 
neutrophils, and the PGH2 production by purified COX enzymes, as described in Sections 2.7 and 2.8 
respectively. As the ZnO 30nm NPs had the greatest effect on keratinocyte re-epithelialisation these 
were specifically selected for this study. In the 5-LOX inhibition assay, ZnO 30nm NPs were assessed 
at the same doses used for the scratch repair assay. ZnO 30nm NPs significantly inhibited LTB4 
production in a dose-dependent manner with an IC50 of approximately 3 µg/mL (Figure 4.20).  
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In the 5-LOX pathway, AA is primarily converted to LTA4 prior to its conversion to LTB4. 
This conversion is facilitated by the enzyme LTA4 hydrolase, which exhibits zinc-dependent epoxide 
hydrolase and peptidase activity (364). It has been shown for purified LTA4 hydrolase, from human 
and guinea pig sources, that this enzyme and zinc ions are present at equimolar concentrations (364). 
However, when the zinc concentrations exceeds a 1:1 molar ratio (zinc:enzyme) the LTA4 hydrolase 
activity is impaired, thus reducing the conversion of LTA4 to LTB4 (364, 365). Furthermore, 
micromolar concentrations of zinc ions inhibit of LTB4 formation in intact human neutrophils 
stimulated with the calcium ionophore A23187 (365). However, the authors suggested that this effect 
was primarily mediated through a direct effect on LTA4 hydrolase but rather that zinc was able to 
inhibit the activity of 5-LOX directly. This was supported by a study demonstrating that at 10 µM, 
Zn
2+
 completely inhibited purified recombinant 5-LOX (366). It is well established that ZnO NP 
dissolution forms zinc ions and complexes in aqueous solutions (335). However, it is harder to discern 
is the rate dissolution due to the many parameters which affect this process, including: NP size, NP 
surface modification, the solvent the NPs are suspended in, and the pH and temperature of the 
environment (336, 337, 367-371). These factors can regulate the rate of ZnO NP uptake and 
subsequent availability of intracellular zinc ions. It is therefore likely that the ZnO 30nm NPs 
decreased LTB4 formation via inhibiting LTA4 hydrolase or 5-LOX, due to the availability of 
sufficient zinc ions in these porcine neutrophils. However, more research is required to determine its 
precise role in these cells, and the rate of dissolution and concentration of zinc ions under the 
incubation conditions and relatively short incubation period.  
The ZnO 30nm NPs were also evaluated in the COX inhibition assay at 0.1 and 1.0 µg/mL, 
for both COX-1 and COX-2 isoenzymes. Although ZnO 30nm NPs did not significantly inhibit  
COX-1, it inhibited COX-2 PGH2 production by 27 + 4% at 0.1 µg/mL and by 30 + 2% at 1.0 µg/mL, 
as shown in Figure 4.21. Whilst COX-2 was inhibited preferentially, the literature does not support 
direct inaction of the COX-2 enzyme by ZnO. It was initially proposed that the NPs may be binding to 
the final PG products in the purified enzyme cell free reaction system and was masking the detection 
of PGF2α via EIA. This hypothesis was disproved following the direct comparison of the  
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PG screening EIA stand curves in the presence and absence of spiked ZnO 30nm NPs at 1.0 µg/mL, 
which showed that there was no difference between these curves (Data not shown). Therefore, further 
investigation is necessary  
4.5 CONCLUSION  
 
The literature has demonstrated the application of NPs in a growing number of medical fields (299-
304), however few studies have focused on their potential wound healing benefit. Of particular 
interest is ZnO’s role in the proliferative phase of healing. Although it has shown re-epithelialisation 
enhancing qualities in the literature, the mechanism and particle size-dependence of this effect is 
unclear. In this study we have shown that the ZnO NPs induce dose- and size-dependent cytotoxicity 
in human keratinocytes and fibroblasts. Furthermore, their ability to promote keratinocyte re-
epithelialisation occurred in a dose-, particle size- and agglomeration-dependent manner, with the 
non-dispersed particulates of smaller primary particle size promoting the most rapid repair.  This 
enhancement was shown to be cell type-dependent, as these NPs had no effect on fibroblasts. 
Moreover, the ZnO NPs had a greater effect on the re-epithelialisation of primary HEK than in the 
immortalised HaCaT cells, which have a p53 mutation that prevents cell cycle arrest and subsequently 
facilitates faster NP uptake. This suggests that ZnO’s enhancing properties are independent of the cell 
cycle. This in vitro study also showed that other metal oxide NPs, such as TiO2, also possess wound 
healing potential. The TiO2 NPs were of a similar primary particle size to the most effective ZnO 
material, suggesting this observation of enhanced re-epithelialisation may not be material specific, but 
instead a particle size-dependent effect. Although a mechanism of action was not elucidated, we 
demonstrated that the ZnO NPs do not induce expression of the proliferation marker Ki-67, nor 
mediate the rate of adhesion of keratinocytes in culture. In addition, the ZnO NPs did not alter 
expression of the integrin β1 cell adhesion and migration marker CD29, however there are many other 
families of cell surface proteins that the NPs may potentially interact with. Moreover, the ZnO NPs 
were shown to inhibit the 5-LOX and COX-2 dependent pathways of inflammation at similar 
concentrations to that which stimulated re-epithelialisation in the immortalised and primary 
keratinocytes. 
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These in vitro findings demonstrate the wound healing potential of ZnO NPs through its 
ability to modulate two key phases of repair; inflammation and proliferation. Its effects have the 
potential to both minimise microbial colonisation and chronic wound formation, whilst assisting 
epidermal cell re-epithelialisation for accelerated wound closure. Although the literature supports its 
re-epithelialisation enhancing effects in vivo, this in vitro study has outlined the need to further  
reassess ZnO’s effects in an intact animal model for wound healing with respect to particle size-
dependency.  
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CHAPTER 5: AN IN VIVO INVESTIGATION OF 
ZnO NANOPARTICLES ON WOUND HEALING 
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5.1 INTRODUCTION 
  
Key phases of the wound repair process can be modulated in vitro as demonstrated by the 
experimental findings that have been discussed and examined in detail in Chapters 3 and 4.  
These studies have demonstrated that the MNPs, particularly the marine oils, have strong  
anti-inflammatory activities that inhibit the production of inflammatory LTs and PGs. Furthermore, 
the smallest ZnO NP investigated (ZnO 30nm) was shown to enhance re-epithelialisation and also 
inhibit some of the pro-inflammatory pathways.  
Inflammation and proliferation are essential phases of healing and both can be optimized to 
accelerate in vivo wound repair. High levels of pro-inflammatory AA metabolites can prolong the 
inflammatory phase and delay wound closure, however the inflammatory response is vital to 
commence the healing process. It is therefore possible that the strong anti-inflammatory activity 
observed from the marine oils may be counterproductive for acute wound repair, and more suited to a 
chronic wound repair model in which the inflammation is exacerbated due to excessive host tissue 
destruction and microbial colonisation. 
As discussed in Section 4.1.1, ZnO NPs have been reported to enhance in vivo  
re-epithelialisation (84, 314, 325, 326), however the studies described in Chapter 4 were the first  
to exam their in vitro effects in a size-dependent manner. Furthermore, the ZnO 30nm NP 
demonstrated only modest inhibition of inflammatory metabolite production at the optimal dose for 
enhancing re-epithelialisation. These findings indicate that the ZnO NPs are better suited for treating 
an acute wound healing model than the MNPs 
Due to the limitations of an in vitro system, ZnO’s wound healing properties can only be 
further explored in an intact animal model. Although its effect on enhanced re-epithelialisation was 
observed in vitro, this is just one process which encompasses the proliferative phase, as outlined in 
Section 1.2.3. In addition, its effects on inflammation, proliferation and remodelling can be explored 
histologically.  
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In this Chapter, the in vivo experiments were conducted to investigate ZnO’s effects in a 
murine wound repair model, and the results are presented and examined in detail. The aims of these 
studies reported were specifically to (i) determine the reproducibility of ZnO’s re-epithelialisation 
promoting activity observed in vitro, and (ii) identify whether the in vivo effects on wound healing 
parameters are size, agglomeration and nanomaterial dependent.  
5.2 MATERIALS AND METHODS 
 
A thorough explanation of the materials and methodology for the experimental procedures used to 
generate the results presented in this chapter are shown in Chapter 2. The following is a brief 
summary of the specific protocols utilised in the experiments described in Chapter 5. This in vivo 
animal study was conducted after approval was obtained from the RMIT Animal Ethics Committee 
(Project approval AEC# 1428). 
5.2.1 Experimental animals 
Seven-week-old female C57BL/6 mice were sourced from the Animal Resources Centre 
(Murdoch, Western Australia) and housed in groups of 4 for a 1 week acclimatization period at the 
RAF (RMIT Bundoora), prior to use, as outlined in Section 2.13.1. 
5.2.2 Nanoparticle solution preparation 
The nano-sized and bulk particulates were supplied by Micronisers Pty. Ltd.  
(Melbourne, Australia) and weighed and suspended in Milli-Q at a final concentration of 20 mg/mL.  
The particulates were sonicated for 30 mins for both sterilization and to disperse the particles  
in solution prior to use. Working solutions were formed by diluting the stock solution in saline 
(vehicle control), as outlined in Section 2.13.2. 
5.2.3 Wound repair model 
Eight-week-old female C57BL/6 mice were sedated using isoflurane (Appendix 4) and their 
backs were shaved and wiped with 70% ethanol to sterilize the skin. Mice were injected 
subcutaneously with 0.05 mg/kg buprenorphine for analgesia prior to creating a 5 mm circular 
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incision on their backs utilising a punch biopsy (Stiefel, Australia). The wounds were treated once 
with the nanomaterials (20 µL of a 0.5 µg/mL suspension) or vehicle (saline), and the mice were 
individually housed for the experimental period, as outlined in section 2.13.3. 
5.2.4 Monitoring  
Each mouse was monitored hourly for 4 hrs post-wounding procedure for alertness, activity, 
posture, breathing pace, appearance of the wound and other key clinical observations to ensure the 
mice were not in discomfort (Appendix 5). Mice were then monitored twice daily for 14 days and the 
progression of wound repair was documented photographically, at a fixed distance as outlined in 
Section 2.13.4. 
5.2.5 Tissue preparation and processing for paraffin embedding and sectioning 
Mice were humanely culled by CO2 euthanasia (Appendix 6) on days 7 and 14, and the 
wounds were dissected and placed into 10% NBF for 3 days prior to tissue processing. The processed 
tissue was embedded in paraffin and 3 µm sections were cut using a rotary microtome, as outlined in 
Section 2.14.1. 
5.2.6 Haematoxylin and Eosin (H&E) 
H&E was utilised to assess tissue morphology and leukocyte infiltration of formalin-fixed 
paraffin-embedded sections. The sections were dewaxed, hydrated, rinsed and stained with  
H&E, dehydrated, cleared in xylene and then mounted with DPX, as outlined in Section 2.14.2  
(Appendix 7).  
5.2.7 Picro-Sirius Red 
Picro-Sirius Red was utilised to determine the total collagen deposition and prevalence  
of collagen subtypes I and III in formalin-fixed paraffin-embedded-sections. The sections  
were dewaxed, hydrated, rinsed and stained in Picro-Sirius Red (Abcam, USA), washed in  
acidified water, dehydrated, cleared in xylene and then mounted with DPX, as outlined in Section 
2.14.3 (Appendix 8).  
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5.2.8 Immunohistochemistry (IHC) 
Immunohistochemistry was utilised to investigate the extent of cell proliferation (Ki-67), 
epidermal remodelling (CK-14), and vascular remodelling (SMA β4) in formalin-fixed paraffin-
embedded sections. The sections were dewaxed, hydrated and rinsed prior to Tris-EDTA antigen 
retrieval. Each section was blocked in BSA and incubated in primary antibody overnight. Washed 
sections were then incubated in the appropriate HRP conjugated secondary antibody, and incubated 
prior to a final wash and development by DAB. The sections were then dehydrated, cleared in xylene 
and then mounted in DPX as outlined in Section 2.14.4 (Appendix 9) for imaging and analysis as 
outlined in Section 2.15. 
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5.3 RESULTS 
 
5.3.1 ZnO 30nm NPs enhance wound repair in a dose-dependent manner in vivo  
Female C57BL/6 mice were utilised to assess the effects of the ZnO 30nm NPs in a wound repair 
model in vivo. In the initial dose-ranging study, a 5 mm circular incision was made in the centre of the 
shaved back of each mouse and the wound was treated with the NPs at either 0.05, 0.1, 0.5 and  
1.0 µg/mL, to determine the optimal concentration. Images of the wounds were captured daily for  
14 days, commencing on day 3, and digital analysis of the day 5 and 7 images revealed that the  
ZnO 30nm NPs optimally enhanced wound repair at 0.5 µg/mL (Figure 5.1). This concentration was 
subsequently utilised to compare the wound healing effects of ZnO 30nm NPs to the other materials, 
i.e. ZnO 200nm, sZnO 30nm and TiO2 25nm. At this dose, the ZnO 30nm NPs significantly enhanced 
wound repair on days 4-7 when compared to the saline-only treated wounds (Figure 5.2), whilst the 
other materials had no effect on wound repair (Figure 5.3). Examination of the images presented in 
Figure 5.4, clearly show that the ZnO 30nm NP treated wounds are visually smaller those in the 
control group. This effect is particularly evident on days 5, 6 and 7. Furthermore, the ZnO 30nm NP 
treated wounds were clearly smaller on day 7 than the wounds treated with the other materials  
(Figure 5.5). During the 14 day experimental period, the health of the mice were of top priority, and 
mouse weights were closely monitored and utilised as a key welfare indicator. As shown in  
Figure 5.6, all the mice maintained a healthy body weight and no significant changes were seen in this 
parameter during the observation period.  
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Figure 5.1: ZnO 30nm NP dose optimisation for treating skin punch biopsy wounds.  
Wounds created on the shaved backs of female C57BL/6 mice were treated with ZnO 30nm NPs and 
imaged on days 3-14. Mean % repair of control + SEM are shown for days 5 and 7. One-way 
ANOVA with Bonferroni’s post-hoc analysis was conducted (*p<0.05 & ***p<0.001, n=12 for the 
control and 0.5 µg/mL treatment group, and n=2, 5 and 3 for the 0.05 µg/mL, 0.1 µg/mL and 1.0 
µg/mL treatment groups, respectively).  
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Figure 5.2: The effect of ZnO 30nm NPs in a mouse model of wound repair. Wounds created on 
the shaved backs of female C57BL/6 mice were treated with either saline (20 µL; vehicle control) or 
ZnO 30nm NPs (20 µL of a 0.5 µg/mL suspension) and imaged on days 3-14. Mean % repair  
of control + SEM are shown for days 3-10. Two-way ANOVA with Bonferroni’s post-hoc analysis 
was conducted (*P<0.05, n=11 days 3, 4 and 6; n=12 days 5 and 7; n=4 days 8-10). 
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Figure 5.3: The effects of the ZnO 200nm particulate, sZnO 30nm and TiO2 25nm NPs in a 
mouse model of wound repair. Wounds created on the shaved backs of female C57BL/6  
mice were treated with either saline (20 µL; vehicle control) or the materials of interest  
(20 µL of a 0.5 µg/mL suspension) and imaged on days 3-14. Mean % repair of control + SEM  
are shown for days 3-10. Two-way ANOVA with Bonferroni’s post-hoc analysis was conducted 
(*P<0.05, n=8 days 3-7 and n=4 days 8-10).  
 
ZnO 200nm
3 4 5 6 7 8 9 10
0
20
40
60
80
100
Control
ZnO 200nm
Day
%
 R
ep
a
ir
 o
f 
co
n
tr
o
l
 
sZnO 30nm
3 4 5 6 7 8 9 10
0
20
40
60
80
100
Control
sZnO 30nm
Day
%
 R
ep
a
ir
 o
f 
co
n
tr
o
l
 
TiO2 25nm
3 4 5 6 7 8 9 10
0
20
40
60
80
100
Control
TiO2 25nm
Day
%
 R
ep
a
ir
 o
f 
co
n
tr
o
l
 
 131 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4: A photographic comparison of the effect of the ZnO 30nm NP in a mouse model of 
wound repair. Wounds created on the shaved backs of female C57BL/6 mice were treated  
with either saline (20 µL; vehicle control) or ZnO 30nm NPs (20 µL of a 0.5 µg/mL suspension) 
and imaged on days 3-14. Sample images from days 3-10 are shown.  
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Figure 5.5: A photographic comparison of the effects of the different materials in a mouse 
model of wound repair. Wounds created on the shaved backs of female C57BL/6 mice  
were treated with either saline (20 µL; vehicle control) or the materials of interest (20 µL of a  
0.5 µg/mL suspension) and imaged on days 3-14. Sample images from day 7 are shown.  
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Figure 5.6: The effect of the nanomaterials on body weight in a mouse model of wound repair. 
Wounds created on the shaved backs of female C57BL/6 mice were treated with either saline  
(20 µL; vehicle control) or the materials of interest (20 µL of a 0.5 µg/mL suspension) and the body 
weights were recorded daily. Mean % weight change + SEM are shown for days 3-13. Control body 
weight at day 0 was 18 + 0.5 g. Two-way ANOVA with Bonferroni’s post-hoc analysis was 
conducted (n=11 for control and ZnO 30nm days 3, 4 and 6, n=12 for control and ZnO 30nm days 5 
and 7, n=8 for ZnO 200nm, sZnO 30nm and TiO2 25nm days 3-7, and n=4 for all materials days 8-
13). 
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5.3.2 ZnO 30nm NPs show more ordered healing of the epidermis in vivo 
To compare the quality of healing in the ZnO 30nm NP and saline-only treatment groups,  
the epidermis of the wounds were assessed for indicators of accelerated and well-ordered repair. 
Firstly, the wounds were either excised on day 7 or 14, in order to evaluate both the tissue 
morphology mid-repair and upon wound resolution and remodelling. Formalin-fixed, paraffin-
embedded sections were cut for analysis by H&E and IHC. The width of the epidermis across each 
section was assessed in H&E stained sections, whilst basal and proliferating keratinocytes were 
identified with anti-cytokeratin-14 and Ki-67 antibodies, respectively. Figure 5.7 depicts 
representative images of the wounds treated with the ZnO 30nm NPs or saline-only on days 7 and 14. 
Measurements of the epidermal thickness revealed that the width was significantly reduced in the ZnO 
30nm NP treated wounds, as shown in Figure 5.8. Treatment of wounds with the other materials did 
not influence this repair parameter (Figure 5.8 and 5.9). However, no difference was found when the 
wound length was measured and compared in the ZnO 30nm NP and saline-only treatment  
groups (Figure 5.10). As shown in Figure 5.10, staining of the basal keratinocytes with the  
anti-cytokeratin-14 antibody revealed a significant decrease in the number of keratinocytes expressing 
this marker in the ZnO 30nm NP treatment group on day 7 (Figure 5.11). Comparison of the 
expression of this marker between the day 7 and 14 wounds, by expressing the data against the day 7 
control, indicates that the ZnO 30nm NPs accelerate the return of this marker towards basal levels by 
day 7 (Figure 5.12). Figure 5.13 depicts the epidermis stained by the CK-14 marker. Additionally, 
there was a significant reduction in the number of proliferating keratinocytes in the epidermis of  
ZnO 30nm NP treated wounds, as shown in Figure 5.14. Similarly, the comparative expression of  
Ki-67 on day 7 and day 14 against the day 7 control shows ZnO 30nm NP treated wounds returning 
towards basal levels by day 7. Figure 5.15 depicts staining by the Ki-67 proliferation marker and the 
presence of this protein in the keratinocyte nucleus.  
 
 
   
 135 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7: A photographic representation of the saline-only (control) and ZnO 30nm NP treated wounds. A skin wound was created  
on the shaved back of each mouse utilising a disposable 5 mm biopsy punch and treated with either saline (20 µL; vehicle control) or ZnO 30nm NPs  
(20 µL of a 0.5 µg/mL suspension). On days 7 and 14 the mice were culled and the wounds excised for histological analysis by H&E. Two representative 
images of the day 7 wounds and 1 representative image of the day 14 wounds were shown from each experimental group. 
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Figure 5.8: The effect of the ZnO 30nm and ZnO 200nm particulates on the epidermal width of 
healing mouse wounds. Wounds were treated with either saline (20 µL; vehicle control) or the 
materials of interest (20 µL of a 0.5 µg/mL suspension).  The width of the epidermis across the length 
of the wound was measured in H&E stained sections. Mean % epidermal width of control + SEM are 
shown. Unpaired Two-tailed T-tests were conducted (*p<0.05, n=11 day 7 and n=4 day 14 for  
ZnO 30nm, and n=5 day 7 and n=4 day 14 for ZnO 200nm). 
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Figure 5.9: The effect of the sZnO 30nm and TiO2 25nm NPs on the epidermal width of healing 
mouse wounds. Wounds were treated with either saline (20 µL; vehicle control) or the materials  
of interest (20 µL of a 0.5 µg/mL suspension).  The width of the epidermis across the length  
of the wound was measured in H&E stained sections. Mean % epidermal width of control + SEM  
are shown (n=5 for day 7 and n=4 for day 14).  
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Figure 5.10: The effect of the ZnO 30nm NP on the wound length of healing mouse wounds. 
Wounds were treated with either saline (20 µL; vehicle control) or ZnO 30nm NPs  
(20 µL of a 0.5 µg/mL suspension). The wound length was measured from the wound edge,  
noted by the loss of hair follicles, across the base of the epidermis in H&E stained sections.  
Wound length (mm) + SEM are shown (n=7 for day 7 and n=4 for day 14). 
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Figure 5.11: The effect of the ZnO 30nm NP on the expression of cytokeratin-14 in the 
epidermis of healing mouse wounds. Wounds created on the shaved backs of female C57BL/6 mice 
were treated with either saline (20 µL; vehicle control) or ZnO 30nm NPs (20 µL of a 0.5 µg/mL 
suspension). On days 7 and 14 the mice were culled and the wounds excised for histological analysis. 
The sections were stained with anti-cytokeratin-14 (CK-14) antibody by IHC, and positively stained 
basal keratinocytes of the epidermis were counted in 4 fields. Mean % CK-14 expression of control  
+ SEM are shown. Unpaired Two-tailed t-tests were conducted (*p<0.05, n=7 for day 7 and n=4  
for day 14).  
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Figure 5.12: Cytokeratin-14 expression relative to the day 7 control.  Wounds created on the 
shaved backs of female C57BL/6 mice were treated with either saline (20 µL; vehicle control) or  
ZnO 30nm NPs (20 µL of a 0.5 µg/mL suspension). On days 7 and 14 the mice were culled and the 
wounds excised for histological analysis as detailed in Figure 5.11. Mean % CK-14 expression of 
control + SEM are shown. One-way ANOVA with Bonferroni’s post-hoc analysis was conducted 
(***p<0.001, n=7 for day 7 and n=4 for day 14).  
  
 
*** ***
 141 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13: A photographic representation of the staining of basal epidermal keratinocytes in healing mouse wounds. Wounds were treated with 
either saline (20 µL; vehicle control) or ZnO 30nm NPs (20 µL of a 0.5 µg/mL suspension). Wound sections were stained with anti-cytokeratin-14 antibody 
by IHC, and positively stained basal keratinocytes of the epidermis were counted in 4 fields. A representative image is shown from each experimental group 
for each timepoint.  
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Figure 5.14: The effect of the ZnO 30nm NP on the expression of Ki-67 in the epidermis  
of healing mouse wounds.  Wounds were treated with either saline (20 µL; vehicle control) or  
ZnO 30nm NPs (20 µL of a 0.5 µg/mL suspension). The wound sections were stained with anti-Ki-67 
antibody by IHC, and positively stained proliferating keratinocytes of the epidermis were counted in 4 
fields. Mean % Ki-67 expression of control + SEM are shown. One-way ANOVA with Bonferroni’s  
post-hoc analysis was conducted (**p<0.01 and ***p<0.001, n=6 for day 7 and n=4 for day 14). 
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Figure 5.15: A photographic representation of the staining of proliferating epidermal keratinocytes in healing mouse wounds. Wounds were  
treated with either saline (20 µL; vehicle control) or ZnO 30nm NPs (20 µL of a 0.5 µg/mL suspension). Wound sections were stained with anti-Ki-67 
antibody by IHC, and positively stained basal keratinocytes of the epidermis were counted in 4 fields. A representative image is shown  
for each timepoint from each experimental group. The yellow line in the left photo denotes the border between the dermis and the epidermis.  
Control Day 7 ZnO 30nm Day 7 ZnO 30nm Day 14 Control Day 14 
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5.3.3 ZnO 30nm NPs do not mediate leukocyte infiltration in vivo 
The effect of ZnO 30nm NPs on the inflammatory phase of repair was investigated by evaluating the 
dermis for immune cell infiltration. Mouse wounds excised on days 7 and 14, were formalin-fixed and 
paraffin-embedded for sectioning. The sections were stained with H&E and immune cells in the 
dermis of each wound were counted. As shown in Figure 5.16, there was no difference between the 
ZnO 30nm NP treated wounds in the amount of leukocyte infiltrate on days 7 and 14 and saline-only 
treated controls.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16: The effect of the ZnO 30nm NP on the infiltration of leukocytes to the dermis of 
healing mouse wounds. Wounds were treated with either saline (20 µL; vehicle control) or  
ZnO 30nm NPs (20 µL of a 0.5 µg/mL suspension). Immune cells in the dermis of each H&E stained 
section were counted in 4 fields. Mean % leukocyte infiltrate of control + SEM are shown  
(n=8 and n=6 for the control and the ZnO 30nm NP treatment groups respectively, on day 7, and n=4 
on day 14).   
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5.3.4 ZnO 30nm NPs promote the conversion of type III to type I collagen 
To investigate the effect of the ZnO 30nm NPs on the deposition of collagen in the dermis of treated 
mouse wounds, the total collagen deposition and prevalence of collagen type I and III subtypes were 
measured. Mouse wounds excised on days 7 and 14, were formalin-fixed and paraffin-embedded for 
sectioning. The sections were stained with Picro-Sirius Red and examined under brightfield 
illumination and images spanning the length of the wound were captured for analysis by ImageJ to 
determine the quantity of collagen in each section. Polarization of the stained sections enabled the 
identification of the collagen type I and III subtypes by the display of a distinct birefringence.  
Type I collagen displays a yellow-orange birefringence, whilst type III collagen displays a green 
birefringence. The presence of these collagen subtypes in the wound indicates the maturity of the 
healing tissue. In wound repair, fibroblasts deposit type III collagen in a disorderly manner, which is 
later on replaced by type I collagen in a more organised fashion as the healing tissue remodels and 
matures. The ratio of type III to type I collagen is therefore an important indicator of the repair 
process. As shown in Figure 5.17, there was no significant difference in the amount of total collagen 
deposited in the wounds of the ZnO 30nm NP and the saline-only treatment groups. However, there 
was a significant reduction in type III collagen and a significant increase in type I collagen in the 
dermis of the ZnO 30nm NP treated wounds on day 7 (Figure 5.18). This was reinforced by the 
significant reduction in the ratio of type III:I collagen in ZnO 30nm NP treated wounds on day 7 
(Figure 5.19). Images representing the display of collagen and its subtypes in wound sections are 
shown in Figures 5.120 and 5.21.   
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Figure 5.17: The effect of the ZnO 30nm NP on the deposition of collagen in the dermis of 
healing mouse wounds. Wounds were treated with either saline (20 µL; vehicle control)  
or ZnO 30nm NPs (20 µL of a 0.5 µg/mL suspension). The collagen content of each  
wound section was identified using Picro-Sirius Red and quantitated in 4 fields via ImageJ.  
Mean % collagen of control + SEM are shown (n=4). 
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Figure 5.18: The effect of the ZnO 30nm NP on the prevalence of collagen type I and III 
subtypes in the dermis of healing mouse wounds. Wounds were treated with either  
saline (20 µL; vehicle control) or ZnO 30nm NPs (20 µL of a 0.5 µg/mL suspension).  
Polarization microscopy of Picro-Sirius Red stained slides enabled the identification of collagen  
type I and III subtypes by the display of a distinct birefringence in 4 fields of each section.  
Mean % collagen subtype + SEM are shown. One-way ANOVA with Bonferroni’s post-hoc analysis 
was conducted (*p<0.05, n=4). 
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Figure 5.19: The effect of the ZnO 30nm NP on the collagen type III to type I ratio in the dermis 
of healing mouse wounds. Wounds were treated with either saline (20 µL; vehicle control) or  
ZnO 30nm NPs (20 µL of a 0.5 µg/mL suspension). Polarization microscopy identified collagen type 
I and III subtypes, as described in Figure 5.18. Mean ratio collagen subtype III:I + SEM are shown. 
Unpaired Two-tailed t-tests were conducted (**P<0.01, n=4). 
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Figure 5.20: A photographic representation of the collagen staining on day 7 in the dermis of 
healing mouse wounds. Wounds were treated with either saline (20 µL; vehicle control) or  
ZnO 30nm NPs (20 µL of a 0.5 µg/mL suspension). The collagen content and subtypes I and III  
in each wound section were identified using Picro-Sirius Red and polarization microscopy.  
Type I collagen displays a yellow-orange birefringence, whilst type III collagen displays a green 
birefringence. Image analysis was conducted via ImageJ. Scale bar = 50µM.  
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Figure 5.21: A photographic representation of the collagen staining on day 14 in the dermis of 
healing mouse wounds. Wounds were treated with either saline (20 µL; vehicle control) or  
ZnO 30nm NPs (20 µL of a 0.5 µg/mL suspension). The collagen content and subtypes in each  
wound were identified by their distinct birefringence, as described in Figure 5.20. Scale bar = 50µM. 
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5.3.5 ZnO 30nm NPs do not mediate vascular remodelling 
The effect of ZnO 30nm NPs on vascular remodelling and angiogenesis was investigated in the 
dermis of treated mouse wounds. The formation of a new microvascular network throughout the 
granulation tissue is essential to provide newly formed tissue with nutrients and oxygen.  
Both the number and average size of the vessels was noted in the dermis of wounds treated with the 
ZnO 30nm NPs or saline-only. Mouse wounds excised on days 7 and 14, were formalin-fixed and  
paraffin-embedded for sectioning. The sections were stained by IHC, with anti-sma (B4) antibody and 
the vessels in the dermis were identified. As shown in Figures 5.22 and 5.23, the ZnO 3nm NPs did 
not influence remodelling of the microvascular network.  
 
 
 
 
 
 
 
Figure 5.22: The effect of the ZnO 30nm NP on the vascularization in the dermis of healing 
mouse wounds.  Wounds were treated with either saline (20 µL; vehicle control) or ZnO 30nm NPs 
(20 µL of a 0.5 µg/mL suspension). Wound sections were stained with anti-sma (B4) antibody  
by IHC, and the positively stained vessels were counted in each section across 4 fields.  
Mean vessel count/field + SEM are shown (n=6 for day 7 and n=4 for day 14). 
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Figure 5.23: The effect of the ZnO 30nm NP on the blood vessel size in the dermis of healing 
mouse wounds.  Wounds were treated with either saline (20 µL; vehicle control) or ZnO 30nm NPs 
(20 µL of a 0.5 µg/mL suspension). Wound sections were stained with anti-sma (B4) antibody  
by IHC, and the size of each blood vessel was measured in each section across 4 fields.  
Mean vessel area/field + SEM are shown (n=6 for day 7 and n=4 for day 14). 
 
 
Day 7
Control ZnO 30nm
0
50
100
150
200
Treatment
M
ea
n
 v
es
se
l 
a
re
a
/f
ie
ld
 (

m
2
)
 
Day 14
Control ZnO 30nm
0
50
100
150
200
Treatment
M
ea
n
 v
es
se
l 
a
re
a
/f
ie
ld
 (

m
2
)
 
 153 
 
5.4 DISCUSSION  
 
5.4.1 The ZnO NPs enhance in vivo wound repair in a dose- and particle size-dependent 
manner 
The in vitro studies described in chapter 4, clearly demonstrated the ability of the ZnO NPs to 
enhance re-epithelialisation in cell culture systems of both immortalised and primary human 
keratinocytes. These findings warranted further investigation in vivo, especially using ZnO 30nm NPs, 
which were the most efficacious in vitro. This effect was cell type, material size and agglomeration 
dependent, but was not necessarily a nanomaterial specific effect.  
 Consequently, the comparative effects of ZnO 30nm, ZnO 200nm, sZnO 30nm and  
TiO2 25nm were investigated in vivo to identify whether the in vitro observations translated 
effectively to an intact animal model for wound healing. Although the 0.1 µg/mL dose was the most 
effective concentration in vitro for ZnO 30nm NPs, the optimal dose for treating the mouse skin 
wounds was shown to be a single (20 µL) dose of 0.5 µg/mL (Figure 5.1). This ZnO 30nm dose 
doubled the extent of wound repair on day 5, compared to the saline-only treated control group.  
The ZnO 30nm NPs were then compared to the ZnO 200nm particulate and the sZnO 30nm and  
TiO2 25nm NPs at the same optimal dose of 0.5 µg/mL. While the ZnO 30nm NPs reproducibly 
caused significant enhancement of wound repair on days 4-7 the other materials had no effect  
(Figures 5.2 and 5.3). This contrasted with the significant in vitro effect seen for the TiO2 NPs and 
reinforces the biological significance of this activity and its dependence on particle size and 
agglomeration. Although TiO2 25nm NPs had no effect in this in vivo study, it has been reported that 
wound closure can be enhanced by using a TiO2 nanocomposite dressing (311). Interestingly, 
transmission electron and scanning electron microscopy of these TiO2 NPs showed a particle size of 
25-35nm (311), which was similar to the primary particle size of the TiO2 NPs used in our study. 
Unfortunately, the concentration of the TiO2 NPs used in the dressing was not reported and it is also 
possible that in our in vivo study, the ZnO 30nm and the TiO2 25nm NPs may be optimally effective 
at different concentrations. 
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There have been a limited reports assessing ZnO’s wound healing potential, as shown in 
Table 1.1. In 1991, Agren et al. (314) demonstrated that ZnO (25g/L) infused into a cotton gauze 
compress or bovine collagen sponge, enhanced the repair of porcine partial-thickness wounds by 
promoting re-epithelialisation. Its healing properties were further supported in a later study in 2006  
by Cangul et al. (323), which showed that rabbit full-thickness skin wounds treated on a daily basis 
with a ZnO pomade, healed significantly faster than an untreated control group over 21 days. 
Evaluation of the wound area on days 7, 14 and 21 revealed that the ZnO pomade significantly 
enhanced wound closure by 22 % and 20% on days 14 and 21, respectively (323). Following 
histological analysis, it was revealed that the neutrophil count was significantly lower in the ZnO 
pomade treated wounds, whilst granulation tissue deposition was significantly quicker. In contrast, the 
evaluation of the mouse tissue in the present study was not suggestive of a reduced leukocyte 
infiltration. A limitation in Cangul’s study was the lack of an appropriate vehicle control, which was 
required to compensate for the other potentially bioactive components of the pomade formulation. A 
recent study in 2012 by Arslan et al. (325), also demonstrated the wound healing potential of ZnO in 
rabbits. A 20% ZnO ointment (80% Vaseline) was applied daily to second-degree partial-thickness 
burns. In accord with Agren et al. (314), the ZnO treatment enhanced wound closure by stimulating 
re-epithelialisation. In a another recent study, in 2013 by Kumar et al. (326), ZnO, when combined in 
a β-chitin hydrogel bandage was shown to enhance wound closure. Partial-thickness skin wounds, 
created on the backs of Sprague Dawley rats were dressed with a ZnO infused bandage, which was 
replaced each week for 3 weeks (326). Photographic analysis of the wounds revealed that repair was 
enhanced in week 2 and 3 in the ZnO treatment group by 15% and 10% respectively, when compared 
to the untreated wounds. However, the β-chitin hydrogel bandage alone also demonstrated similar 
wound closure rates (326). Histological analysis assessing re-epithelialisation and collagen deposition 
in the wound showed that the ZnO infused β-chitin hydrogel bandage enhanced these repair 
parameters when compared to both the bare wounds and the β-chitin bandage alone. This finding 
demonstrated that the ZnO component of the dressing was likely to be the sole cause for these 
histological observations (326).  
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As stated above, the single application of ZnO 30nm NPs (20 µL of a 0.5 µg/mL suspension) 
in the present study, significantly enhanced wound repair by a similar amount to that observed in the 
aforementioned studies. Interestingly, the studies were conducted in different species, with a different 
method of ZnO application and in different wound types, yet its overall effect on closure rate was 
similar. This suggests that there may be a rate-limitation on its repair-enhancing properties.  
Zinc deficiency has been associated with delayed wound healing and decreased wound strength (352). 
Although its supplementation in people who are not zinc deficient is thought to provide little benefit 
to wound closure (372), it has been shown that zinc plasma levels are significantly lowered post-
injury, thus limiting the zinc concentration at the wound site. Furthermore, it has been suggested that 
this loss of zinc occurs via three different mechanisms, i.e. via urinary excretion, wound exudates, and 
redistribution to the liver (373-376). It is therefore possible that through its replacement, either by zinc 
ions or by dissolution of ZnO, more efficient wound repair is enabled. The studies reviewed above 
and described in Table 1.11, also highlight the beneficial effects of zinc on the histological appearance 
of the tissue. This is of equal or arguably greater importance than the wound closure rate. Several 
studies have shown that re-epithelialisation, immune cell infiltration, collagen deposition and blood 
vessel formation are important parameters used for the analysis of healing wounds. To further 
investigate the effects of the materials on these parameters in the present study, the wounds were 
excised on days 7 and 14 for morphological and histological analysis.  
5.4.2 ZnO 30nm NP treated wounds display better tissue morphology of the epidermis on day 
7 when compared to control 
Formalin-fixed and paraffin-embedded sections were stained with H&E to investigate the morphology 
of the tissue mid-repair and upon wound resolution and remodelling. ZnO 30nm NP treated wounds 
clearly displayed better healing of the epidermis on day 7. This was evident as the wounds showed 
greater continuity of the epidermis and a better organization of the keratinocytes (Figure 5.7). 
Additionally, fewer red blood cells were seen in the dermis. By day 14, no difference was apparent. 
Furthermore, the epidermal width was quantitated for all treatment groups. ZnO 30nm NP treated 
wounds demonstrated a 28 + 5 % reduction in the width of the epidermis on day 7 when compared  
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to control (Figure 5.8), however no significant difference was found on day 14. A similar observation 
was also noted in Arslan’s study (325), whereby the application of a 20% ZnO ointment to rabbit burn 
wounds significantly reduced the thickness of the epidermis in comparison to a clinically relevant 
silver sulfadiazine preparation. Comparatively, the ZnO 200nm particulate and the sZnO 30nm and 
TiO2 25nm NPs did not significantly influence the width, and thus organization, of the epidermis on 
day 7 or 14 (Figures 5.8 and 5.9). Additionally, the wound length was measured in ZnO 30nm treated 
formalin-fixed paraffin-embedded sections. The wound length was measured from the wound edge, 
noted by the loss of hair follicles, across the base of the epidermis in H&E stained sections.  
Although no difference between the treatment groups was found, the wound length was reduced from 
an incision with a 5 mm diameter to 4 mm and 3 mm on days 7 and 14, respectively (Figure 5.10). 
This is likely due to the nature of wound repair in rodents, whereby healing by contraction assists 
closure (377).  
 The epidermis of healing wounds treated with the ZnO 30nm NPs was further investigated 
histologically. Staining for cytokeratin-14 by IHC, of the keratinocytes encompassing the basal layer 
enabled the clear identification and quantification of these cells. ZnO 30nm NP treated wounds 
demonstrated a 24 + 6 % reduction in basal keratinocytes on day 7, whilst no difference was found on 
day 14 (Figure 5.11). Furthermore, the ZnO 30nm NPs appear to accelerate the return of this marker 
to basal levels quicker than in the saline-only treatment group (Figure 5.12). Staining for Ki-67 by 
IHC, identified the keratinocytes proliferating in the epidermis. Interestingly, Ki-67 expression was 
significantly reduced by 43 + 7 % in ZnO 30nm NP treated wounds on day 7, however by day 14 no 
difference was found (Figure 5.14). It was also shown that Ki-67 expression had returned to near 
basal levels in the ZnO 30nm NP treated wounds by day 7, thus indicating an accelerated repair of the 
epidermis. 
To further investigate the effect of ZnO 30nm NPs on wound repair the dermis was assessed 
for leukocyte infiltration, collagen deposition and vascular remodelling.   
 
 157 
 
5.4.3 ZnO 30nm NPs do not mediate leukocyte infiltrate to the dermis on days 7 or 14 
Leukocyte infiltration was examined in vivo, as the ZnO 30nm NPs demonstrated both 5-LOX and 
COX-2 inhibiting activity at low doses in vitro (Figures 4.20 and 4.21). As shown in Figure 1.6 and 
outlined in Section 4.4.10, the 5-LOX metabolites are primarily involved in leukocyte chemotaxis and 
adhesion to the endothelium, whilst the COX metabolites function by inducing vasodilation and 
increasing vascular permeability. The combination of these roles combined assist and accelerate 
leukocyte infiltration to the wound (26). Formalin-fixed and paraffin-embedded tissue from day 7 and 
14 mice wounds were sectioned and stained with H&E and the inflammatory cells in the dermis were 
counted. As shown in Figure 5.16, no difference in the amount of leukocyte infiltrate was found 
between the treatment groups on these days. Although ZnO has shown mild anti-inflammatory ability 
(330, 362, 363), this result was somewhat expected, due to the onset time of the inflammatory phase 
in acute wound repair. In normal healing wounds, inflammation typically commences upon injury and 
remains for 2-5 days (378). It is therefore likely that by day 7 the inflammatory phase had settled in 
both treatment groups. To better evaluate ZnO’s effect on the inflammatory phase, sampling tissue 
from an earlier time point may prove favourable, such as on day 3 or 5, when leukocytes amass within 
the wounded tissue.  
5.4.4 ZnO 30nm NP treated wounds show faster remodelling of collagen in the dermis 
Following the inflammatory phase, the deposition of collagen by fibroblasts is integral to facilitate the 
proliferation and migration of keratinocytes from the wound edge (41). As outlined in Section 1.1, 
collagen is the most abundant ECM protein found in the skin (3). Although there are 5 common 
subtypes of collagen (I-V), types I and III are found in the dermis and provide structural integrity to 
healing tissue. During the early proliferative phase, collagen type III is secreted from fibroblasts in a 
disorderly manner. It is only during tissue maturation and remodelling that it is replaced by type I 
collagen in a more organised fashion and provides greater tensile strength to the new skin (18, 42).  
As outlined in Table 1.11, the published literature supports ZnO’s involvement in the 
stimulation of collagen deposition in the dermis. This was shown in Kumar’s study (326).  
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Further in support of zinc’s effect, is the report that an oral supplement of zinc sulfate can assist both 
collagen deposition and the wound tensile strength of excisional wounds created on the backs of 
albino rats (84). Furthermore, poor collagen synthesis and wound tensile strength has been observed 
in zinc deficient rats, which was indicated by insufficient crosslinking of collagen fibres (379, 380). 
Collagen deposition and the prevalence of collagen type III and I were therefore evaluated in 
the ZnO 30nm NP treated mice wounds. The formalin-fixed and paraffin-embedded tissue collected 
from day 7 and 14 mice, was sectioned and stained with Picro-Sirius Red to identify the collagen 
content across the length of the dermis. Although the ZnO 30nm NPs did not significantly enhance the 
deposition of collagen in this study (Figure 5.17), a disparity in the ratio of type III:I collagen was 
evident between treatment groups on day 7. Type III and I collagen was distinguished by using 
polarization microscopy of the Picro-Sirius Red stained sections, by the display of a distinct 
birefringence. As noted in Section 5.3.4, type I collagen displays a yellow-orange birefringence, 
whilst type III collagen displays a green birefringence. By this method ZnO 30nm NP treated wounds 
demonstrated a 15 + 2 % reduction in type III collagen and a similar increase in type I collagen in the 
dermis, when compared to control (Figure 5.18). Furthermore, the ZnO 30nm NP treated animals 
showed a significantly lower collagen III:I ratio on day 7 (Figure 5.19). Remarkably, the collagen III:I 
ratio in the dermis of ZnO treated animals on day 7 mirrored that of the day 14 wounds, indicating 
that collagen remodelling was complete in the NP treatment group, but was still incomplete and 
ongoing in the control group. This was also supported by comparison of images obtained with 
polarized microscopy. The green birefringence (type III collagen) was seen to be more prevalent in 
the saline-only treated mice when compared to those treated with ZnO 30nm NPs on day 7  
(Figure 5.20). These results demonstrate that the ZnO 30nm NPs facilitate maturation and remodelling 
of the collagen in the dermis. Collagen also provides support for the growth and organization of the 
microvasculature in wound repair. 
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5.4.5 ZnO 30nm NPs do not mediate vascular remodelling   
For successful wound closure, the fibroblast recruitment, granulation tissue formation, collagen 
deposition, re-epithelialisation and angiogenesis must occur simultaneously (4). As outlined in 
Section 1.2.3, angiogenesis is the growth of new blood vessels for the restoration of oxygen and 
nutrient rich blood to the site of damage (43). This process is stimulated by tissue hypoxia and growth 
factors secreted from immune, epidermal and endothelial cells (18, 32-34, 37-39). Vessel sprouting 
and branching occurs throughout the granulation tissue to reinstate a microvasculature network,  
which is later remodelled by MMPs to both diminish vessel density and assist in better arrangement 
(42, 43, 45). Although studies on zinc’s effects on angiogenesis are limited (84, 381), it was 
imperative that the effect of ZnO 30nm NPs on angiogenesis was investigated in the present study due 
to the importance of this process in wound healing. The quantity and size of the vessels in the dermis 
of ZnO 30nm NP and saline-only treated mice were therefore evaluated histologically. Day 7 and 14 
mouse wounds were excised, formalin-fixed, paraffin-embedded and sectioned for staining by IHC 
with anti-sma (B4) antibody. Although no difference was found in the number of vessels present in 
the dermis, nor the size of the vessels on days 7 and 14 (Figures 5.22 and 5.23), the ZnO NPs did not 
impair angiogenesis or vascular remodelling. Figure 5.22 also revealed that the average number  
of vessels in the wound was nearly identical on both sampling days. This suggests that vascular 
remodelling was already complete by day 7, and perhaps an earlier tissue sampling timepoint is 
required to further evaluate ZnO’s effect on angiogenic processes.  
5.5 CONCLUSION  
 
In this study, female C57BL/6 mouse skin punch biopsy wounds demonstrated accelerated repair on 
days 4-7, when treated with an optimal dose of the ZnO 30nm NPs. This effect confirmed the in vitro 
findings that ZnO 30nm NPs enhance re-epithelialisation. However, the other materials had no effect, 
highlighting the material size and agglomeration dependency of its in vivo activity. Excised wound 
tissue from ZnO 30nm NP treated mice was examined histologically to assess the NPs capacity to 
mediate inflammation, re-epithelialisation, collagen deposition and remodelling, and angiogenesis. 
Although the ZnO 30nm NPs did not affect leukocyte infiltration, nor vascular remodelling on day 7, 
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a profound effect on re-epithelialisation and collagen remodelling was evident. The wound width was 
markedly reduced in ZnO 30nm NP treated wounds when compared to control on day 7.  
Additionally, the number of cells expressing cytokeratin-14 and Ki-67 was significantly reduced.  
Ki-67 expression, on day 7, in ZnO 30nm NP treated wounds was similar to that of the day 14 animals 
and showed more-ordered healing of the epidermis. Furthermore, the ratio of type-III to  
type-I collagen was significantly reduced in the NP treated mice, which demonstrated  
faster collagen remodelling.  
This study forms a valuable foundation for the further assessment of the ZnO NPs in wound 
repair. These particles not only supported ZnO’s re-epithelialisation enhancing potential, which  
was observed in vitro and documented in the literature, but also demonstrated a direct effect  
on collagen remodelling. This effect is likely to facilitate the formation of high tensile strength skin. 
Interestingly, these effects were observed from a single ZnO NP aqueous application, and its  
full potential may be masked by the dilution or partial removal by wound exudate. Improving the 
delivery of the NPs to the wound is therefore the next step in the continuation of this research. 
Although we have not been able to determine a molecular mechanism of action for the enhanced 
wound closure, we have identified that it aids the epidermal and collagen remodelling processes to 
accelerate repair. Accelerated rate of closure also minimises the risk of microbial colonisation, thus 
preventing the transition of an acute wound to a chronic state. Though further studies are required,  
to help determine the optimal delivery mechanism or frequency of NP application, this study has 
clearly highlighted ZnO’s potential for routine use in wound management.  
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CHAPTER 6: GENERAL DISCUSSION  
AND CONCLUSIONS 
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6.1 GENERAL DISCUSSION 
 
Wound repair is a multi-faceted process that is essential to the restoration of damaged tissue and to 
safeguard organism survival. It is dependent upon the successful transition of the core wound healing 
phases, which are: haemostasis, inflammation, proliferation and remodelling. A fault at any phase can 
prolong wound closure and encourage the formation of chronic wounds. Acute and chronic wound 
sufferers present a substantial economic burden to Australia’s health care system (6), due to the time-
consuming and costly methods of treatment (382, 383).  Improvements to wound management will 
therefore lead to better clinical outcomes, improved patient quality of life and a reduction in the costs 
to Australia’s healthcare system.  
This project primarily focused on the modulation of the inflammatory and proliferative phases 
of repair, both of which are vital to immune cell infiltration and re-epithelialisation of keratinocytes 
for wound closure. The core materials of interest were three MNPs, specifically CO2 oil, DME oil and 
5β-scymnol, and nanoparticulate ZnO. These compounds were utilised to challenge representative 
systems of inflammation and proliferation in vitro, in order to determine their potential benefit in vivo.  
We found that the NZGLM derived marine oils were strong inhibitors of the 5-LOX and COX 
pathways, however they also proved inhibitory to the repair of scratched monolayer cultures of 
keratinocyte and fibroblast, at concentrations that were 10-fold less than those which cause a loss in 
cell viability. Consequently, their potential to interfere with migratory or proliferative pathways at 
subcytotoxic concentrations demonstrates that their application as topical wound healing agents may 
be limited. However, their potent anti-inflammatory activity may be applicable in treating chronic 
wounds. Chronic wound sufferers present with non-healing wounds primarily due to an overactive 
inflammatory response and modulation of this phase with the marine oils may improve the rate of 
wound closure. While the shark bile sterol, 5β-scymnol, did not impair the scratch closure of 
keratinocytes and fibroblasts, it displayed limited anti-inflammatory ability, and therefore minimal 
wound healing potential regarding these processes.  
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On the other hand, ZnO has shown wound healing potential in the literature (84, 314, 322, 
323, 325, 326), although the particle size effect has not been investigated. The in vitro study in 
Chapter 4, was the first to show the importance of NP size on ZnO’s re-epithelialisation enhancing 
effect, whereby smaller sized particles were more effective. Additionally, we observed that NP 
agglomeration is required to stimulate this process and that other nanomaterials of a small primary 
particle size, such as TiO2, can similarly promote keratinocyte re-epithelialisation. Moreover, these 
enhancement effects may be independent of the cell cycle, as discussed in Section 4.4.4. The NPs also 
elicited these effects at concentrations which did not hinder nor stimulate the growth of fibroblasts. 
This was an important observation as insufficient or excessive collagen deposition has harmful 
implications on the wound closure rate and strength of a newly resolved wound. Furthermore, ZnO 
exhibited modulation of the two key inflammatory pathways, 5-LOX and COX-2, thus strengthening 
its wound healing properties. 
The ZnO NPs were selected for the evaluation of their wound healing capacity in vivo, and to 
verify the in vitro observations. Female C57BL/6 mice were wounded by punch hole skin biopsy and 
treated with a single dose of the ZnO 30nm NPs. Not only did the topical application of the ZnO NPs 
significantly enhance the wound closure rate in vivo when compared to vehicle-treated controls, but 
the size- and agglomeration-dependency of this effect was verified. Histology of the skin wounds 
revealed that the ZnO NPs assisted both the acceleration of epidermal remodelling and the transition 
of type-III to type-I collagen in the dermis, whilst immune cell infiltration and angiogenesis was 
unimpeded. Although ZnO’s mechanism of action remains unclear, it appears to not influence 
keratinocyte proliferation, the rate of cell adhesion or mediate integrin β1 binding, as was investigated 
in vitro.  
Several in vivo studies are in accord with our observations, such as those conducted by Agren 
et al. (314), Cangul et al. (323), Arslan et al. (325) and Kumar et al. (326) (outlined in Section 5.4.1) 
However, ZnO’s effect on improved wound closure rate has also been contended in the literature.  
A study by Aksoy et al. (324) showed that the daily application of a 40% ZnO ointment to full-
thickness skin wounds on the ears of albino New Zealand female rabbits did not significantly improve 
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the rate of wound closure, or the organization of collagen in the dermis. From our study, we have 
shown that the wound healing activity of the ZnO NPs is dependent upon the physiochemical 
characteristics of the particle itself. It is therefore possible that the particulate used in the ointment of 
Aksoy’s study was not of optimal dose or size.  
These findings suggest that topically applied ZnO NPs are well suited for acute wound repair. 
Acceleration of re-epithelialisation not only improves the wound closure time, but reduces the chance 
of microbial colonisation, which can delay repair and foster poor tissue morphology. Furthermore, the 
application of ZnO NPs promotes the transition of type-III to type-I collagen, and identifies its utility 
in the remodelling phase where it also is likely to increase the tensile strength of the wound. 
Moreover, the application of the ZnO NPs at the dose which elicited the greatest effect had no 
deleterious implications on the other aspects of the healing cascade when investigated both in vitro 
and in vivo. These findings support the clinical relevance for the use of ZnO NPs in routine wound 
management. Furthermore, due to ZnO’s extensive use in sunscreen formulations and in  
over-the-counter products, such as nappy rash cream, it has already undergone extensive regulatory 
risk assessment for topical use in humans. Although ZnO NP’s are highly soluble in aqueous 
environments to release free zinc ions and particulates, its effects were observed at low doses. These 
doses are substantially below zinc’s recommended daily intake of 14 and 8 mg/day in men and 
women, respectively (384), and suggests that the use of these ZnO NPs fall well within the safety 
guidelines.  
As mentioned above, our results suggest that topically applied ZnO NPs have the potential to 
aid the repair of new acute wounds. Therefore, these ZnO NPs may provide clinical assistance in 
many scenarios. These include the management of: cuts, abrasions, lacerations, surgical wounds, 
combat wounds and burns wounds. Furthermore, the ZnO NPs may accelerate the repair of slow 
healing wounds observed in patients with persistent co-morbidities. Wounds are a significant health 
concern and topical treatment is very important in managing repair. This was identified many 
centuries ago in ancient Greece and ancient Egypt, whereby honey was utilised for its antibacterial 
properties (385). Since those times, wound care has substantially developed and numerous agents and 
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dressings are presently available. Nonetheless, more efficient, newer, cheaper and easily accessible 
options are still sought-after. Although more research is required prior to its evaluation in some of the 
aforementioned scenarios, the ZnO NPs have shown strong wound healing potential in this thesis 
which warrants further investigation.  
6.2 CONCLUSIONS AND FUTURE WORK 
 
This project was successfully able to determine the wound healing potential of the MNPs and  
ZnO NPs on the inflammatory and proliferative phases of repair, using in vitro and in vivo models. 
We have found that the MNPs tested exhibit limited wound healing potential, whilst the ZnO NPs 
enhanced an in vitro model of re-epithelialisation and accelerated wound closure in mice  
by promoting epidermal and collagen remodelling. The NP’s wound repair enhancing properties were 
shown experimentally to be dependent upon the characteristics of the particle. We found that  
a particle’s dose, size and agglomeration state are essential parameters responsible for its wound 
healing activity, whereby a low dose of a ZnO NP, with a small primary particle size, was more 
effective than its bulk and monodispersed variant. Although the mechansim of action is still poorly 
understood, evaluation of the keratinocytes exposed to the ZnO NPs in culture has shown that the NPs 
do not appear to enhance cell proliferation, the rate of cell adhesion, or the expression of integrin β1. 
This suggests that other cellular proteins involved in motor function, such as the cytoskeletal proteins, 
require investigation. In addition, the identification of a mechanism of action provides the potential  
to manipulate the scratch repair or the in vivo model systems, and by specifically targeting  
an identified protein or process, we may also discover how to make ZnO NP’s effects greater.   
 This project has reinforced the beneficial use of the ZnO NPs for the management of acute 
wounds. In support of its utility, ZnO is inexpensive, easily accessible and safe for topical application. 
While this thesis has predominantly focused on evaluating the NPs on the basis of their 
physiochemical characteristics, several avenues are available to further assess their mechanism of 
action and biological properties. Furthermore, there are some methods which may enhance its efficacy 
in vivo.  
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As shown in Chapter 4, the ZnO 30nm NPs had the greatest impact on keratinocyte  
re-epithelialisation. It was also the only particle to accelerate wound closure in vivo. As mentioned 
above, ZnO’s mechanism of action requires further investigation. Although the ZnO NPs did not 
mediate expression of the integrin β1 protein, which is involved in keratinocyte adhesion, there are 
several other families of adhesion proteins, such as selectins, CAMs and cadherins which are 
expressed in keratinocytes (358). Furthermore, cytoskeletal proteins also have a vital role in cell 
movement. The cytoskeleton is principally composed of actin microfilaments, intermediate filaments 
and microtubules. Whilst intermediate filaments primarily have an important structural role and do 
not participate in cell motility, actin microfilaments and microtubules possess motor function. Cell 
movement is fundamentally driven by the continuous rearrangement of the actin cytoskeleton. Cell 
movement is achieved via actin polymerisation and de-polymerisation and via its ability to contract 
upon interaction with myosin. Microtubules are also highly dynamic polymers which regulate cell 
contractility and migration (386). Both actin and tubulin contain several zinc binding sites (387), 
which may modulate cell migration when bound. Therefore, it is reasonable to assess the effects  
of low dose ZnO 30nm NPs on the expression and function of these cytoskeletal proteins.  
In Chapter 4, we also observed the keratinocyte re-epithelialisation enhancing ability of the 
TiO2 25nm NPs. Since TiO2 is typically considered chemically inert, poorly soluble and of low 
toxicity, it was suggested that the ZnO 30nm and TiO2 25nm NPs promoted re-epithelialisation on the 
basis of their similar primary particle size. To investigate this further, a thorough study assessing the 
effects of other metal oxides on HaCaT and HEK cell re-epithelialisation is warranted. This study 
may also assist in the identification of the mechanism of action of these NPs.  
To further assess the biological properties and the wound healing benefit of the ZnO NPs, 
evaluating their effect on the growth of common bacterium found in acute and chronic wounds  
(as listed in Table 1.6)  may strengthen their routine use for wound management. Although the 
literature has demonstrated ZnO’s inhibitory effect on the growth of some of these species, such as S. 
aureus, E. coli, Klebsiella and P. aeruginosa (388-391), a larger study assessing its antimicrobial 
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effects in a dose- and particle-size dependent manner is lacking, and may reveal its potential in the 
management of chronic wounds, for which microbial colonisation is problematic.  
Finally, as we demonstrated that the ZnO 30nm NPs were able to enhance wound closure by 
the single application of a 20 µL aliquot of a 0.5 µg/mL dose, future studies could employ a dosing 
regimen that evaluates its wound healing benefit when dosed daily or on alternating days. An 
evaluation by this method has the potential to see a further enhancement in ZnO’s wound healing 
ability, as an increased dosing frequency can reduce both a particle wash-out effect and dilution by 
wound exudate.  Moreover, incorporation of the NPs into a hydrogel-based dressing enables greater 
control of the wound microenvironment and the potential for a sophisticated NP delivery mechanism. 
The dressing can be designed to regulate moisture content of the wound, inhibit microbial 
colonisation, and maintain parameters such as pH and temperature, whereby an acidic wound 
environment (pH 4-6),  kept within a temperature range of 33°C to 35°C, has been shown to favour 
wound resolution (392). Furthermore, with several types of hydrogels available, such as those based 
on collagen, hyaluronic acid, chitosan or alginate, the physiochemical properties of the dressing, such 
as the hydrophilicity, porosity, swelling ratio and degradation can be controlled. These properties can 
be exploited to control the rate of fluid passage from the wound, as well as the rate of NP release from 
the hydrogel, and its ability to diffuse throughout the tissue (393).  
Although this project has highlighted ZnO’s wound healing potential in a dose- and  
particle-size dependent manner, further research as outlined above, is required to both identify its 
mechanism of action and to determine whether greater healing can be achieved with modification of 
the NP delivery method.  
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APPENDICES 
 
Appendix 1: Neutrophil lipoxygenase inhibition 
 
Reagents:  
1. NaCl (9%) 
 NaCl       9.0 g 
H2O       100 mL 
2. Dextran T500 (6%) 
 Dextran      6.0 g 
H2O       70 mL 
NaCl (9%)      10 mL 
3. EDTA (4.5%) 
 EDTA.Na2      4.5 g 
H2O       100 mL 
4 Dulbecco’s (x10 stock solution) 
 NaCl       16 g 
 KCl       0.4 g 
 Na2HPO4      1.8 g 
 KH2PO4      0.4 g 
H2O       200 mL 
5. Dulbecco’s (working solution) 
 Dulbecco’s (x10 stock solution)    100 mL 
H2O       1.0 L 
6. Percoll (working solution) 
 Percoll       58.5 mL 
NaCl (9%)      6.5 mL 
7. Top Percoll gradient 
 Percoll (working solution)    29.5 mL 
 Dulbecco’s (working solution)    15.5 mL 
8. Bottom Percoll gradient  
Percoll (working solution)    34.9 mL 
 Dulbecco’s (working solution)    10.1 mL 
9. Citric acid (167 mM) 
 Citric acid      0.35 g 
 H2O       10 mL 
10. Citric acid/internal standard mixture 
      For n samples add: 
 PGB2 (30 ng/µL)           n x 1.5 µL 
Citric acid            n x 170 µL 
 
 193 
 
Appendix 2: Sample EIA plate layout 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A BLK 2000 2000 BG BG PI PI PI PI PI PI PI 
B BLK 1000 1000 BC BC PI PI PI PI PI PI PI 
C NSB 500 500 VC VC PI PI PI PI PI PI PI 
D NSB 250 250 VC VC PI PI PI PI PI PI PI 
E B0 125 125 VC VC PI PI PI PI PI PI PI 
F B0 62.5 62.5 VC VC PI PI PI PI PI PI PI 
G B0 31.25 31.25 BG BG VC VC VC VC PI PI PI 
H TA 15.6 15.6 BC BC VC VC VC VC PI PI PI 
 
  Additions to well  Additions to well   Additions to well 
D
a
y
  
1
 
Blank /  COX 1 Assayed  COX 2 Assayed  
Non-
Specific 
Binding 
100 µL EIA buffer,  
 50 µL AChE tracer 
 
Background 
(BG) 
 50 µL diluted reaction sample,  
 50 µL AChE tracer,  
 50 µL EIA antiserum 
Background 
(BG) 
 50 µL diluted reaction sample,  
 50 µL AChE tracer,  
 50 µL EIA antiserum 
Maximum 
Binding 
 50 µL EIA buffer,  
 50 µL AChE tracer,  
 50 µL EIA antiserum 
Vehicle 
Control (VC) 
 50 µL diluted reaction sample,  
 50 µL AChE tracer,  
 50 µL EIA antiserum 
Vehicle 
Control (VC) 
 50 µL diluted reaction sample,  
 50 µL AChE tracer,  
 50 µL EIA antiserum 
Total 
Activity 
 
/ 
Potential 
Inhibitor  
(PI) MNP/NP 
 50 µL diluted reaction sample,  
 50 µL AChE tracer,  
 50 µL EIA antiserum 
Potential 
Inhibitor 
(PI) MNP/NP 
 50 µL diluted reaction sample,  
 50 µL AChE tracer,  
 50 µL EIA antiserum 
Standards 
(Std) 
(pg/mL) 
 50 µL Std,  
 50 µL AChE tracer,  
 50 µL EIA antiserum 
 
  Additions to well  Additions to well   Additions to well 
D
a
y
 2
 
Blank 200 µL wash buffer x 5, 
200 µL developing agent, 
 1.0 hr incubation, 405nm 
 COX 1 Assayed  COX 2 Assayed  
Non-
Specific 
Binding 
200 µL wash buffer x 5, 
200 µL developing agent, 
 1.0 hr incubation, 405nm 
Background 
(BG) 
200 µL wash buffer x 5, 
200 µL developing agent, 
 1.0 hr incubation, 405nm 
Background 
(BG) 
200 µL wash buffer x 5, 
200 µL developing agent, 
 1.0 hr incubation, 405nm 
Maximum 
Binding 
200 µL wash buffer x 5, 
200 µL developing agent, 
 1.0 hr incubation, 405nm 
Vehicle 
Control (VC) 
200 µL wash buffer x 5, 
200 µL developing agent, 
 1.0 hr incubation, 405nm 
Vehicle 
Control (VC) 
200 µL wash buffer x 5, 
200 µL developing agent, 
 1.0 hr incubation, 405nm 
Total 
Activity 
200 µL wash buffer x 5, 
200 µL developing agent, 
 5.0 µL AChE tracer, 
 1.0 hr incubation, 405nm 
Potential 
Inhibitor  
(PI) MNP/NP 
200 µL wash buffer x 5, 
200 µL developing agent, 
 1.0 hr incubation, 405nm 
Potential 
Inhibitor 
(PI) MNP/NP 
200 µL wash buffer x 5, 
200 µL developing agent, 
 1.0 hr incubation, 405nm 
Standards 
(Std) 
(pg/mL) 
200 µL wash buffer x 5, 
200 µL developing agent, 
 1.0 hr incubation, 405nm 
 
Figure A.1: Plate layout utilised to assess PGH2 production by purified COX enzymes.  
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Appendix 3: Ethics Approval Letter 
 
 
          Research & Innovation 
GPO Box 2476V 
Melbourne VIC 3001 
Australia 
Tel. +61 3 9925 2251 
Fax +61 3 9925 6599 
 
 
20 February 2015 
 
Associate Professor Paul Wright 
School of Medical Sciences 
RMIT University 
 
Dear Paul, 
 
AEC 1428: Investigating the potential of nanomaterial enhanced dressings for improved wound 
healing. 
 
I am pleased to advise that this project has been approved by the RMIT University Animal Ethics 
Committee (AEC) for the period from 20 February 2015 until 20 February 2018. An approved 
version of the application is attached. 
 
Animals 
Your application has been approved to use up to n=272 C57BL/6 mice over the duration of the 
project. The use of animals in scientific procedures is strictly regulated by the Australian code of 
practice for the care and use of animals for scientific purposes. The above project is conducted under 
a Scientific Procedures and Premises License issued by the Bureau of Animal Welfare. 
Responsibilities of investigators 
1. Associate Professor Paul Wright 
2. Associate Professor Ian Darby 
3. Christian Aloe 
4. Dr Bryce Feltis 
 
Responsibilities of investigators are described in the Australian code of practice for the care and use 
of animals for scientific purposes (section 3). Investigators have a ‘personal responsibility for all 
matters related to the welfare of animals they use and must act in accordance with all requirements of 
the code. This responsibility begins when an animal is allocated to a project and ends with its fate at 
the completion of the project’ (s.3.1.1). 
 
Amendments and extensions 
If you find reason to amend your research method you should advise the AEC and prepare a request 
for minor amendment form. Please note that the AEC may only deal with ‘minor’ amendment 
requests. Major amendments to projects normally require a new project application. 
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Adverse events or unexpected outcomes 
As the primary investigator you have a significant responsibility to monitor the research and to take 
prompt steps to deal with any unexpected outcomes. You must notify the AEC immediately of any 
serious or unexpected adverse effects on animals, or unforeseen events, which may affect the ethical 
acceptability of your project. 
 
Unwell animals must be immediately reported via the care forms available at the RMIT Animal 
Facility. In the case of any emergency, the Animal Welfare Officer, Dr Rebbecca Wilcox, may be 
contacted at any time. In case of any unexpected animal death, the researcher has a responsibility to 
organise an autopsy so as to determine the cause of death. 
 
Investigator guidelines for record keeping 
Investigators are required to adhere to the strict guidelines regarding record keeping for their project. 
Note that records associated with a project ‘should be available for audit by the institution and 
authorized external reviewers’. Failure to maintain proper records may result in a compliance breach 
of the Code and place at risk the researcher’s capacity to carry out research with animals. 
 
Conditions of approval 
The AEC may apply conditions of approval beyond the submission of annual/final reports. There are 
no specific conditions attached to this project, except that described elsewhere in this letter. 
 
Reports 
Approval to continue a project is conditional on the submission of annual and final reports. Annual 
reports are requested in December each year, and must be submitted whether or not the project has 
commenced or is inactive.  
 
Failure to submit reports will mean that a project is no longer approved, and/or that approval will be 
withheld from future projects.  
 
All reports or communication regarding this project are to be forwarded to the secretary.  
 
On behalf of the AEC I wish you well with your research. 
 
Dr Brad Hayward 
Research Ethics Coordinator 
On behalf of  
RMIT Animal Ethics Committee 
 
cc: Ms Tricia Murphy, RAF manager 
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Appendix 4: Isoflurane inhalational anaesthesia 
 
This procedure was used for RMIT University AEC Approval #1428. 
Isoflurane was used for general anesthesia of mice during the punch hole biopsy procedure. This 
method of anesthesia provided an increased level of safety for both the handler and mice, and 
demonstrated quick recovery times. 
 
Anesthesia was performed in the RMIT animal facility procedure room. The setup for inhalational 
anesthetic utilized an isoflurane vaporizer, an oxygen supply gas tank, a supply gas regulator, a 
flowmeter, an induction chamber, a nose cone for the diversion of isoflurane, connecting tubes and 
valves, and an activated charcoal scavenger. 
   
Method of operation: 
1. Check the system to ensure that adequate amounts of supply gas and isoflurane are available 
    for the duration of the procedure.  
2. Make sure the system is set to flow to the induction chamber.  
3. Turn on the supply gas.  
4. Turn on the flowmeter between 500-1000 mL/min.  
5. Place the animal in the induction chamber and seal the top.  
6. Turn on the vaporizer to 5% setting.  
7. Monitor the animal until recumbent.  
8. Flush out the induction chamber with supply gas. This is to control human gas exposure.  
9. Switch the system to flow to the nosecone.  
10. Remove the animal from the induction chamber and position it in the nosecone. Animals need to 
be transferred within 1-2 mins as they can rapidly regain consciousness. 
11. Restart gas flow with flowmeter at 100-200 mL/min and vaporizer at 2-3%. If the animal has 
started responding, gently restrain in nosecone until fully anesthetized again.  
12. Monitor respiration and response to stimulation during the procedure and adjust vaporizer as 
needed.  
13. At completion of the procedure, turn the vaporizer off and allow the animal to breathe supply gas 
until it begins to awaken.  
14. Place the animal in a recovery area with thermal support until fully recovered. 
 197 
 
Appendix 5: Mouse and Wound Monitoring Form 
 
This procedure was used for RMIT University AEC Approval #1428. 
 
Date:  
Mouse  
Clinical observations  
UNDISTURBED  
Activity  
Normal =0; Isolated =1; Inactive =2; Moribund/Fitting =3 
 
Posture  
Normal =0; Hunched =2; Trembling =3 
 
Movement/Gait  
Normal =0; Slight incoordination =1; 
Reluctant to move =2; Staggering/Limb/Paralysis=3 
 
Coat Condition  
Normal/Groomed =0; Rough =1; 
Ruffled/Unkempt =2; Bleeding or Infected or Self-mutilation =3 
 
Eating/Drinking  
Normal =0;  Decreased intake during 1
st
 24hrs =1; 
Decreased intake more than 1 day =2; Decreased intake over 48hrs =3 
 
Breathing  
Normal=0; Rapid, Shallow =1; Rapid, Abdominal breathing =2;  
Labored, Irregular, Skin blue=3 
 
ON HANDLING  
Alertness  
Normal =0; Dull/Depressed =1;  
Little response to handling =2; Unconscious =3 
 
Body Weight  
Normal weight =0; Reduced =1; 
Chronic weight loss >15% =2; >20% loss =3 
 
Dehydration  
None =0; Skin less elastic =1; 
Skin tenting =2; Skin tenting & Sunken eyes =3 
 
Eyes & Nose 
Normal =0; Wetness or Dull =1; 
Discharge/squinty =2; Coagulated Nasal Discharge/Matted eyes=3 
 
Faeces  
Normal=0; Moist but formed =1; Loose, Soiled perianal area  
or Mucoid =2; Watery or no faeces for 48hrs or Blood =3 
 
Urine  
Normal =0; Increased/Decreased =3 
 
Temperature  
WOUND  
(Intact/Clean/Dry/Inflamed/Infected 
 
Treatment/support Fluids, Antibiotics, Mushy food etc.  
 
Criteria for analgesia: If animals show distress after biopsy, they are to be given an analgesic 
injection subcutaneously of buprenorphine – Temgesic 0.05 mg/kg using a 25G needle. If they reach a 
pain/distress score of 6 an analgesic injection intraperitoneally of buprenorphine – Temgesic 0.1 
mg/kg using a 25G needle is given twice daily (every 12 hrs). Criteria for euthanasia: If animals 
show a distress score of 10 (2 each for the 5 criteria) or a score of 3 for any of the following clinical 
observations: Activity, Movement/Gait, Breathing, Alertness, Body weight. 
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Appendix 6: CO2 Euthanasia 
 
This procedure was used for RMIT University AEC Approval #1428. 
Carbon dioxide was utilized to cull mice on days 7 and 14 during the mouse skin wound repair 
studies. This method of euthanasia is considered less stressful than other methods, such as injections, 
which require individual handling of mice, and provides a safe method of operation. As mice were 
individually caged, they were also euthanized individually to prevent overcrowding of the induction 
chamber and to prevent distress from being in contact with unfamiliar mice. 
Euthanasia was performed in the RAF procedure room. The setup for CO2 euthanasia utilized a CO2 
supply gas tank, a supply gas regulator, a flowmeter and an induction chamber.  
Method of operation: 
1. Place rodent inside chamber. 
2. Turn on the supply gas. 
3. A fill rate of 10-30% of the chamber volume per minute with carbon dioxide is deemed   
    humane. 
4. Leave gas to flow until rodent is unconscious. 
5. Turn off the supply gas. 
6. Remove the rodent once you have established it is no longer breathing and does not have a  
    heartbeat. 
7. If rodent is still breathing, repeat steps 1-6. 
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Appendix 7: Haematoxylin and Eosin (H&E) Stain 
 
Haematoxylin and Eosin was utilized to stain basophilic and acidophilic structures in each tissue 
section.  
 
Reagents: 
1. Mayer’s haematoxylin 
2. Scott’s tap water substitute: 
Potassium bicarbonate       2.0 g 
Magnesium sulphate        20 g 
Distilled water        1000 mL 
3. 1% Aqueous eosin 
 
Method: 
1. Dewax sections 
 Xylene         3.0 min  
 Xylene     2.0 min 
 Absolute alcohol     1.0 min  
 Absolute alcohol     1.0 min 
 70% Alcohol     Rinse 
 Tap water     Wash 
2. Mayer’s Haematoxylin         3.0 min 
3. Tap water        Rinse 
4. Scott’s tap water        1.0 min 
5. Tap water        2.0 min 
6. 1% Aqueous eosin        2.0 min 
7. Tap Water        Rinse 
8. Dehydrate through alcohols and clear in xylene 
70% Alcohol        10 dips 
Absolute alcohol       10 dips 
Absolute alcohol       20 dips 
Xylene         1.0 min 
Xylene         2.0 min 
9. Mount in DPX and coverslip 
10. Examine microscopically  
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Appendix 8: Picro-Sirius Red 
 
Picro-Sirius Red was utilized to determine total collagen deposition and prevalence of collagen type I 
and III subtypes in each tissue section. 
 
Reagents: 
1. Picro-Sirius Red staining solution 
2. Acidified water: 
 Glacial acidic acid       5.0 mL 
 Distilled water         995 mL  
 
Method: 
1. Dewax sections 
 Xylene         3.0 min  
 Xylene     2.0 min 
 Absolute alcohol     1.0 min  
 Absolute alcohol     1.0 min 
 70% Alcohol     Rinse 
 Tap water     Wash 
2. Stain sections in Picro-Sirius Red      1.0 hr 
3. Wash in two changes of acidified water      5.0 min 
4. Remove excess H2O by vigorously shaking sections 
5. Dehydrate and clear in xylene  
 Absolute alcohol       10 dips 
 Absolute alcohol       10 dips 
 Absolute alcohol       10 dips 
 Xylene         1.0 min 
 Xylene         2.0 min 
6. Mount in DPX and coverslip 
 
Staining interpretation:  
Light microscopy     
Collagen    Red 
Muscle fibers    Yellow  
Cytoplasm     Yellow 
Polarized light microscopy  
Type I (Thick fibers)   Yellow-orange Birefringence  
Type III (Thin fibers)   Green Birefringence  
 
 201 
 
Appendix 9: Immunohistochemistry (IHC) 
 
IHC was utilized to detect and evaluate specific proteins found in mouse murine wound tissue.  
 
Reagents: 
1. Tris-EDTA antigen retrieval buffer: 
Tris base        1.21 g 
EDTA         0.37 g 
Distilled water        1000 mL 
Tween 20        0.5 mL 
Store RT for 3 months or longer at 4°C 
2. 0.4% PBS-T 
 5x Phosphate buffered saline tablets (Sigma, Australia, Cat. No. P4417)   
Distilled water        1000 mL 
Triton X-100        4.0 mL 
Store at 4°C 
 
Method: 
1. Dewax sections 
 Xylene         5.0 min 
 Xylene     5.0 min 
 Absolute alcohol     1.0 min 
 Absolute alcohol     1.0 min 
 70% Alcohol     Rinse 
 Tap water     Wash 
2. Heat 200 mL Tris-EDTA retrieval buffer in a microwave until boiling 
For each section:  
3. Transfer sections into a staining dish containing boiling retrieval buffer 
4. Place staining dish in a pre-heated 100°C water bath    20 min 
5. Rinse in cold running tap water      2.0 min 
6. Wash twice in 0.4% PBS-T       5.0 min 
7. Block in 5% BSA diluted in 0.4 % PBS-T     30 min 
8. Incubate with primary antibody in a humidified chamber at 4°C  overnight 
9. Wash twice in 0.4% PBS-T       5.0 min 
10. Block with 1.0% H2O2       15 min 
11. Wash in 0.4% PBS-T (2x 5 min)      10 min 
12. Incubate at RT with the appropriate HRP conjugated secondary antibody  
in a humidified chamber       1.0 hr 
13. Wash in 0.4% PBS-T (2x 5 min)      10 min 
14. Incubate in DAB substrate (Staining intensity varies with exposure time)     2-10 min 
15. Dehydrate through alcohols and clear in xylene 
70% Alcohol        10 dips 
Absolute alcohol       10 dips 
Absolute alcohol       20 dips 
Xylene         1.0 min 
Xylene         2.0 min 
16. Mount in DPX and coverslip 
17. Examine microscopically  
